Effects of dietary polyphenols on aspects of cell molecular physiology relevant to metabolic health and ageing by Aziz, Sadat Abdulla
  
 
 
 
Effects of dietary polyphenols on aspects of cell molecular 
physiology relevant to metabolic health and ageing 
 
Sadat Abdulla Aziz 
 
Thesis submitted for the degree of doctor of philosophy  
Institute for Cell and Molecular Biosciences 
Faculty of Medical Sciences 
Newcastle University 
United Kingdom 
 
September 2015  
I 
 
Declaration 
I declare that this thesis titled “Effects of dietary polyphenols on aspects of cell molecular 
physiology relevant to metabolic health and ageing” is my own work that has not been 
submitted for any degree or examination in any university and that all materials used have 
been acknowledged and referenced. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II 
 
Acknowledgement 
I would like to show my sincerest gratitude to my supervisors Prof. Dianne Ford and Prof. 
John Edward Hesketh for their guidance and support. Their consideration and 
understanding have helped me achieved my potential and allowed me to truly enjoy 
completing this project. 
I am very grateful to my family members, especially my beloved wife Bayan and my 
beautiful children Avrest and Vanest, for being with me and accepting my absence even 
during weekends. Your company has been invaluable over the four last years. 
I am also very thankful to my colleagues in the laboratory, especially Dr Luisa Wakeling, 
without whom the past four years would not have been as enjoyable. I truly appreciate 
their help and advice.  
I would like to thank Dr Satomi Miwa from Institute for Cell and Molecular Bioscience for 
her help and support especially with the work related to mitochondrial activity. 
Thank you to all my dear friends for keeping me in touch; your encouragement has been 
a source of happiness during the hard times. 
Finally I would like to thank Ministry of Higher Education and Scientific Research, 
Kurdistan Regional Government/Iraq for the sponsorship. 
 
 
 
 
 
 
 
 
 
 
 
III 
 
Abstract 
Numerous studies indicate a wide range of possible health benefits from 
consumption of dietary polyphenols, including resveratrol and genistein. These effects 
include suppression of cancers, antioxidant functions and protection from diet-induced 
obesity.  
Previous research in the laboratory using the mouse 3T3-L1 adipocyte model 
revealed that resveratrol affected the expression of genes involved in lipogenesis. I 
proposed that genistein, which has some structural similarity to resveratrol and, like 
resveratrol, can act through the estrogen receptor (ER), would have the same actions.  
However, I observed that genistein induced a change in the appearance of cells such that 
they resembled brown, rather than white, adipocytes.  This change in appearance 
included the accumulation of small, multiclocular lipid droplets, typical of brown adipose 
tissue, which contrasted with the large lipid droplets seen white adipocytes.  I thus 
proposed that genistein can induce the development of beige adipocytes (adipocytes with 
characteristics of brown adipocytes but derived from the same lineage as white 
adipocytes).   In support of this hypothesis, genistein reduced mRNAs of genes that 
characterise white adipocytes (Acaca, Fasn, Fabp4, Lipe, Rarres2, Retn) and increased 
mRNAs of genes expressed specifically in brown adipocytes (Ucp1, Tnfrsf9) and of genes 
recognised as mediators of white to brown adipocyte interconversion (Sirt1, Cebpb, 
Ppargc1a) in a dose- and time-dependent manner. Measurement of mitochondrial 
activity revealed that basal oxygen consumption rate and mitochondrial proton leak were 
higher in genistein treated cells, consistent with the respiratory characteristics of beige, 
rather than white, adipocytes.  
The presence of the ER antagonist fulvestrant reduced none of these effects of 
genistein on 3T3-L1 cells, indicating that this action of genistein is not through the ER. 
However, the responses of Ucp1 and Cebpb genes to genistein were significantly 
attenuated by EX-527, which is a specific and potent Sirt1 inhibitor.  A moderate increase 
(2 fold) in Sirt1 mRNA level was observed in response to treatment of 3T3-L1 cells with 
genistein. However, there was an increase of approximately 12 fold in Sirt1 protein, which 
further indicated that increased Sirt1 action is a key mediator in the change I observed. 
This effect of genistein on Sirt1 expression was not unique to adipocytes; a similar ER-
independent effect was measured in MCF-7 breast cancer cells. 
Again to develop previous work conducted in the laboratory on novel actions of 
resveratrol, I proposed that genistein would affect histone expression.  I observed that 
genistein repressed transcription from a histone H3.1 (variant H3b) promoter-reporter 
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construct but increased the expression of histone H3 and H4 proteins.  Genistein had 
differential actions on specific histone variant mRNAs. Notably histone H3d and H3.3 
mRNAs were increased whereas all other variants measured were reduced.  The ER 
antagonists fulvestrant and G15 did not affect any of these responses, indicating that, like 
the other actions studied in this body of work, these effects of genistein were though 
pathways independent of ERs.  Observations of these ER-independent actions of genistein 
on histone expression extended also into 3T3-L1 cells. Gene expression through specific 
alterations in chromatin structure may thus be one of the mechanisms through which 
genistein has its reported beneficial effects. 
In further work exploring ER-dependent versus ER-independent actions I 
determined if genistein had any effects on expression of ERs, since there is evidence that 
17β-estradiol has some autoregulatory feedback action via repression of ER expression.  
Here I made the potentially important observation that genistein has selective actions on 
ERα versus ERβ, reducing mRNA corresponding to ERα while increasing ERβ mRNA.  Again, 
these responses were not affected by ER antagonists.  This action may be of benefit in the 
prevention or treatment of breast cancer, where ERα activity is generally detrimental 
while ERβ activity appears to be of benefit. 
Finally, I developed the previous research on actions of resveratrol in 3T3-L1 cells 
by determining if the action of resveratrol to reduce mRNAs for the enzymes fatty acid 
synthase and acetyl Co-A carboxylase, measured previously and that I reconfirmed in the 
current work, was accompanied by a change in DNA methylation of the corresponding 
gene promoter regions, which I proposed to be a plausible mechanism of regulation given 
other reported effects of reseveratrol to alter DNA methylation.  However, there was no 
effect of resveratrol on DNA methylation in the regions measured.   
Together, the findings reported in this thesis indicate that a diet with a high 
genistein content may protect against obesity and other features of the metabolic 
syndrome by encouraging the development of beige, rather than white, adipose tissue.  
Such actions appear to be through pathways independent of the ER.  Alterations in histone 
expression may be one of the mediating pathways, but at present I have no evidence of 
any causal link between the observed effects of genistein on histone expression and on 
adipocyte gene expression profile and phenotype.  Despite excluding effects through the 
ER as a component of these actions of genistein, I obtained preliminary evidence that 
modifying the expression of ERs may be an action of genistein relevant to reported cancer-
protective actions.   
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Chapter 1 
1. Introduction  
1.1. Dietary polyphenols 
Natural polyphenols occur most abundantly as water-soluble secondary 
metabolites of plants (Ho, 1992) and are primarily produced by plants in response to 
external stress stimuli such as infection and UV irradiation. Their primary functions are to 
protect plants against fungal and bacterial infection, and they might act as signals that 
regulate processes of symbiosis (Mandal et al., 2010). 
Structurally, polyphenols contain an aromatic ring carrying more than one (phenol) 
hydroxyl substituent. Some polyphenols including isoflavones, stilbenes and lignans, 
structurally and possibly functionally resemble 17β-estradiol, which is the mammalian 
endogenous estrogen hormone. These compounds may thus have some effects through 
activating estrogen receptors (Daayf, 2008) or their action is likely to be through other 
pathways.  
In recent years, there has been a worldwide trend towards promoting the 
consumption of some dietary polyphenols to derive potential health beneficial effects. 
The dietary polyphenols resveratrol and genistein are the main focus of the current work. 
The particular actions studied relate to their possible use as agents to reduce lipogenesis, 
and thus to alleviate obesity-related health problems such as cardiovascular disease, type-
2 diabetes and non-alcoholic fatty liver disease.   
1.1.1. Classification of polyphenols 
The structural and chemical diversity of plant polyphenols have led to the use of 
different systems of classification. However, this group of compounds are generally 
classified as flavonoids, phenolic acids, polyphenolic amides and non-flavonoid 
polyphenols. Over 4000 flavonoids have been recognised and are characterised by having 
two phenolic rings as well as one heterocyclic ring. Isoflavones, one of the subgroups of 
the flavonoids, are characterized by the second phenolic ring binding to the C3 of the 
heterocyclic ring. The isoflavones most commonly consumed in human diets are genistein, 
diadzein and glycitein. They occur in general in the greatest abundance in the leguminous 
plant family which includes peas and beans (Tsao, 2010). 
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The stilbenes are a separate group of dietary polyphenols belonging to the non-
flavonoid division and characterised by having two phenolic rings connecting via a 
methylene bridge. In the context of the human diet resveratrol is the representative of 
this group that has been studied most extensively (Soleas et al., 1997; Tsao, 2010; Yang 
and Xiao, 2013) 
1.1.2. Genistein 
Like other dietary polyphenols, notably diadzein and glycitein, genistein is  
abundant in peas and beans (Tsao, 2010). Because of its structural similarities with 
estrogen, it is also described as a non-steroidal phytoestrogen (Manach et al., 2004). 
Genistein is one of the active components of several traditional medicinal plants, 
particularly plants used in traditional Chinese medicine, and it has been used for centuries 
to treat several health disorders (Lee et al., 2004; Sham et al., 2014). A wide range of 
possible health benefits related to consuming genistein have been indicated in numerous 
in vitro and in vivo studies. These possible positive actions include anti-cancer activity 
(Wang et al., 2002), antioxidant effects (Sales and Resurreccion, 2013), and antilipogenic 
activity (Kim et al., 2010). Several pathways and mechanisms through which genistein 
might regulate cellular activities at the molecular level have been identified and include 
estrogenic effects (Magee and Rowland, 2004), tyrosine kinase inhibition (Kasai and 
Kikuchi, 2010) and epigenetic effects (Fang et al., 2005; Dolinoy et al., 2006). To elucidate 
further how genistein can influence cell and tissue biology, thereby the implications for 
human health of consuming genistein, further work is required. 
1.1.2.1. Chemical structure of genistein 
The attachment of the second phenolic ring of genistein to C3 of the heterocyclic 
ring and the relatively similar pattern of distribution of the hydroxyl groups lend a 
structural and probably functional similarity between genistein and 17β-estradiol 
(Ogbuewu et al., 2010). The glycosylated form of genistein (glycone) is known as genistin 
and it carries the sugar moiety on C7 of the first phenolic ring of the parental genistein 
backbone (Coward et al., 1993). The structure of genistein, genistin and 17β-estradiol are 
shown in Figure 1. 
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Figure 1. 1: Chemical structures of genistein, genistin and 17β-estradiol 
1.1.2.2. Sources of genistein 
Genistein is particularly abundant in soya and its related products such as soya 
milk, soya sauce and tofu (Horn-Ross et al., 2000; Yamamoto et al., 2001; Otaki et al., 
2009). Genistein is present in these types of food in different forms including genistin 
(genistein glycone) and genistein aglycone (Messina et al., 2006). The process of 
fermentation used to produce products such as tofu dramatically increases the ratio of 
aglycone to genistin. The concentration of isoflavones (mainly genistein, daidzein and 
glycitein) in the soyabean plant is highly variable and it depends on environmental factors 
such as temperature (Zhang et al., 2002) and microbial infection (Formela et al., 2014). In 
general, the isoflavone concentration of fresh soyabeans ranges between  600 and 4000 
mg/kg while the isoflavone content of soymilk is estimated to be between 30 and 170 
mg/L (Manach et al., 2004). In comparison to other isoflavones in these food products, 
the concentration of genistein is particularly high and has been estimated to comprise 
approximately 50% (Delmonte et al., 2006). Trace of genistein are found in other types of 
food including wheat bran, bread (white or whole grain), oatmeal, rice (white or brown, 
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boiled) and some vegetables, for example, raw tomato, watercress, okra, mushroom, 
cucumber, sprouting broccoli and aubergine (Liggins et al., 2000). 
1.1.2.3. Daily intake of genistein 
Based on epidemiological and experimental studies, it has been proposed that a 
daily intake of at least 60 mg of isoflavones (Valtueña et al., 2003) or consumption of 
around 25 g of soya protein per day is required to drive health beneficial effects of 
genistein and to keep the concentration in blood within a physiologically active level. In 
some Asian countries, particularly Japan and China, where there is a low incidence of 
cancer and other chronic diseases, the amount of dietary isoflavone consumption is 
typically high and it has been estimated to be around 20-50 mg per day, with about 10% 
of the Asian population consuming around 100 mg of isoflavones per day, with older 
Japanese people having even higher intakes (Messina et al., 2006). In contrast, in some 
European countries including the UK, and also in the United States, daily dietary isoflavone 
intake is typically low, and has been estimated to be around 1 mg per day (Marie-Agnes 
et al., 2003; Chun et al., 2007), This low level of isoflavone intake may be insufficient for 
biological activity (Horn-Ross et al., 2002; Valtueña et al., 2003).  
1.1.2.4. Genistein absorption, metabolism and excretion 
Genistein aglycone is absorbed mainly within the small intestine by passive 
diffusion. The glycosylated form of genistein (genistin) is less readily absorbed (Messina 
et al., 2006). Genistin is deglycosylated by both bacterial and intestinal β-glucosidase 
enzymes, and this processing is to release genistein aglycone comprises the primary route 
for absorption (Setchell et al., 2002; Cederroth et al., 2012). After absorption, it appears 
that genistein is largely conjugated with glucuronic acid (Setchell, 2000; Chen et al., 2005; 
Zhou et al., 2008) or sulfate, particularly within the liver and enterocytes (Ronis et al., 
2006), through the action of UDP-glucurunosyltransferases (UGTs) and sulfotransfrases 
(SULTs) (Williamson and Manach, 2005). These post-absorptional modifications of 
genistein increase solubility and may be important for transport by the blood as well as 
for renal excretion. Genistein has a high affinity for serum albumin, which thus may be an 
important carrier for cell and tissue delivery (Cao et al., 2013a). In comparison with other 
isoflavones including diadzein, genistein has a slightly longer half-life (8.5 h) within the 
blood (Izumi et al., 2000; Cohen et al., 2011). The longer half-life is likely to be relevant to 
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bioavailability of the tissues and cells. Genistein is excreted predominantly through the 
urinary system and biliary tract (Seow et al., 1998; Watanabe et al., 1998; Zhou et al., 
2008). Most genistein excreted into the intestine via bile can be re-absorbed through 
enterohepatic circulation, particularly after their de-conjugation by glucuronidase 
enzymes within the intestine (Sfakianos et al., 1997; Zhou et al., 2008). Therefore, the 
entero-hepatic circulation is also considered important for genistein bioavailability (Wang 
et al., 2006). The process of absorption of genistein is shown in Figure 2.  
 
Figure 1. 2: Genistein absorption, metabolism and entero-hepatic circulation. After ingestion, β-
glucosidase enzymes catalyse the conversion of genistin into genistein. Genistein is passively absorbed 
by the intestine. The absorbed genistein either enters into the circulation unchanged or after its 
conversion into genistein glucuronide and sulfate by glucurunosyltransferase or sulfotransferase within 
the enterocytes. The genistein glucuronide excreted into the intestine via bile is reabsorbed by the 
intestine after its deconjugation by β-glucuronidase within the intestine. 
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1.1.2.5. Genistein bioavailability 
Under physiological conditions genistein bioavailability is highly variable and 
depends on the type of food matrix (liquid or solid), individual and cultural habits, 
chemical form of the isoflavone (glycosylated or not) (Jefferson and Williams, 2011) and 
even perhaps sex as its bioavailability appears to be higher in females than in males 
(Cassidy et al., 2006). Fermented dietary isoflavone sources generally have higher 
bioavailability than non-fermented sources because of the conversion of the glycosylated 
form to aglycone by the microbial β-glycosidase enzymes involved in processing, thus 
releasing a moiety available for direct passive absorption by intestinal cells (Chen et al., 
2012). Nanoparticle technology offers some promise to elevate the bioavailability of 
pharmacological agents, including genistein (Tang et al., 2011; Ha et al., 2013). 
The highest physiological plasma concentrations of genistein (5 µM) have been 
recorded among the Japanese. This is likely to be related to cultural eating habits 
(Banerjee et al., 2008). High concentrations of genistein (2.53 µM) have also been 
measured in the blood of infants feeding soya milk (Setchell et al., 1997). Interestingly, 
very high plasma concentrations (4-27.1 µM) of genistein were measured in prostate 
cancer patients after oral administration of two different doses of genistein (300 mg/day 
for 28 d then 600 mg/ day for another 56 d) (Miltyk et al., 2003). Genistein is not 
distributed uniformly between the body tissues. A different genistein concentration was 
measured in different tissues under conditions in which the concentration of genistein in 
the blood was 6-8 µM, for example, liver 7.3 pmol/mg, mammary gland 2.5 pmol/mg, 
ovary 1 pmol/mg, thyroid 1.18 pmol/mg, brain 0.04 pmol/mg (Chang et al., 2000). 
Variations in genistein concentration between different tissues may be a reason 
underlying tissue-dependent physiological and pharmacological effects of genistein. 
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1.1.2.6. Health benefits of genistein 
Benefits to health attributed to consumption of genistein in the diet include cancer 
suppression, antioxidant effects and anti-lipogenic action. The following sections provide 
some pieces of evidence in support of this claim.  
1.1.2.6.1. Anticancer effects of genistein 
Cancer is characterised by uncontrolled cell division as a result of a genetic defect 
affecting proto-oncogenes and tumor-suppressor genes followed by local and systemic 
spread. The process of cancer development (carcinogenesis) can be divided into several 
stages including initiation, promotion, progression and invasion (Lodish et al., 2004). A 
considerable body of literature focuses on anti-cancer effects of genistein. 
Epidemiological, clinical and experimental studies support the view that genistein can 
have impact on different stages of the process of carcinogenesis including initiation, 
promotion, propagation and invasion, and may also selectively induce cancer cell damage 
and apoptosis (Kim et al., 2014).  
Epidemiological studies have revealed that the incidence of cancer among 
Japanese and Chinese people is particularly low compared to other populations. As 
already noted, this might be related to a substantially higher intake of dietary isoflavones 
(Nagata, 2000; Yamamoto et al., 2003; Kurahashi et al., 2007; Lampe et al., 2007; Banerjee 
et al., 2008; Iwasaki et al., 2008; Lee et al., 2009). Other supportive evidence includes the 
finding that dietary supplementation of genistein has reduced risk of cancer in a 
chemically induced prostate cancer in rat and in a transgenic mouse model of prostate 
cancer (Mentor-Marcel et al., 2001; Wang et al., 2002; Mentor-Marcel et al., 2005). 
Similarly, genistein has been found to impair properties related to cancer progression and 
proliferation in different cell models including breast cancer cells (MCF-7) (Fan et al., 
2013), human prostate cancer cells (PC3 and DU145) (Chiyomaru et al., 2012), ovarian 
cancer cells (Gercel-Taylor et al., 2004), and human leukemic mast cells (Alexandrakis et 
al., 2003).  
One beneficial model of action of genistein is likely to be impairment of cancer cell 
survival and induction of cell cycle arrest (Hewitt and Singletary, 2003) and apoptosis 
(Thasni et al., 2008). The induction of cell cycle arrest and apoptosis in cancer cells by 
genistein appears to be related to the activation of the P53 pathway in response to DNA 
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damage and hyperproliferation. Pronounced effects of genistein on P53 signalling were 
reported in colon cancer cell models (HCT-116 and SW-480) (Zhang et al., 2013b). In 
addition, genistein appears to down-regulate the expression of some genes involved in 
cancer invasion and metastasis including matrix metalloproteinase-3 (MMP3) and matrix 
metalloproteinase-2 (Yu et al., 2012; Betancourt et al., 2014), These zinc-dependent 
enzymes are responsible for tissue matrix as well as non-matrix protein degradation 
(Duffy et al., 2000; Nagase et al., 2006) and are typically expressed at high levels in highly 
invasive cancers (Balduyck et al., 2000).  
Genistein may also decrease the risk of cancer development through epigenetic 
modulation of factors which are important in the process of carcinogenesis, including 
human telomerase reverse transcriptase (hTERT). Genistein (100 µM) treatment was 
found to decrease hTERT expression in both benign and malignant breast cancer cell lines 
(MCT10AT and MCF-7), an effect that seems to be mediated via remodelling the 
chromatin structure by increasing H3K9 trimethylation and decreasing H3K4 
dimethylation, which are markers of gene repression (Li et al., 2009). Moreover, genistein 
was found to decrease the DNA methylation status of some tumor suppressor genes 
including phosphatase and tension homolog (PTEN) via reducing the expression and 
activity of the DNMT enzymes (Xie et al., 2014). 
1.1.2.6.2. Antioxidant effects of genistein 
Reactive oxygen species, particularly imbalanced oxidative stress, are mediators 
of molecular and structural damage of cellular components including DNA and other 
cellular organelles, and are widely considered to be a principle cause of cellular and 
systemic disturbances including life threating diseases such as vascular damage, 
neurodegenerative disease and cancer (Sales and Resurreccion, 2013). Any agent with the 
ability to decrease or prevent oxidative damage could potentially be used to reduce these 
effects of free radicals. Genistein is one of the dietary agents with possible potent anti-
oxidant properties. Over the past few decades, several studies have revealed that 
genistein, even at physiological levels (0.1 to 5 µM), can protect human lymphocytes and 
human leukaemia T-cells from iron-induced oxidative damage (Foti et al., 2005). Likewise, 
genistein can reduce oxidative stress-associated cardiovascular disorders (Arai et al., 
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2000; Nagata, 2000) and protect DNA in human skin fibroblasts from damage by UV light 
(Iovine et al., 2011). 
It has commonly been assumed that genistein has direct antioxidant activities 
because of its ability to donate protons from its hydroxyl groups to oxidized substrates 
within the cell (Pietta, 2000; Rimbach et al., 2003; Rimbach et al., 2004; Kruk et al., 2005). 
However, genistein can also reduce oxidative stress indirectly by enhancing the expression 
and activity of antioxidant enzymes. The expression and/or the activities of several 
enzymes including superoxide dismutase (SOD) (Ho et al., 2003; Borra´s et al., 2006; Park 
et al., 2010) catalase (Park et al., 2010; Georgetti et al., 2013), glutathione peroxidase 
(GPX) (Hernandez-Montes et al., 2006; Georgetti et al., 2013) and quinone oxidoreductase 
1 (NQO1) (Wiegand et al., 2009), were seen to be increased by genistein in both in vivo 
and in vitro studies.  
Genistein may also improve cellular defence against oxidative stress via 
stimulating the expression of metallothionein (MT). it should be noted that MT is a protein 
that chelates metal ions and is responsible for the storage of heavy metals within the cell 
and thus protection from the hazardous effects of metal ion-related free-radical 
generation and toxicity (Perron and Brumaghim, 2009).  
In contrast, however, there are some concerns that dietary flavonoids including 
genistein may under some conditions have pro-oxidant effects (Halliwell, 2008). For 
example, a high dose of genistein (200 µM) was found to induce reactive oxygen species 
formation in primary pig muscle cells (Chen et al., 2014). 
1.1.2.6.3. Other effects of genistein 
In addition to anti-cancer and anti-oxidant activities, genistein has been reported 
to have several other health beneficial effects. For instance, multiple lines of evidence 
support the view that genistein can increase bone density and osteogenesis, especially in 
individuals who are at high-risk of osteoporosis including postmenopausal women and 
elderly people (Setchell and Lydeking-Olsen, 2003). Additionally, a cohort study showed 
that the incidence of bone fracture was low among Chinese postmenopausal women who 
consumed more than 38 mg of soya isoflavone per a day (Zhang et al., 2005). Another 
likely beneficial effect of genistein relates to inhibition of angiogenesis, particularly in 
cancer, via decreasing expression of vascular endothelial growth factor receptors(VEGFR) 
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and epidermal growth factor receptors (EGFR) (Wang et al., 2011; Yu et al., 2012).  
Genistein may also act as an antihypertensive agent by improving the vascular endothelial 
nitric oxide (NO) level as a consequence of upregulating the expression level of endothelial 
nitric oxide synthase (eNOS), which is involved in the synthesis of nitric oxide (Si and Liu, 
2008). Genistein can also have an anti-diabetic action. Dietary genistein (0.02% w/w) 
supplementation in the C57BL/KsJ-bd/bd mouse, which is a model of type 2 diabetes, was 
found to result in an improved metabolic profile including lower blood glucose, improved 
glucose tolerance, and reduced plasma total cholesterol, triglyceride and free fatty acids 
(Ae Park et al., 2006). 
1.1.2.7. Adverse effects of genistein 
There are controversial reports of possible adverse effects of genistein, especially 
on the reproductive system. High consumption of genistein could possibly be associated 
with infertility and reproductive disorders as a consequence of structural and functional 
similarity with 17β-estradiol. In female mice, for example, genistein was found to increase 
uterine weight and led to follicular ovarys and irregular estrous cycle though without any 
effects on fertility (Cimafranca et al., 2010). However, perinatal exposure of female rats 
with genistein led to fertility abnormalities (Nagaoa et al., 2001). There are also conflicting 
data about effects of genistein on the male reproductive system. For example, antenatal 
and postnatal genistein exposure in rodents had no adverse effects on the male 
reproductive system including sperm quality and testicular size (Nagaoa et al., 2001; 
Fieldena et al., 2003). In contrast, other studies found that genistein consumption in the 
same species was associated with a reduction in testicular size, spermatogenesis and 
urogenital abnormalities (Atanassova et al., 2000; Wisniewski et al., 2003).   
With respect to actions on other systems, there is a large body of conflicting data 
concerning genistein toxicity, and results from in-vivo compared with in-vitro studies 
seem particularly discordant. In vitro, it was found that genistein had genotoxic effects 
and promoted micronucleus formation in several cell lines including Chinese hamster V79 
cells, human lymphoblastoid cells, and human blood lymphocytes (Morris et al., 1998; 
Kulling et al., 1999; Virgilio et al., 2004). Conversely, in female Wistar rats genistein had 
potent antigenotoxic effects against a polycyclic aromatic hydrocarbon, 
dimethylbenz[a]anthracene (DMBA), which included impeding micronucleus formation 
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and preventing chromosome aberrations (Pugalendhi et al., 2009). Also it was 
demonstrated that genistein had no mutagenic or clastogenic effects in mice and rats 
when treated with 20 mg or 2000 mg genistein per kilogram body weight for 14 days 
(McClain et al., 2006). Similarly, in humans oral administration of 300 mg to 600 mg of 
genistein per day for 84 days had no measured genotoxic effects (Miltyk et al., 2003), and 
it was concluded that subchronic and chronic exposure to genistein (50, 150, 500 mg/kg 
per day for 4-52 weeks) did not result in any systemic toxicity in dogs (McClain et al., 
2005).   
1.1.2.8. Proposed mechanisms of action of genistein 
Genistein appears to have pleiotropic cellular actions thus it is difficult to attribute 
physiological effects to specific actions at the molecular level. However, there is good 
evidence that genistein can act as an estrogen receptor (ER) ligand. Lower concentrations 
of genistein (up to 3.7 µM) appear to have estrogen-like effects (Chen and Donovan, 2004; 
Magee and Rowland, 2004) in different cell models including MCF-7 (breast cancer) cell, 
HeLa (human cervical epithelial cells), Caco-2 (human intestinal) cell, KS483 (murine 
preosteoblastic) cells and mouse bone marrow cells (Maggiolini et al., 2001; Dang et al., 
2003; Chen and Donovan, 2004). Effects of genistein mediated through its action as an ER 
ligand depends on the ERα/ERβ ratio. In cells with a high ERα/ERβ ratio genistein appears 
to stimulate proliferation and inhibit apoptosis, while in cells where this ratio is low 
genistein seems to induce cell cycle arrest and stimulate apoptosis (Pons et al., 2014). The 
action of genistein at higher concentrations appears to be via other cellular pathways 
(Dang et al., 2003). Actions measured at higher concentrations include inhibition of 
tyrosine kinase and topoisomerase activities (Salti et al., 2000; Chen and Donovan, 2004; 
Kasai and Kikuchi, 2010). Additionally, genistein was found to reduce expression of 
topoisomerase II in HeLa cells (Zhou et al., 2009). Genistein could thus induce cell cycle 
arrest and promote apoptosis via inhibition of tyrosine kinase and/or topoisomerase 
(Schmidt et al., 2008). Likewise, this function of genistein can be maintained through 
decreasing the expression of cell cycle regulatory factors, including cyclin D, and 
increasing accumulation of cyclin B (P62) protein at G2/M, which is an important indicator 
of cell cycle arrest (Cappelletti et al., 2000; Hewitt and Singletary, 2003; Chen and 
Donovan, 2004).  
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Genistein may also act as a ligand for transcription factors including PPARγ (Dang 
et al., 2003) and PPARα (Kim et al., 2004). Genistein also can directly inhibit the function 
of GLUT4 and GLUT1 transporters, which are involved in the transport of dehydroascorbic 
acid, glucose, methylglucose and deoxyglucose across the cellular membranes (Vera et 
al., 1996; Bazuine et al., 2005; Chou et al., 2010).  
Genistein has additionally been shown to have epigenetic actions including effects 
on DNA methylation and histone modification. Some of these actions may be through 
decreasing the expression of DNMT enzymes; genistein (50-100 µM) decreased DNMT 
expression and activity in a dose and time dependent manner in MCF10AT, MCF-7 and 
MDA-MB-213 cells (Li et al., 2009; Zhang et al., 2013a; Xie et al., 2014). Further, genistein 
was also found to increase the expression level of histone deacetylase enzymes (Zhang et 
al., 2013a). 
Additionally, genistein can act as a potent antioxidant, as discussed in section 
1.1.2.6.2, providing another possible mode of action through which genistein could 
prevent cellular and DNA damage. In summary, many molecular actions of genistein have 
been demonstrated most of which actions may underline some of the physiological 
manifestations of genistein consumption. However, further research in this area is 
merited to attribute unequivocally specific beneficial outcomes to particular molecular 
actions.   
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1.1.3. Resveratrol  
Like genistein, resveratrol is a dietary polyphenol. However, resveratrol (3,5,4 
trihydroxystilbene) belongs to the stilbene group (Tsao, 2010; Yang and Xiao, 2013). Again, 
similar to genistein, resveratrol has been described as a phytoestrogen because of its 
structural similarities with 17β-estradiol. It appears that resveratrol can act on the ER as 
either an agonist and/or antagonist (Bhat et al., 2001). Observed biological effects of 
resveratrol include epigenetic actions some of which are likely to be attributable to 
altering the S-adenosylmethionine to S-adenosylhomocysteine ratio or activating 
enzymes that catalyse DNA methylation (DNMTs) and histone modification (Sirt1) (Park et 
al., 2012a). Resveratrol also has been found to affect the expression of genes involved in 
the modification of lifespan including Sirt-1, Sirt-3, Sirt-4 and Forkhead box O genes 
(FOXO1, FOXO3a) (Das et al., 2011). Other observed actions to reduce features associated 
with aging include improved aortic elasticity and reduced inflammation and vascular 
endothelial damage (Pearson et al., 2008). 
1.1.3.1. Structure of resveratrol  
Resveratrol exists as cis and trans-resveratrol isomers (Anisimova et al., 2011). 
Trans-resveratrol is sensitive to UV light irradiation, which causes its conversion to cis-
resveratrol (Frémont, 2000). Most studies of biological action have been on tans-
resveratrol, which is biologically active whose form is most easily available commercially 
(Pervaiz, 2003). Plant tissues contain resveratrol in glycosylated and methylated forms in 
addition to the parent compound (Bavaresco et al., 2002; Regev-Shoshani et al., 2003; 
Moreno-Labanda et al., 2004). The chemical structures of resveratrol are shown in Figure 
3. 
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Figure 1. 3: The chemical structures of parental resveratrol comprising trans and cis resveratrol, 
methylated resveratrol and resveratrol glycone found in plant tissue. 
1.1.3.2. Sources of resveratrol in the diet 
Resveratrol is present in both edible and non-edible parts of some plants. The 
concentration of resveratrol in plant parts depends on various environmental stress 
factors including infection and ultra violet light exposure (Soleas et al., 1997; Stervbo et 
al., 2007). Resveratrol accumulates at high concentrations in red grape skin, and 
consequently it is relatively abundant in red wine (Wilfred, 2006). Resveratrol 
concentration in wine ranges between 0.1 and 15 mg for trans-resveratrol and 0.1 and 29 
mg for tans-resveratrol-glucoside per litre (Frémont, 2000; Baptista et al., 2001; Moreno-
Labanda et al., 2004; Mark et al., 2005). Other sources of resveratrol include peanut 
(Sobolev and Cole, 1999; Sanders et al., 2000; Chen et al., 2002; Akhtar et al., 2013) and 
the root of Japanese knotweed (Polygonum cuspidatum) which is a medical plant used 
particularly in Japan and China to treat conditions including cough and hypertension 
(Vastano et al., 2000). The concentration of trans-resveratrol in the edible parts of the 
peanut ranges between 0.02 and 7.8 µg per gram (Sales and Resurreccion, 2013) while 
the content per gram of polygonum cuspidatum root was measured to be 1653 µg of 
glycosylated trans-resveratrol and 523 µg of trans-resveratrol (Sales and Resurreccion, 
2013). Resveratrol is present also in other plant products including grape berries, 
blueberries and bilberries (Lyons et al., 2003; Wang et al., 2013a) as well as pistachio nuts 
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(Sales and Resurreccion, 2013). It has been suggested that genetically modified organisms 
including bacteria, yeast and some plants can also provide a dietary source of resveratrol 
at sufficient concentrations to improve health (Jeandet et al., 2012). 
1.1.2.3. Resveratrol absorption, metabolism and excretion 
Routes for absorption, metabolism and secretion of resveratrol are very similar to 
those of genistein. Like genistein, the aglycosylated form of resveratrol is much more 
readily absorbed than glycosylated resveratrol (Meng et al., 2004) because relatively non 
polar (lipid soluble) aglycone can be absorbed passively by the intestinal epithelial cells 
(Yongmei et al., 2003; Velderrain-Rodriguez et al., 2014). Whereas glycosylated 
resveratrol undergoes deglycosylation by intestinal and bacterial β-glycosydase enzymes, 
it also appears to be absorbed through the sodium/glucose co-transporter-1 (SGLT1) 
(Sales and Resurreccion, 2013). Most resveratrol absorbed is conjugated with glucuronic 
acid and sulphate within the enterocytes and liver (Goldberg et al., 2003; Kaldas et al., 
2003; Walle, 2011; Teng et al., 2012). As a result of these post-absorption modifications 
only a trace of untransformed resveratrol can be measured in the blood (Goldberg et al., 
2003; Walle, 2011). Conjugated resveratrol may act as a pool to provide an active form of 
resveratrol to cells after deconjugation by tissue glucuronidase and sulfatase enzymes 
(Walle, 2011; Patel et al., 2013). Albumin and lipoproteins are important carrier molecules 
through which resveratrol may be delivered to cells thereby increase the half-life (Jannin 
et al., 2004). The half-life of resveratrol within the plasma was estimated to be about 7-
14 h (Walle et al., 2004). Primary routes of resveratrol excretion are through urine and 
bile (Walle et al., 2004). Like genistein, resveratrol excreted into the intestinal lumen in 
bile can be reabsorbed through the entero-hepatic circulation, which is thus an important 
route through which resveratrol is bioavailable (Marier et al., 2002; Walle et al., 2004) . 
1.1.2.4. Resveratrol bioavailability 
The rapid metabolism of resveratrol by liver and intestinal cells means that only 
traces of trans-resveratrol are found in the blood, hence it is essential to evaluate 
potential health benefits of resveratrol through in vivo studies (Asensi et al., 2002) as well 
as in vitro (where an advantage may be that specific molecular mechanisms are more 
tractable to perturbation and analysis). Two independent studies in human volunteers 
16 
 
revealed that absorption of parent molecule is relatively high while its bioavailability is 
very low as a result of its rapid metabolism (Goldberg et al., 2003; Walle et al., 2004). 
Furthermore, maximum concentrations reached appear to vary between different tissues. 
The highest concentrations have been measured in intestinal epithelial cells, stomach, 
liver, kidney and cardiac cells, whereas the lowest concentrations were reported in brain 
and testis (Vitrac et al., 2003; Wang et al., 2008a; Liang et al., 2013; Velderrain-Rodriguez 
et al., 2014). 
Studies in animals showed that after intravenous injection of 20 mg of trans-
resveratrol in the rabbit, the plasma concentration of resveratrol peaked (38.4-47.2 µM) 
within 5 minutes followed by a sharp reduction (0.7-1.1 µM) within an hour. The same 
pattern was observed in mouse and  rat (Asensi et al., 2002). A study in human, rat and 
mouse showed that resveratrol (glycone and aglycone) was rapidly metabolised into 
glucuronated and sulphated forms, especially within the intestinal cells, after oral 
administration (Meng et al., 2004). Lipid nanoparticle technology has been developed 
with a view to increase resveratrol bioavailability and could potentially augment the likely 
health benefits of resveratrol consumption (Neves et al., 2013),  
1.1.2.5. Health benefits of resveratrol 
Like genistein, resveratrol has been the subject of substantial body of research 
aimed to determine if dietary consumption can deliver health benefits leading to claims 
that resveratrol may protect against conditions including cancer, oxidative stress and 
obesity. A critical overview of the research on this topic is provided below. 
1.1.2.5.1. Anticancer effects of resveratrol 
Like genistein, there has been extensive focus on the potential anti-cancer effects 
of resveratrol. Several studies have indicated that resveratrol may affect different stages 
of carcinogenesis including initiation, promotion and propagation (Sales and 
Resurreccion, 2013) by suppressing growth, proliferation, and inducing apoptotic 
pathways. These effects have been observed in a variety of different cancer cell types 
(Aggarwal et al., 2004; Khan et al., 2010; Lin et al., 2012a) including prostate  (Harper et 
al., 2007; Seeni, 2009; Wang et al., 2010b; Sheth et al., 2012), breast cancer (Lee et al., 
2012b; Díaz-Chávez et al., 2013), gastric cancer (Yang et al., 2013) and some others 
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(Aggarwal et al., 2004). Moreover, resveratrol (5 µM) inhibited the growth of B16 
melanoma cells which is a highly invasive murine tumor cell model (Asensi et al., 2002).   
There are several suggested mechanisms and pathways through which resveratrol 
may exercise anti-cancer activities. For example, resveratrol was demonstrated to 
interfere with tumor initiation via activation of the P53 pathway which is an important 
check point in detecting DNA damage before cells undergo further proliferation (Chow et 
al., 2010). Resveratrol was also shown to reduce the expression and activity of telomerase 
(hTLMA), specifically in cancer cells, by affecting the human telomerase reverse 
transcriptase (hTERT) subunit of the telomerase complex (Lanzilli et al., 2006). Moreover, 
resveratrol, like genistein, was found to reduce matrix metalloproteinase-9 (MMP9) 
expression and activity in BALB/C mouse and 4T1 cells, suggesting that it may also protect 
against tumor invasion and metastasis through stabilising cell to cell contacts (Lee et al., 
2012b). Other studies show that cancer protective effects of resveratrol may be mediated 
through up-regulation of microRNAs that target oncogenic genes (Tili et al., 2010; Qin et 
al., 2014). Resveratrol may also affect cancer cell properties through altering the DNA 
methylation status of cancer related genes, such as RASSF-1α (Zhu et al., 2012), which 
belongs to the RAS associated domain family and is potentially involved in tumor 
suppression (Clark et al., 2012).  
1.1.2.5.2. Antioxidant effects of resveratrol 
Like genistein, resveratrol is also a dietary agent with antioxidant activities that appear 
to be both direct and indirect in relation to ameliorating oxidative damage. The direct 
action of resveratrol as an anti-oxidant is by virtue of the free hydroxyl groups on its 
phenolic backbone and consistent with these predicted chemical properties resveratrol 
has been shown to act as a free radical scavenger (Murias et al., 2005; Hoshino et al., 
2010). Resveratrol can also stimulate the activity (Lee et al., 2003) and the expression of 
anti-oxidant enzymes including glutathione peroxidase, catalase, hemeoxidase-1 and 
superoxide dismutase (Ungvari et al., 2007; Bujanda et al., 2008). Investigators 
demonstrated that resveratrol could protect primary coronary arterial endothelial cells 
from oxidative damage induced by UV-light and H2O2 (Ungvari et al., 2007). Additionally, 
resveratrol decreased oxidative damage in HUVEC cell exposed to H2O2. However, pro-
oxidant actions including induction of free radical formation has also been measured and 
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found to be time, dose and cellular condition dependant. For example, malignant cells are 
more susceptible to be affected by the pro-oxidant effects of resveratrol than normal cells 
(Heiss et al., 2007; Sun et al., 2010). 
1.1.2.5.3. Resveratrol and lifespan 
A body of work has shown positive effects of resveratrol on lifespan particularly in 
model organisms including S. cerevisiae (Howitz et al., 2003), C. elegans, the fruit fly 
(Drosophila melanogaster) (Wood et al., 2004), fish (Nothobranchius furzeri) (Valenzano 
and Cellerino, 2006; Valenzano et al., 2006) and mice (Baur et al., 2006). However, there 
are inconsistencies between studies. For example, mice fed a high-fat diet, which reduced 
lifespan, lived as long as mice which consumed a normal diet when the diet was 
supplemented with resveratrol while resveratrol did not affect the lifespan of those mice 
which fed a normal diet (Baur et al., 2006). Resveratrol has been reported to reduce 
features of aging such as aortic elasticity, inflammation and vascular endothelial damage 
(Pearson et al., 2008). 
A possible explanation for the ability of resveratrol to extend lifespan in some 
systems is through the activation of the NAD-dependent histone deacetylase enzyme Sirt1 
(Cherniack, 2010; Tollefsbol, 2010; Vetterli and Maechler, 2011). In respect to this activity, 
resveratrol may mimic some of the effects of dietary restriction, in which Sirt1 has a likely 
role (Guarente, 2013). However, this view has become the subject of vigorous challenge 
because of questions about whether resveratrol is a direct activator of Sirt1 or else its 
positive activations are a consequence of other beneficial effects of resveratrol 
(Kaeberlein et al., 2005; Park et al., 2012b). In addition, resveratrol has been reported to 
regulate the expression and activity of other age related genes including SIRT3, SIRT4 
Forkhead box O (FOXO1, FOXO3a) and Pre-B cell colony enhancing factor (PBEF) (Das et 
al., 2011). 
1.1.2.5.4. Other effects of resveratrol 
In addition to anti-cancer, anti-oxidant activities and actions to extend life span 
several other beneficial effects of resveratrol that are consistent with the ability to 
promote health or extend life span have been documented.  For example, resveratrol may 
stimulate mitochondrial biogenesis (Csiszar et al., 2009) and activity, mostly as a result of 
inducing PGC1α activity via activation of Sirt1 (Lagouge et al., 2006). Another effect of 
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resveratrol relates to anti-diabetic actions. It was reported that resveratrol can have 
insulin-like effects by reducing blood glucose (hypogycemic) and lipid (hypolipidemic) in 
streptozotocin-induced diabetic rats (Su et al., 2006; Thirunavukkarasu et al., 2007). 
Moreover, resveratrol appears to protect the vascular system through increasing the 
expression of the endothelial nitric oxide synthase (eNOS), which is responsible for 
protecting vascular integrity, in a dose and time dependent manner, as shown in human 
umbilical vein endothelial cells (HUVEC) (Wallerath et al., 2002). Resveratrol has also been 
reported to protect against neurodegenerative diseases including Alzheimer`s  and 
Parkinson`s diseases (Sun et al., 2010). Other reported actions include prevention of 
platelet aggregation, thrombosis (Delmas et al., 2005) and inflammation (González et al., 
2011). 
1.1.2.6. Proposed mechanism of action of resveratrol 
Of particular relevance to the current work, a significant body of knowledge is 
accumulating regarding diverse actions of resveratrol on lipogenesis. It is widely accepted 
that resveratrol  can reduce the expression of peroxisome proliferator-activated receptor-
γ (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), which are the vital 
transcription factors for the initiation and maintenance of the process of lipogenesis by 
virtue of their roles in regulating the expression of lipogenic enzymes including fatty acid 
synthase, adipocyte protein-2 and lipoprotein lipase (Zhang et al., 2012). Resveratrol may 
also affect lipogenesis and lipid catabolism by mediating mitochondrial biogenesis and 
function via activation of PGC1α by Sirt1. The stimulatory effects of resveratrol on Sirt1 
were demonstrated in both cell (3T3-L1) and animal (male FVB/N mouse) models by 
looking at the PGC1α acetylation status (Lin et al., 2002; Fischer-Posovszky et al., 2010; 
Lasa et al., 2012).  
Other proposed mechanisms of action of resveratrol on lipogenesis relate to its 
inhibitory effects on the insulin signalling pathway. There is evidence that resveratrol can 
interact directly with and thus inhibit the insulin receptor, based on work in 3T3-L1 cells 
(Kwon et al., 2012). In the human hepatoma cell model (HepG2), resveratrol also has been 
reported to inhibit acetyl Co-A carboxylase activity, which is a key enzyme in the process 
of lipogenesis, through activation of the AMPK signalling pathway, (Zang et al., 2006). In 
addition, resveratrol was demonstrated to inhibit SREBP1c via the Sirt1/FOXO1 signalling 
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pathway, which was followed by a reduction in lipid biogenesis and accumulation in 
HepG2 cells and male Wistar rats (Bujanda et al., 2008; Wang et al., 2009).  
1.2. Adipose tissue physiology 
Obesity involves an increase in the mass of adipose tissue as a result of an increase 
in the level of fat accumulation within the cytoplasm of pre-existing adipocyte cells 
(adipocyte hypertrophy) and/or differentiation of new undifferentiated cells into 
adipocytes (adipocyte hyperplasia) (Ali et al., 2013). This process may include the 
synthesis and storage of ectopic fat within the cells of vital organs including the liver, 
which leads to impairment of their physiological performance (Morino et al., 2008). 
Obesity is one of the major health issues worldwide, and is associated with cardiovascular 
disease, type-2 diabetes (Poirier et al., 2006), decreased life expectancy (Blüher et al., 
2003) and increased risk of cancer (Sorisky, 1999). The occurrence of obesity has increased 
over time due to multiple lifestyle and demographic factors, and it has been predicted 
that about 58% of the world`s population will be obese by 2030 (Kelly et al., 2008). Obesity 
is considered one of the main causes of death throughout the world and has been 
estimated to account for around 2.8 million deaths a year (Sorisky, 1999; WHO, 2012). 
Figure 4 
 
Figure 1. 4: Obesity is a dynamic process and it can be affected by life style and diet. It results from 
adipocyte hyperplasia and hypertrophy. It is also associated with an increase in the risk of cardiovascular 
disease (CVD), diabetes, cancer, and decreases life expectancy.  
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1.2.1. Adipocyte tissue phenotype and biochemistry 
The two principal adipocyte phenotypes are white and brown adipocytes. These 
cells are distinct from each other morphologically and functionally. White adipocytes are 
involved in the process of lipogenesis and storage of fat while brown adipocytes have a 
role in thermoregulation and convert the proton electro chemical gradient of the 
mitochondrion into heat rather than ATP. The presence of brown adipocyte tissue is 
associated with lower risk of obesity and its related disorders.  
1.2.1.1. White adipose tissue 
White adipocytes synthesize and store fat in the form of triglycerides, and release 
it as a source of energy as required (Lafontan, 2005) depending on nutritional status. 
When energy  availability is high, white adipocytes store energy in the form of triglycerides 
and release it in the form of free fatty acids during periods of energy deprivation (Sorisky, 
1999). Initially white adipocyte tissue was considered to be primarily a passive repository 
for energy storage. However, with greater knowledge about the biochemistry of white 
adipose tissue has come the realisation that white adipocytes are highly active and 
responsive (Kim and Moustaid-Moussa, 2000), and actively communicate with other cells 
by receiving, synthesizing and sending biological signals in the form of biologically active 
peptides and proteins which are known as adipokines. Through adipokines, adipocytes 
play important roles in integrating and regulating the overall physiological and metabolic 
activity of adipose tissue and other organs (Frühbeck et al., 2001; Ali et al., 2013). The role 
of white adipose tissue in energy homeostasis is shown in Figure 5. 
By serving as a specific repository for excess lipid white adipose tissue can be 
considered to have protective functions in terms of controlling  lipotoxic damage 
stemming from high levels of circulating non-esterified fatty acids (NEFAs) (Unger, 2003) 
and decreasing ectopic fat accumulation (Boden et al., 2005; Morino et al., 2008). 
Consequently, these functions reduce inflammatory responses in metabolically active 
tissues including muscle, liver and brain (Szabo et al., 2005; Reyna et al., 2008; Wang et 
al., 2008c; Youssef-Elabd et al., 2012; Piya et al., 2013). Ectopic lipid biosynthesis and 
storage is associated with the development of several metabolic disorders, in particular 
diabetes mellitus type-2, non-alcoholic fatty liver disease and cardiovascular disease 
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(Anderson et al., 2003; Trujillo and Scherer, 2005; Kadowaki et al., 2006; Poirier et al., 
2006; Morino et al., 2008).  
 
Figure 1. 5: the role of white adipose tissue in energy homeostasis. White adipocytes synthesize and store 
fat in the form of triglycerides and release it as a source of energy as required. The released lipid is 
transported in the blood as free fatty acids or by lipid carriers including albumin and/or lipoproteins. 
Adipokines, which are synthesised by white adipose tissue, have regulatory effects on the overall 
physiological and metabolic activity of adipose tissue and other organs. 
1.2.1.1.1. White adipocyte differentiation 
Adipogenesis is the process through which preadipocytes differentiate into 
mature adipocytes (Rosen and Spiegelman, 2000). It is a dynamic process (Spalding et al., 
2008; Ali et al., 2013) affected by factors including  the level of fat accumulation within 
cells (DiGirolamo et al., 1998; Cinti et al., 2005), stage of pregnancy,  breast feeding and 
medication (Prins et al., 1997; Morroni et al., 2004). 
Lipogenesis is a well-coordinated processes and is tightly regulated by co-
operative interactions between several transcription factors including C/EBPs, PPARs 
(which belong to the ligand dependent nuclear hormone receptor superfamily) (Yeh et al., 
1995; Mandrup and Lane, 1997; Brey et al., 2009; Ali et al., 2013) and SREBPs (a family of 
membrane bound transcription factors) (Shao and Espenshade, 2012). Actions of 
CCAAT/enhancer-binding proteins β/δ (C/EBPβ/δ) coordinate early stages of  adipocyte 
differentiation (Cornelius et al., 1994), which is followed by up-regulation of C/EBPα and 
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PPARγ. Increased C/EBPα and PPARγ activity induces adipogenic genes leading to fat 
synthesis and accumulation within the cells (Rosen et al., 2002; Farmer, 2006).  
In general, C/EBPα and  PPARγ are considered the principle transactivators of 
lipogenesis-related genes (Sorisky, 1999; Tang and Lane, 1999; Rosen et al., 2002), and 
their expression is considered essential for the induction of white adipocyte 
differentiation and lipogenesis (Tang and Lane, 1999; Linhart et al., 2001; Koutnikova et 
al., 2003; Farmer, 2006; Lefterova and Lazar, 2009).  
1.2.1.1.2. Genes that characterise white adipocytes 
Numerous genes coding for enzymes and other proteins including adipokines with 
key roles in lipid metabolism are expressed selectively in white adipocytes and thus can 
be used as functional markers of this cell phenotype.  Those of particular relevance to the 
current study are fatty acid synthase (FAS), acetyl Co-A carboxylase (ACC), adipocyte 
protein 2 (AP2), hormone sensitive lipase (HSL), chemerin and resistin. 
1.2.1.1.2.1. ACC and FAS 
Acetyl co-A carboxylase (ACC) and fatty acid synthase (FAS) are the key and rate-
limiting enzymes in the process of fatty acid biosynthesis and lipogenesis. Acetyl Co-A 
carboxylase (ACC) catalyses the carboxylation of acetyl Co-A to malonyl Co-A, then fatty 
acid synthase (FAS) catalyses palmitate generation from malonal Co-A and acetyl Co-A as 
shown in Figure 6. The expression of both enzymes is highly upregulated at the early 
stages of lipogenesis and thus can be used as a cellular marker for commitment to the 
process of differentiation of precursor cells into white adipocytes (Hellerstein et al., 1996; 
Ameer et al., 2014).  
 
Figure 1. 6: The role of Acetyl Co-A carboxylase (ACC) and fatty acid synthase (FAS) in fatty acid synthesis.  
ACC catalyses the conversion of acetyl Co-A into malonyl Co-A, then FAS converts malonyl Co-A into 
palmitate. 
Fatty acid synthase (approximately 260 kDa molecular weight) is a multifunctional 
cytosolic enzyme, encoded by a gene (FASN) located on the long arm of human 
24 
 
chromosome 17 (Jayakumar et al., 1994; Shah et al., 2006). There are two human ACC 
genes: ACACA, which is co-localised on the same chromosome as FAS, and ACACB, located 
on chromosome 12. They encode ACC-α (265 kDa) and ACC-β (280 kDa) respectively 
(Barber et al., 2005). In contrast to ACC-α, which is a cytosolic enzyme and involved in the 
process of lipogenesis, ACC-β is a mitochondrial enzyme and opposes mitochondrial β-
oxidation by generating mitochondrial malonyl Co-A (Postic and Girard, 2008). 
Regulation of these enzymes occurs at different levels. However, transcriptional 
regulation seems to be the predominant cellular mechanism through which cells control 
the long-term activities of these enzymes (Sul and Wang, 1998), and  can be influenced by 
several factors including substrate availability, hormonal factors and developmental stage 
(Hillgartner et al., 1995; Sul and Wang, 1998). Transcription of both genes is under the 
control of lipogenesis-related transcription factors including SREBP1c, ChREBP, C/EBPα 
and PPARγ. Thus, any change in the expression and/or activities of these transcription 
factors affect the process of lipogenesis through modulating the expression of these key 
enzymes (Wu et al., 1999; Lefterova et al., 2008; Postic and Girard, 2008). Pharmacological 
inhibition of fatty acid synthase was found to be associated with a reduction in both food 
intake and marked loss of body weight in the mouse, whereas administration of an ACC 
inhibitor decreased fatty acid synthesis but did not affect these other variables (Loftus et 
al., 2000).  Dysregulation of the expression and activity of these enzymes may be 
associated with pathological conditions including breast cancer; inhibition of FAS was 
found to be effective in reducing proliferation of cancer cells in rats and mice (Puig et al., 
2009). 
1.2.1.1.2.2. AP2 and HSL 
Hormone sensitive lipase (HSL) is expressed at the early stages of white adipocyte 
differentiation during growth arrest of preadipocyte cells while adipocyte protein 2 (AP2) 
is expressed predominantly at the terminal stages of differentiation. AP2 and HSL have 
thus been recognised as markers of maturing preadipocytes (Spiegelman and Green, 
1980; Amri et al., 1991; Sorisky, 1999). However, AP2 was shown to be expressed at a low 
level in adipocyte progenitor cells (Shan et al., 2013). 
 HSL is a cytosolic lipase enzyme and appears to be the key enzyme in the process 
of lipolysis (Yeaman, 2004; Arner and Langin, 2007). It is involved in fatty acylglycerol 
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hydrolysis (Thompson et al., 2010). In the human HSL gene (LIPE) is located on 
chromosome 19 (Kraemer and Shen, 2002) and it was found to be expressed at basal 
levels in several tissues including the supra-renal gland, macrophages, muscle cells, testis 
and pancreatic β cells (Khoo et al., 1993; Kraemer et al., 1993; Yeaman, 2004). HSL plays 
crucial roles in lipid biogenesis and enhances lipid accumulation within adipose tissue 
(Sekiya et al., 2004). Deletion of the gene in mice was associated with the development 
of a brown adipocyte phenotype (Osuga et al., 2000) and led to a significant increase in 
the expression level of UCP1 among white adipocyte depots (Ström et al., 2008).  
Adipocyte protein 2 (AP2), also known as fatty acid binding protein 4 (FABP4), 
belongs to the family of intracellular lipid-binding proteins. The human gene (FABP4) is 
located on chromosome 8. AP2 is believed to act as a carrier protein for cytosolic fatty 
acids and it plays a role in lipid accumulation and distribution among cellular 
compartments including mitochondria, peroxisomes and the endoplasmic reticulum 
(Furuhashi and Hotamisligil, 2008; Thompson et al., 2009; Thompson et al., 2010; Scifres 
et al., 2011; Smathers and Petersen, 2011). High levels of circulating AP2 in obese mice 
was associated with obesity-related disorders including type-2 diabetes (Cao et al., 
2013b). However, mice lacking AP2 were protected from type-2 diabetes, non-alcoholic 
fatty liver and atherosclerosis (Hotamisligil, 2006; Furuhashi et al., 2008). Inhibition of AP2 
in mice using the pharmacological agent BMS309403 led to reduced symptoms associated 
with atherosclerosis and diabetes mellitus type-2 (Furuhashi et al., 2007). AP2 expression 
was down-regulated when Sirt1 was over-expressed in 3T3-L1 cells (Picard et al., 2004). 
1.2.1.1.2.3. Chemerin and resistin 
Chemerin and resistin are adipokines of particular relevance to the present study 
and have been used as markers of mature white adipocytes in other studies (Qiang et al., 
2012; Sharp et al., 2012). Expression of both adipokines in brown adipocytes is very low 
(Steppan et al., 2001; Goralski et al., 2007) and appears to be down-regulated upon the 
induction of white to brown adipocyte inter-conversion (Seale et al., 2007; Qiang et al., 
2012). Moreover, a direct correlation between chemerin and resistin expression was 
found in human adipose tissue (Lehrke et al., 2009).  
The gene that encodes chemerin has been named both tazarotene-induced gene-
2 (TIG2) and retinoic acid receptor responder-2 (RARRES2), and is located on human 
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chromosome 7 (Huang et al., 2010). Chemerin interacts with the chemokine-like receptor 
1 (CMKLR1). It is involved in the inflammatory process where it acts as a chemoattractant 
to attract inflammatory cells into the site of injury (Ernst and Sinal, 2010). Chemerin is 
secreted predominantly by adipocytes and its presence seems to be essential in inducing 
adipocyte differentiation as its knockdown by siRNA in 3T3-L1 cells was sufficient to block 
differentiation programs (Goralski et al., 2007). A direct correlation between chemerin 
expression and body weight was observed in obese human subjects compared with lean 
subjects (Roman et al., 2012). The serum level of chemerin was found to be abnormally 
high in obese-diabetic mice and humans (Stejskal et al., 2008; Ernst et al., 2010). Chemerin 
appears to increase the risk of obesity related disorders including insulin resistance in both 
obese human subjects and primary human skeletal muscles (Sell et al., 2009; Roman et 
al., 2012). 
Resistin, or adipocyte secreted factor (ADSF), is related to a group of proteins 
known as resistin-like molecules. The gene (Retn) is located on human chromosome 19 
(Jamaluddin et al., 2012). Expression of resistin correlates with the process of lipogenesis. 
Its knockdown by siRNA in differentiated 3T3-L1 cells ameliorated fatty acid β-oxidation 
and  reduced lipogenesis as a result of down-regulation of carbohydrate responsive 
element binding protein (ChREBP) and its downstream genes (fatty acid synthase and 
acetyl Co-A carboxylase) (Ikeda et al., 2013). High levels of circulating resistin have been 
found to have detrimental effects on the development of cardiovascular diseases, 
diabetes mellitus type-2 and other obesity related disorders (Filková et al., 2009). 
Furthermore, a direct link between resistin and insulin resistance has been established  in 
both humans and rodents (Schwartz and Lazar, 2011).  
1.2.1.2. Brown adipose tissue  
In contrast to white adipose tissue, the presence of brown adipose tissue reduces 
fat storage. Brown adipose tissue functions metabolically to dissipate energy in the form 
of heat (Lowell and Spiegelman, 2000). Brown adipocytes are characterised by having 
small multi-locular fat droplets (Cinti et al., 1997; Ravussin and Galgani, 2011; Lee et al., 
2012c), and the cytoplasm of brown adipocytes is densely packed with mitochondria. The 
mitochondria of brown adipocytes can be distinguished from those of white adipocytes 
by the presence of uncoupling protein-1 (UCP1) which is responsible for dispersing stored 
27 
 
energy as heat by uncoupling ATP synthesis from electron transport (Matthias et al., 2000; 
Cannon and Nedergaard, 2004; Frontini et al., 2007). Absence of or defects in UCP1 
activity in brown adipose tissue have been seen to be associated with obesity, metabolic 
disorders (Nedergaard et al., 2007; Cannon and Nedergaard, 2009) and defective adaptive 
thermogenesis (Golozoubova et al., 2001; Meyer et al., 2010) in humans and mice. 
 The ectopic presence of brown adipocytes in the skeletal muscle of transgenic 
mice protected them against metabolic disorders (Almind et al., 2007). In addition, the 
induction of the expression of genes that are characteristically expressed in brown 
adipocytes in the murine white adipocyte cell line models, 3T3-L1, was demonstrated to 
be associated with a sharp reduction in the expression level of white adipocyte marker 
genes including  Retn (resistin) (Seale et al., 2007), Rarres2 (chemerin) (Qiang et al., 2012) 
and Acaca (acetyl Co-A carboxylase) (Kamiya et al., 2012). It appears that the quantity of 
brown adipose tissue is sex dependent (Rodríguez-Cuenca et al., 2002). Women appeared 
to have more functional brown adipose tissue than men as measured using positron 
emission tomography-computed tomography (PET/CT) (Cohade et al., 2003; Yeung et al., 
2003; Cypess et al., 2009).  
A strategy to prevent obesity and its related disorders may thus be to increase 
brown adipose tissue mass, which could be achieved by stimulate browning of white 
adipocytes or encouraging the differentiation of adipocyte precursor cells along lineage 
with a brown adipocyte phenotype. 
1.2.1.2.1 Classification of brown adipocytes 
Brown adipocytes can be divided into classical brown and beige/brite (brown-in-
white fat) adipocytes. Classical brown and beige adipocytes are distinguished by distinct 
gene expression profiles and their embryological origin (Giralt and Villarroya, 2013). As 
already noted, the basal expression level of UCP1 is particularly high in classical brown 
adipocytes. However, beige adipocytes express UCP1 at high levels only under specific 
conditions, in particular with β-adrenergic stimulation or exposure to a cold (Waldén et 
al., 2011; Harms and Seale, 2013). The unique set of genes expressed in beige adipocytes 
includes CD-137, which can be used to distinguish beige adipocytes from other cells (Sharp 
et al., 2012; Wu et al., 2012).  
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Classical brown adipocytes originate from the same precursor cells as myocytes, 
characterised by the expression of Myf5 which is a myogenic transcription factor 
(Timmons et al., 2007; Seale et al., 2008; Kajimura et al., 2009). In contrast, beige 
adipocytes have the same origin as white adipocytes (Himms-Hagen et al., 2000; 
Granneman et al., 2005; Petrovic et al., 2010; Wu et al., 2012). However, it is not clear 
whether beige adipocytes originate from trans-differentiation of white adipocytes or from 
other undifferentiated cells within white adipose tissue repositories (Rosenwald et al., 
2013; Wang et al., 2013c), as illustrated in Figure 7. 
 
Figure 1. 7: Origins of brown adipocytes. Classical brown adipocytes originate from Myf-5 positive cells, 
Beige adipocytes transdifferentiate from mature or undifferentiated white adipocyte precursor cells. The 
presence of brown adipocytes in body is associated with low body weight, decreases risk of cardiovascular 
disease, diabetes and metabolic disorders, besides increasing adaptive thermogenesis.  
 
1.2.1.2.3. Thermogenesis 
The control of body temperature is achieved largely as a result of cellular 
metabolic activity that generates heat, and adapts to regulate body temperature in 
response to environmental and physiological changes (Mrozek et al., 2012). ATP is the 
main source of energy, which is generated as a result of electron transfer from reduced 
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form of nicotinamide adenine dinucleotide (NADH) or Flavin adenine dinucleotide (FADH) 
to oxygen to generate water through a chain of protein complexes comprising NADH 
oxidoreductase (complex I), succinate-Q reductase (complex II), cytochrome bc1 (complex 
III) and chytochrome c oxidase (complex IV). Ubiquinone (coenzyme Q) and cytochrome c 
shuttle electrons between complex I, complex II, complex III and complex IV. A proton-
gradient is generated within mitochondrial intermembrane space and mitochondrial 
matrix as a result of protons being pumped through complex I, complex III and complex 
IV from the mitochondrial matrix into the intermembrane space as electrons are 
transported. In the absence of UCP1, protons return into the mitochondrial matrix 
through ATP synthase complex, thus driving ATP synthesis (Berg et al., 2002). However, in 
response to a sudden and/or chronic change in the environmental temperature or in 
response to physiological factors such as hormonal stimuli or disease alternative 
thermogenic pathways, including shivering and non-shivering thermogenesis, are 
invoked.  
Shivering thermogenesis is an action of the skeletal muscle (Block, 1994; 
Golozoubova et al., 2001) to maintain body temperature within the physiological range 
by increasing cellular metabolic activity (Meyer et al., 2010; Cannon and Nedergaard, 
2011). However, this response is transient and cannot be sustained for  a long period of 
time due to muscular damage and/or exhaustion (Bal et al., 2012). Non-shivering 
thermogenesis generates heat as a result of proton transport across the inner 
mitochondrial membrane by uncoupling protein-1, thereby dissipating the proton from 
electro-chemical gradient and uncouples mitochondrial electron transport ATP synthesis, 
which leads to energy being released as heat (Golozoubova et al., 2001; Golozoubova et 
al., 2006). This process is shown in Figure 8. 
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Figure 1. 8: Non-shivering thermogenesis. Proton transport across the inner mitochondrial membrane by UCP1 leads to dissipation of the mitochondrial proton electro-chemical 
gradient. The gradient is generated as a result of proton transport from the mitochondrial matrix into the mitochondrial intermembrane space as electron transport occurs through 
complex I, complex III and complex IV. Electron transport is thus uncoupled from ATP synthesis and the energy released as heat.
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1.2.1.2.4 Anatomical distribution of brown adipose tissue 
Human infants almost certainly have relatively large depots of brown adipose 
tissue compared with adults (Gilsanz et al., 2013). The process of shivering thermogenesis 
does not contribute substantially to heat generation in human neonate. Thus, brown 
adipose tissue is particularly important  for maintaining the body temperature (Ravussin 
and Galgani, 2011). It was a longstanding view that the human adult has no brown adipose 
tissue (Barrington and Maisey, 1996; Engel et al., 1996). However, positron emission 
tomography (PET) after administration of flourodeoxyglucose and histological studies 
have more lately found that adult humans can have substantiated depots of brown 
adipose tissue regardless of age (Hany et al., 2002; Yeung et al., 2003; Zingaretti et al., 
2009) mainly distributed in distinct regions including the neck and supraclavicular region, 
with small depots being detected in the mediastinum, paravertebral and perinephric 
regions of the body (Nedergaard et al., 2007; Sacks and Symonds, 2013). It remains 
unclear if these depots found in adult humans are truly brown adipocytes or if they would 
be more accurately described as beige adipocytes (Sharp et al., 2012).  
Brown adipose tissue in rodents is located principally within the axillary, 
interscapular, periaortic and perirenal regions of the body (Lee et al., 2014). 
1.2.1.2.5 Genes that characterises brown adipose tissue  
Brown adipocytes are characterised by expressing a distinct set of genes that are 
involved in the process of differentiation or confer the specialised function of non-
shivering thermogenesis. Additionally, these genes are a useful research tool since they 
can be used to distinguish brown adipocytes from other cell types and to distinguish 
between classical brown and beige adipocytes. The genes that can be used to identify 
brown adipocytes include uncoupling protein-1 (UCP1) and CD-137. 
1.2.1.2.5.1. UCP1 
Uncoupling protein 1 belongs to the UCP superfamily that also in turn includes 
UCP2 and UCP3, which are specific mitochondrial membrane anion transporters. UCP1 is 
the product of a single gene (UCP1), which is located on human and mouse chromosomes 
4 and 8 respectively. The UCP1 gene consists of 8 exons and codes for protein with a 
molecular weight 32-23 kDa across species (Mozo et al., 2005). The promoter and 
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different distal enhancer regions of the UCP1 genes include several putative sites for 
binding of transcription factors that play important roles in adipose cell physiology. These 
include two C/EBP binding sites, a PPRE (peroxisome proliferator activated receptor 
response element), a TRE (thyroid hormone response element), and a RARE (retinoic acid 
response element). Activation at all of these sites appears to be important in the 
transcriptional activation of UCP1 (Yubero et al., 1994; Rim and Kozak, 2002; Cannon and 
Nedergaard, 2004; Karamanlidis et al., 2007). 
Knockout of UCP1 in mice (Kontani et al., 2005; Feldmann et al., 2009) was 
associated with obesity and cold sensitivity. In contrast, only minor deficiencies in non-
shivering thermogenesis were observed in UCP2 and UCP4 knockout mice (Mozo et al., 
2005). Thus, UCP1 appears to be the protein primarily responsible for the induction of 
non-shivering thermogenesis (Golozoubova et al., 2001; Golozoubova et al., 2006). In 
agreement, over expression of UCP1 in an adipocyte-specific transgenic mouse model 
(Kopecky et al., 1996)  was associated with a lean phenotype and protection against high-
fat-diet-induced obesity with improved blood lipid profile (Rossmeisl et al., 2005). 
Similarly, ectopic expression of UCP1 in the liver of a dietary-induced mouse model of 
obesity was associated with reduced body weight and reduction in obesity-related 
disorders including hyperphagia and insulin resistance. In addition, the activity of the key 
lipogenic enzyme acetyl Co-A carboxylase was reduced (Ishigaki et al., 2005). Consistent 
with these  in vivo studies overexpression of UCP1 in 3T3-L1 cells reduced lipid content 
and affected lipid distribution such that fat droplets had the paucilocular appearance that 
is the characteristic of brown adipocytes (Si et al., 2007). 
UCP1 activity has been found to be affected by factors including nutritional status 
specific diet components and genetic background. Palmitate and retinoic acid were found 
to activate and induce UCP1-dependent thermogenesis in both primary mouse brown 
adipocytes and mitochondria from rat brown adipose tissue (Shabalina et al., 2008; 
Divakaruni et al., 2012). Ephedrine and caffeine also stimulated expression of UCP1 in 
both brown and white adipose tissue depots of obese human subjects (De Matteis et al., 
2002). A single nucleotide polymorphism (SNP) at the transcriptional start site of the 
human UCP1 gene was found to reduce UCP1 expression (Esterbauer et al., 1998; Rose et 
al., 2011). Furthermore, carriers of this SNP had a reduced response to dietary induced 
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thermogenesis compared with non-carriers (Nagai et al., 2003) and were more susceptible 
to obesity (Sramkova et al., 2007).  
1.2.1.2.5.2. CD-137 
CD-137 is a member of the tumor necrotic factor receptor family (alternatively 
known as TNFRSF9). It plays important roles in the regulation of cellular mediated 
immunity (Melero et al., 2008) and has recently been discovered to be selectively 
expressed in beige rather than classical brown adipocytes (Wu et al., 2012; Fu et al., 2014). 
The expression of CD-137 led to the classification of some brown adipocyte depots 
including human epicardial and visceral paracardial fat depots as beige rather than 
classical brown adipose tissue (Sacks et al., 2013). 
1.2.1.2.6. Mediators of brown adipocyte differentiation 
Several enzymes and transcription factors including Sirt1, C/EBPβ and PGC1α, 
appear to be involved in the process of white to brown interconversion in response to 
environmental and physiological stimuli. These factors have been defined as mediators of 
white to brown adipocyte transdifferentiation. However, the contribution of these factors 
in this process is complex and likely to be affected by several other cellular and molecular 
factors.  
1.2.1.2.6.1. Sirt1  
Sirt1 is an enzyme that modifies proteins by NAD-dependent lysine deacetylation 
and it is well-preserved among species. Mammalian cells express seven functionally 
distinct sirtuins, Sirt1 to Sirt7. Sirt1, which is a mammalian homolog of yeast Sirt2, is 
involved in several vital processes including inflammatory and metabolic pathways 
(Revollo and Li, 2013; Davenport et al., 2014). Sirt1, yeast Sirt2 and homologes in other 
species have been proposed as mediators of the lifespan extension observed in response 
to dietary restriction. Sirt1 expression was decreased with age in the liver of old mice (Jin 
et al., 2011) and life expectancy was improved upon its activation (Mitchell et al., 2014). 
In addition, pharmacological activation of Sirt1 was reported to have several health-
beneficial actions including improvement in the blood lipid profile and amelioration non-
alcoholic fatty liver (Mitchell et al., 2014) and diabetes (Qiao and Shao, 2006).  
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Sirt1 expression and activity have been reported to change in response to several 
factors including low energy intake (Walker et al., 2010), exercise (Suwa et al., 2008), and 
some dietary agents such as genistein (Rasbach and Schnellmann, 2008), resveratrol 
(Lagouge et al., 2006; Rodgers et al., 2008; Fernandez-Marcos and Auwerx, 2011; Price et 
al., 2012) and α-lipoic acid (Fernández-Galilea et al., 2015).  
Previous studies have shown that Sirt1 expression was reduced in obese humans 
and mice (Guarente, 2013), while its over-expression in mouse adipocyte depots and in 
the 3T3-L1 adipocyte model led to a dramatic reduction in the expression level of the key 
regulatory factors of lipogenesis CEBPα and PPARγ in parallel with reduced fat 
accumulation. In agreement, expression of CEBPα and PPARγ was increased when Sirt1 
expression was reduced using siRNA (Picard et al., 2004). Also Sirt1 knockdown in mice 
exacerbated the progression of non-alcoholic fatty liver which was coincident with an 
increase in the expression level of lipogenic enzymes comprising acetyl Co-A carboxylase 
and fatty acid synthase (Wang et al., 2010a). It also reduced activity of PPARα, a key 
activator of fatty acid β-oxidation. These responses were mediated through inactivation 
of PGC-1α (Purushotham et al., 2009). 
 Sirt1 appears to act as a co-repressor of PPARγ through docking with PPARγ 
cofactors including nuclear receptor co-repressor (NCoR), and silencing mediators of 
retinoid and thyroid hormone receptors (SMRT) (Picard et al., 2004). Moreover, miRNA-
146b, which targets Sirt1 mRNA, was showed to enhance adipogenesis via increasing 
PPARγ expression as a result of an increase in the acetylation level of FOXO1 (Ahn et al., 
2013). In vitro, Sirt1-mediated deacetylation of PPARγ was reported to be followed by 
activation of brown adipocyte genes. Thus PPARγ has dual effects on lipogenesis and 
whether it activates expression of genes that contribute to the white or brown phenotype 
depends on its acetylation status (Qiang et al., 2012).  
Sirt1 appears to have pivotal roles in the development of beige adipocytes as an 
increase in the expression of Sirt1 in a transgenic mouse model which increased the 
expression level of brown adipocyte marker genes, including Ucp1 and Cebpb, among 
white adipose tissue depots while the white adipocyte marker genes, Rarres2 (chemerin) 
and Retn (resistin), were found to be reduced. However, the expression of Ucp1 and 
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Cebpb in classical brown adipocytes was shown to be unaffected by increased expression 
or Sirt1 knock-down in transgenic mice (Qiang et al., 2012). 
The activities of Sirt1 and PGC1α are closely linked (Aquilano et al., 2010). An 
increase in the expression level of Sirt1 affected by knockdown of miR-32a, an 
endogenous miRNA against Sirt1 mRNA, enhanced the browning of white adipocytes 
which was coincident with PGC1α deacetylation in mouse and 3T3-L1 cells (Fu et al., 
2014).  PGC1α is a key stimulating factor for mitochondrial biogenesis which occurs at a 
high level during the development of brown adipocytes (Rodgers et al., 2005; Guarente, 
2007; Fernandez-Marcos and Auwerx, 2011).  
1.2.1.2.6.2. C/EBPβ 
C/EBPβ is a member of C/EBP (CCAAT/ enhancer binding protein) family of basic 
leucine zipper transcription factors, which consists of six distinct proteins that play 
prominent roles in several vital cellular processes including the cell cycle (Tsukada et al., 
2011), cell differentiation (Calkhoven et al., 2000) and metabolic homeostasis (Roesler, 
2001). C/EBPβ is a positive regulator of Sirt1 (Jin et al., 2011). 
C/EBPβ has recently been recognised as a conspicuous player in the development 
of classical brown and beige adipocytes, and has been used as a characteristic marker of 
brown adipocytes (Qiang et al., 2012). Its expression appears to be critical for the 
differentiation of brown adipose tissue in mice (Tanaka et al., 1997).  In addition, an 
overexpression of C/EBPβ in human skin fibroblasts, mouse skin fibroblasts and 3T3-L1 
cells was shown to be sufficient to convert these cells into brown adipocytes (Karamanlidis 
et al., 2007; Kajimura et al., 2009). Likewise, knock-down of C/EBPβ in parallel with 
PRDM16 (positive regulatory domain contain 16) overexpression in C2C12 myoblast cells 
was arguably sufficient to prevent differentiation of these cells into brown adipocytes by 
as measured using UCP1 and PGC1α expression as markers. Consistently, the C/EBPβ 
deficient mouse embryo was reported to have depleted brown adipose tissue and caused 
a reduction in the expression level of UCP1 (Kajimura et al., 2009). In addition, defective 
thermogenesis was observed in the C/EBPβ knockout mouse (Carmona et al., 2005). 
Replacement of C/EBPα with C/EBPβ in mouse led to the development of a lean 
phenotype (Chen et al., 2000) with higher energy expenditure as a result of an increase in 
the expression level of UCP1 within white adipocyte depots (Chiu et al., 2004).  
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Observations concerning miRNA-155, which is an endogenous microRNA against 
C/EBPβ mRNA, also provide supporting evidence that C/EBPβ is important for the 
development of beige adipose tissue. Specifically, the presence of miRNA-155 was 
negatively correlated with both classical brown and beige adipocyte phenotypical 
changes. Moreover, deletion of miRNA-155 in the mouse was effective in inducing the 
browning of white adipocytes as indicated by the gene expression profile (Chen et al., 
2013b).  
 It was suggested that the action of C/EBPβ may be through binding to the cAMP 
response element (CRE) within the promoter of genes including the PGC1α genes that 
confer the brown/beige adipocyte phenotype. However, later work has shown that 
activation of the PGC1α promoter by CEBPβ was mediated through a sequence which was 
separate from the CRE and has been termed the C/EBPβ response element (Wang et al., 
2008b). 
1.2.1.2.6.3. PGC1α 
Peroxisome proliferator activated receptor gamma coactivator 1 α (PGC1α) 
belongs to a family of transcriptional co-activators that in turn includes PGC1β and PGC1-
related co-activators. PGC1α is involved in the regulation of several metabolic pathways 
including glycolysis, gluconeogenesis, remodelling of brown and white adipocytes as well 
as fat metabolism (Puigserver and Spiegelman, 2003). PGC1α is expressed mainly in 
tissues that are very active metabolically including skeletal muscle and brown adipose 
tissue (Finck and Kelly, 2006). PGC1α is a central factor in regulating mitochondrial 
biogenesis and activity (Lin et al., 2002; Austin and St-Pierre, 2012) by controlling the 
functions of nuclear respiratory factor 1 and 2 (NRF1 and 2), which control the 
transcription of mitonuclear respiratory complex proteins and the mitochondrial 
transcription factor A (TFAM) (Santos and Kowluru, 2011). The N-terminus of PGC1α 
associates with histone deacetylation complexes including steroid receptor coactivator-1 
(SRC1) and  CREB binding protein/P300 (Finck and Kelly, 2006). Thus there is a view that 
PGC1α has histone remodelling activity and makes DNA available for transcription factors 
to transcribe target genes. 
PGC1α undergoes several posttranslational modifications that modulate its 
function, specifically acetylation (Lagouge et al., 2006; Gerhart‐Hines, 2007), 
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phosphorylation, ubiquitination and methylation (Fernandez-Marcos and Auwerx, 2011). 
The functional effects of PGC1α acetylation to inhibit activity are well-defined. Sirt1 is one 
of the enzymes that can deacetylate PGC1α. So this is likely to be one of the main actions 
of Sirt1 through which its effects to protect against features of aging are mediated 
(Rodgers et al., 2005; Lagouge et al., 2006; Gerhart‐Hines, 2007). Acetylation of PGC1α by 
general control non-repressed protein-5 (GCN5) during conditions of high energy 
availability represses its activity (Gerhart‐Hines, 2007; Fernandez-Marcos and Auwerx, 
2011). It also prevents its association with the transcriptional complexes it forms with 
C/EBPβ and PPARγ to stimulate the differentiation of brown adipose tissue (Fu et al., 
2014).  
Activation of PGC1α by Sirt1 enhances mitochondrial biogenesis (Pereira et al., 
2012). Likewise, the activation results in a sharp increase in the expression level of 
enzymes  that catalyse β-oxidation, specifically medium chain acyl-co-A dehydrogenase, 
carnitine acyltransferase and carnitine palmitoyl transferase both in vivo and in vitro 
including C2C12 cell line, mouse embryonic fibroblast (MEFs), primary mouse muscle cells, 
HepG2 cells and in mice  (Kim et al., 2004; Kim et al., 2005; Gerhart‐Hines, 2007).  
Consistent with the PGC1α being a key orchestrator of brown adipose tissue 
development (Uldry et al., 2006; Harms and Seale, 2013), overexpression in human 
primary subcutaneous white adipocytes and the mouse white adipocyte model 
(3T3F442A) promoted expression of UCP1 and mitochondrial biogenesis (Puigserver et al., 
1998; Tiraby et al., 2003). Also consistent with PGC1α having an important role in brown 
adipose tissue development, the PGC1α null mouse was seen to have a defective 
thermogenesis and poorer survival under cold condition (Lin et al., 2004). The stimulatory 
effect of PGC1α on the UCP1 expression appears to be mediated through recruitment of 
PPARγ and the thyroid receptor onto the UCP1 promoter (Puigserver et al., 1998; Tiraby 
et al., 2003). In the same way, PGC1α acts as a coactivator of PPARα to increase UCP1 
expression (Barberá et al., 2001) and it also associates with the retinoic acid receptor to 
augment UCP1 expression (Liang and Ward, 2006).  
38 
 
1.2.1.2.7. Molecular mechanisms that regulate genes expressed in 
brown adipocytes  
The classical mechanism of activating the expression of genes that are key 
determinants of the activity of brown adipose tissue is through the activation of β-
adrenergic receptors (Cannon and Nedergaard, 2004; Mattsson et al., 2011). This is, then, 
followed by the activation of adenylyl cyclase which triggers an increase in the level of 
cAMP that in turn activates protein kinase A. this process lead to  the activation of cAMP 
response element binding protein (CREBP), which activates genes that are under the 
control of cAMP response element (CRE) including UCP genes and PGC1α (Cannon and 
Nedergaard, 2004).  
Tri-iodothyronine (T3) binds to and activates thyroid receptor β (TRβ), which is a 
nuclear receptor. Subsequently, it stimulates brown adipocyte differentiation through 
inducing genes under the control of thyroid response element (TRE). T3 also increases the 
sensitivity of the β-adrenergic stimulated pathways of CRE mediated gene activation. In 
addition, brown adipose tissue type 2 deiodinase (D2) expression is up-regulated by T3 
providing a feed-forward activation mechanism to generate T3 from thyroxine (T4), the 
inactive form of thyroid hormone (Martinez de Mena et al., 2010). Figure 9 shows the 
interactions between the β-adrenergic and T3-mediated pathways through which genes 
acting in brown adipocyte development are stimulated. 
The mechanisms switching on the gene expression profile that characterises beige 
adipocytes are not well-understood but several hypothetical models have been suggested 
in this regards. Plausible and well-rehearsed proposed mechanisms include the 
involvement of Sirt1 either by deacetylating and thus activating PPARγ (Qiang et al., 2012) 
or PGC1α (Fu et al., 2014). Downstream of the latter activity, PGC1α, can act as a 
coactivator of PPARα and may act in concert with retinoic acid receptor to induce brown 
adipocyte phenotypical changes (Barberá et al., 2001; Liang and Ward, 2006). C/EBPβ may 
also stimulate the expression of UCP1 through binding to the cAMP response element 
(CRE) and/or C/EBPβ response element (C/ERE) within the promoter (Wang et al., 2008b; 
Chen et al., 2013b). Binding of PRDM16 (positive regulatory domain contain 16) with 
PPARγ and/or C/EBPβ, with subsequent activation of the genes that characterises brown 
39 
 
adipocytes also appears to be important in brown adipocyte differentiation (Seale et al., 
2008; Kajimura et al., 2009).  
 
Figure 1. 9: Effects of β-adrenergic receptor (β3 and β1) activation and T3 on brown adipocyte gene 
expression. Following activation of β-adrenergic receptors (β1 and β3) with adrenergic receptor activators 
like nicotine amide (NE), adenylyl cyclase (AC) is activated. The active adenylyl cyclase catalyses 
conversion of ATP into cyclic-adenosine monophosphate which is followed by protein kinase-A (PKA) 
activation leading to activation of the cyclic adenosine monophosphate response element binding protein 
(CREBP) by phosphorylation. The activated CREBP enhances the expression of genes under the control of 
cyclic adenosine monophosphate response element (CRE) including UCP1 and PGC1α. Thyroid receptor 
activation by tri-iodothyronine (T3) triggers UCP1, PGC1α and D2 expression through the thyroid response 
element (TRE). T3 can also be generated from thyroxine (T4) by type2 deiodinase (D2). The Β2-adrenergic 
receptor is a negative regulator of AC.   
 
1.2.1.2.8. External factors that affect brown adipocyte development 
External influences on the development of beige adipose tissue are not well 
understood  (Collins et al., 2010). The development and maintenance of beige adipose 
tissue appear to be a dynamic process (Frontini and Cinti, 2010) and may be affected by 
environmental, physiological and dietary factors including exposure to cold, adrenergic 
stimulation (Cinti, 2009; Barbatelli et al., 2010), energy intake (Cinti, 2011), exercise 
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(Bostrom et al., 2012), hormonal status (Quarta et al., 2012) and micronutrient availability 
(Fernández-Galilea et al., 2015).  
A body of work has shown that exposure to cold in humans and rodents was 
associated with an increase in the mass of brown adipose tissue, which generally has been 
assumed to have resulted from trans-differentiation of pre-existing white adipocytes into 
brown adipocytes (Huttunen et al., 1981; Murano et al., 2009; Saito et al., 2009; van 
Marken Lichtenbelt et al., 2009; Bostrom et al., 2012; Vitali et al., 2012). Also, adrenergic 
stimulation in the rat was found to increase the amount of brown adipocyte-like cells 
among white adipocyte depots characterised by accumulation of paucilocular fat droplets 
and an increase in the mitochondrial content of the cells (Himms-Hagen et al., 2000). High 
temperature has been reported to have the opposite effects of cold temperature and 
enhance brown to white adipose tissue interconversion in rats (Cancello et al., 1998).  
A high fat diet also was reported to promote the expression of genes that 
characterise brown adipocytes including UCP genes, in both brown and white adipocyte 
depots in mouse (Rippe et al., 2000). Such a diet led to improved thermogenesis in human 
subjects (Nagai et al., 2003). In contrast, fasting reduced the expression of UCP1 in the 
brown adipose tissue of rat (Champigny and Ricquier, 1990). In general, however, there is 
a paucity of knowledge about the effect of diet on brown adipose tissue development; 
thus research in this area is required  (Fromme and Klingenspor, 2010). 
Effects of hormonal status on brown adipose tissues are revealed by several 
studies. For example, ovariectomized mice gained weight in parallel with a reduction in 
the expression level of UCP1 within brown adipose tissue (Pedersen et al., 2001). In 
another study on mice, progesterone and testosterone were found to have the opposing 
effects on UCP1 expression in brown adipose tissue.  Expression was stimulated by 
progesterone but inhibited by testosterone (Rodríguez et al., 2002). Also, estrogen 
substitution in ovariectomized rats was found to stimulate UCP gene expression in both 
brown and white adipose tissue depots (Pedersen et al., 2001). 
Some lines of evidence suggest that a brown adipocyte phenotype could be 
achieved by manipulating the transcriptional pattern of target cells through ectopic 
expression of specific transcription factors or genes responsible for phenotypic features 
of brown adipocytes. For example, over expression of Sirt1 (Qiang et al., 2012), PGC1α 
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(Tiraby et al., 2003), C/EBPβ (Karamanlidis et al., 2007; Kajimura et al., 2009), PRDM16 
(Seale et al., 2007) and UCP1 (Ishigaki et al., 2005) have all been observed to induce 
features of the brown/beige adipocyte phenotype. Similarly, deletion or knock down of 
some genes that contribute to white adipocyte physiology including HSL (Osuga et al., 
2000; Ström et al., 2008) and fat specific protein 27 (FSP27), which participates in fat 
droplet formation (Tanaka et al., 2014), was sufficient to reprogram white adipocytes into 
brown-like adipocytes in transgenic mice.  
It is likely that epigenetic mechanisms, such as DNA methylation, histone 
modification and miRNAs, play roles in determining adipocyte fate. These processes could 
affect events such as recruitment of transcription factors to regulate gene expression 
profiles that confer the brown adipocyte phenotype. At present, however, detailed 
knowledge about how epigenetic modification affects adipocyte physiology is lacking 
(Sugii and Evans, 2011). The influential role of miRNAs in determining the phenotype of 
adipocytes is however being uncovered. For instance, the presence of miRNA-155, which 
is an endogenous anti C/EBPβ, was sufficient to interfere with the development of primary 
mouse brown adipocytes and the differentiation of brown adipocytes from white 
adipocytes, while deletion or reducing its expression counteracted these effects (Chen et 
al., 2013b). Others found that knock-down of miRNA-32a, which is an endogenous miRNA 
against Sirt1, promoted white to brown adipocyte interconversion as a result of an 
increase in the expected deacetylation and activation of  PGC1α in mice and 3T3-L1 cells 
(Fu et al., 2014). 
Alpha-lipoic acid (100-250 μM), which is an antioxidant dietary compound (Durrani 
et al., 2010), was also revealed to induce browning of white adipocytes through its 
stimulatory effects on the expression and activity of Sirt1, which was followed by an 
increase in mitochondriogenesis and an augmented expression level of UCP1, in a human 
cell model of fully differentiated subcutaneous preadipocytes (Fernández-Galilea et al., 
2015).  
Rosiglitazone, a PPARγ agonist, was also found to enhance mitochondrial 
biogenesis and UCP1 expression in mouse white adipose tissue (Sell et al., 2004; Bogacka 
et al., 2005; Petrovic et al., 2008).   
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1.2.1.2.9. Effects of genistein and other polyphenols on UCP1 
expression and mitochondrial activity 
Genistein was reported to restore mitochondrial function and biogenesis in both 
cell and animal models including cerebral ischemia in a mouse model, rat primary 
neuronal cell culture (Adams et al., 2012; Qian et al., 2012), , T47D (a breast cancer cell 
model) (Pons et al., 2014) and rabbit primary renal proximal tubular cells (Rasbach and 
Schnellmann, 2008). A likely mediating mechanism is up-regulation of Sirt1 and PGC1-α 
expression (Rasbach and Schnellmann, 2008). Likewise, genistein may indirectly regulate 
Sirt1 activity through inducing AMP-activated PK (AMPK) which increases the intracellular 
level of the Sirt1 activator NAD. These effects of genistein on AMPK have been observed 
under normal and inflammatory conditions in both cell and animal models including 
rodents, 3T3-L1 and prostate cancer cells (Hwang et al., 2005; Cederroth et al., 2008; Park 
et al., 2010; Wang et al., 2013b). In addition, PGC1α phosphorylation by AMPK appears to 
be important for subsequent PGC1α deacetylation by Sirt1 (Canto et al., 2009; Fernandez-
Marcos and Auwerx, 2011). It has been shown that genistein can prevent mitochondria 
mediated cellular apoptosis either via down-regulation of Bax, which is a pro-apoptotic 
protein factor interfering with mitochondrial function by disturbing mitochondrial outer 
membrane permeability (Adams et al., 2012), or as a result of genistein`s  antioxidant 
activities (Qian et al., 2012). 
Genistein (5-50 mg/Kg per a day) was also found to increase UCP1 expression in 
white adipose tissue depots in mice (Penza et al., 2006). Moreover, the obesogenic effects 
of high caloric diet in mice were diminished in the presence of genistein (0.2%, 0.4% 
genistein for 12 weeks) through stimulating an increase in the expression of PGC1α, 
mitochondrial medium chain acyl Co-A dehydrogenase, UCP2, and mitochondrial 
biogenesis  (Lee et al., 2006).  
Several other studies have confirmed the beneficial effects of dietary isoflavones 
on mitochondrial functionality, particularly upregulation of UCP protein. For example, 
shorter-term (14 days) and chronic (180 days) exposure of rats to soya protein (which 
contains isoflavone including genistein and diedzein) reduced body weight and energy 
expenditure besides increasing UCP expression in brown and white adipose tissue 
(Takahashi and Ide, 2008; Torre-Villalvazo et al., 2008). Similarly, soya protein (5000 mg 
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isoflavones/Kg of diet) alone and/or in combination with exercise in rats stimulated the 
expression of PGC1α and  PPARα, and reduced the lipid content of the liver as well as 
epididymal adipose tissue (Morifuji et al., 2006). 
Treatment of rats for 14 days with black soya bean skin extract (0.2, 1 and 2% of 
diet), which is a rich source of polyphenols including epicatechin and procyanidin, was 
reported to prevent dietary induced obesity by stimulating fat catabolism through 
increasing the UCP1 and UCP2 expression in both brown and white adipose tissue depots 
(Kanamoto et al., 2011). Furthermore, high UCP1 expression and oxygen consumption 
rate was reported in rodents treated with isoflavone-rich plant extract (Puerariae 
thomsonii) and soya based diets (Lephart et al., 2004; Kamiya et al., 2012).  
Diadzein (50 mg per kilogram body weight), which is present in soyabeans together 
with genistein, was found to invoke UCP1 expression and prevented an increase in the 
body weight (Crespillo et al., 2011). Similarly, resveratrol (30 mg/Kg/day for 6 weeks) was 
also demonstrated to increase UCP expression and mitochondriogenesis in brown 
adipocytes and muscle cell of rats (Alberdi et al., 2013).  
1.2.1.3. Effects of genistein on adipocyte physiology 
Various reported effects of genistein both in vivo and in vitro are commensurate 
with an effect on fat metabolisms. However, the molecular mechanism through which 
genistein affects fat metabolism is not understood fully. The impact of genistein on lipid 
metabolism appears to be dose and time dependant. In vitro, lower doses of genistein (up 
to 1 µM) were reported to inhibit lipogenesis, and the effect appeared to be estrogen 
receptor-dependent since it was reversed in the presence of the estrogen receptor 
antagonist ICI 164,382. However, higher concentrations of genistein (>10 µM) were 
observed to stimulate lipogenesis in primary mouse bone marrow and KS483 cells through 
a mechanism that appeared to be estrogen receptor-independent (Dang et al., 2003). 
Similarly, 50 µM genistein stimulated lipogenesis in primary human synovial fibroblasts 
(Relic et al., 2009). Conversely, in vivo in the mouse a lower dose of genistein (50 mg/Kg 
per a day) enhanced lipogenesis while high dose of genistein (200 mg/Kg per a day) 
reduced lipid accumulation (Penza et al., 2006). 
Overall, however, it appears that genistein has the potential to affect lipid 
biogenesis in a beneficial manner either by inhibiting the process of lipogenesis and/or 
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through improving the process of lipolysis and fat metabolism. In support of this view the 
expression of key transcription factors and their downstream genes involved in the 
process of lipid biogenesis, including PPARγ, liver X receptor (LXR) and retinoid X receptor-
α, declined when  genistein was included (2000 or 4000 mg genistein/Kg) in a diet that 
induced obesity in mice (Kim et al., 2010). Also, genistein was observed to interfere with 
the expression  and activity of sterol regulatory element binding protein-1 (SREBP-1) (Kim 
et al., 2010), which is a membrane bound transcription factor involved in the regulation 
of the lipid biogenesis (Horton et al., 2002) through its action to down-regulate site-1 
protease (S1P) (Shin et al., 2007). SIP is a serine protease and is required for SREBP-1 to 
be activated and translocated into the nucleus (Espenshade, 2006). Genistein (50 µM)  
also reduced fat synthesis and accumulation in 3T3-L1 cells by decreasing the expression 
level of C/EBPα and its downstream genes including fatty acid synthase (Zhang et al., 
2009), and possibly by decreasing glucose uptake via  its direct inhibitory action on the 
transmembrane glucose transporter GLUT4 (Bazuine et al., 2005).  
Treatment of obese Zucker rats with genistein led to a reduction in the blood 
triglyceride and cholesterol level and decreased  fat accumulation within the liver (Mezei 
et al., 2003). Similarly, male Sprague-Dawley rats exposed to genistein (0.03, 0.3, or 1.2 
mg/day) for 5 days during the neonatal period were protected against high fat diet 
induced non-alcoholic fatty liver and body weight gain, consistent with an observed  
increase in the β-oxidation indicated by an increase in the expression level of PPARα 
(Huang et al., 2011). Also, genistein (10-100 µM) prevented fat accumulation within the 
cytoplasm of HepG2 cells and there was an increase in the level of β-oxidation indicated 
by an increase in the expression level of carnitine palmitoyltransferase 1 (CPT1) and 
PPARα (Kim et al., 2004). The effect of genistein on fat catabolism, particularly in the 
context of fatty liver, may be mediated through PPARα (Kim et al., 2004; Kim et al., 2005) 
and its downstream genes including carnitine palmitoyltransferase and very long chain 
acyl Co-A dehydrogenase (Kim et al., 2005; Kim et al., 2010). 
Genistein was also found to enhance PGC1α expression (Lee et al., 2006), 
consistent with mitochondrial biogenesis (Puigserver et al., 1999; Liang and Ward, 2006), 
UCP1 expression (Neve et al., 2000; Liang and Ward, 2006) and fatty acid β-oxidation (Lee 
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et al., 2015). Another regulatory effect of genistein on lipid metabolism may be related to 
its up-regulatory effect on Sirt1 expression (Rasbach and Schnellmann, 2008).  
1.2.1.4. Effects of resveratrol on adipocyte physiology 
Extensive studies have shown that resveratrol can modulate the lipogenic process 
and reduce lipid accumulation in adipocyte tissue. Similar to reported actions of genistein, 
resveratrol has been demonstrated to interfere with or reduce several lipid-related health 
problems including non-alcoholic fatty liver, and to improve the plasma lipid profile by 
reducing the expression levels and/or activities of transcription factors and enzymes with 
roles in lipid biogenesis. For example, resveratrol was shown to reduce adipocyte 
proliferation and differentiation in preadipocytes taken from patients with Simpson 
Golabi-Behmel syndrome (SGBS), which is an over-growth syndrome (Fischer-Posovszky 
et al., 2010). Another study demonstrated that resveratrol was able to prevent 
hepatosteatosis in HBV (hepatitis B virus) X protein transgenic mice and HepH2 cells co-
incident with a reduction in the activity and expression of the liver X receptor-α (LXRα). 
LXRα increases expression of sterol regulatory element-binding protein-1c (SREBP-1c), 
leading to a reduction in the expression of lipogenic enzymes including FAS and ACC (Lin 
et al., 2012b; Jin et al., 2013). Similarly, the supplementation of a high fat diet with 
resveratrol for 60 days reduced body fat mass, improved the blood lipid profile and 
reduced plasma insulin concentration in male mice and reduced the expression level of 
PARP-γ and SREBP-1, while stimulating Sirt1 expression (Andrade et al., 2014b). In 
contrast, dietary resveratrol (30 mg/kg body weight/day for 6 weeks) in rats was found to 
have no effect either on the mRNA of lipogenesis-related transcription factors (SREBP1c 
and PPARγ) or their downstream genes (FAS, ACC, LPL); however, the activities of FAS and 
ACC were significantly reduced (Alberdi et al., 2011). 
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1.3. Estrogen receptors 
Estrogen receptors belong to the steroid/thyroid superfamily of intracellular 
receptors (Evans, 1988). There are two principle estrogen receptors (ERs), ERα (Green et 
al., 1986) and ERβ (Kuiper et al., 1996), which are products of distinct genes. The ERα gene 
is located on human chromosome-6 and the ERβ gene is on human chromosome-14 
(Krzystyniak, 2002; Herynk and Fuqua, 2004). Each ER gene consists of eight exons 
separated by seven intronic regions (Ascenzi et al., 2006). Due to the use of alternative 
promoters ERs are expressed as different variants depending on tissue and cellular 
conditions (Li et al., 2000; Hirata et al., 2001; Ascenzi et al., 2006). ERs show wide 
distribution throughout the body tissues and are involved in physiological and 
pathophysiological process including growth, development, adipogenesis and cancer 
(Dunnwald et al., 2007; Lee et al., 2012a). 
1.3.1. Structure of estrogen receptors 
Estrogen receptors have three main domains: the N-terminal domain (A/B-
domain), DNA binding domain (C-domain) and the ligand binding domain (D/E/F-domain) 
(Beato, 1989). The detail of ER is shown in Figure 10 
 
Figure 1. 10: Domains of the estrogen receptor that shows the N-terminus domain (A/B), DNA binding 
domain (C), hinge domain (D), ligand binding domain (E) and F-domain. Regions responsible for activation 
(AF-1 and AF-2) are also indicated. 
ERα and ERβ show extensive similarity and are highly conserved particularly in the 
DNA-binding domain (Mosselman et al., 1996; Kuiper et al., 1997) and ligand-binding 
domains. The main variability between the receptor subtypes is confined to the hinge 
domain (D-region), F-region and N-terminal domain (Mosselman et al., 1996). 
Each of the ERs domains has a specific function. The D/E/F domain is involved in 
processes including nuclear localization, binding with ligands and heat-shock proteins, 
dimerization and transactivation (Tsai and O'Malley, 1994), while the C-domain, the DNA 
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binding domain, contains two zinc fingers, which play a crucial role in recognising and 
binding to the estrogen response element (ERE) of target genes (Ascenzi et al., 2006).  
ERs have two domains known as activation function domains (AFs). AF-1 is a part 
of A/B region at the N-terminus of the ER while AF-2 is towards the C-terminus. The AF-1 
domain can activate gene expression in the absence of ligand when it is phosphorylated 
through the action of kinase enzymes as a result of extracellular stimuli (Marino et al., 
2006). However, AF-2 domain responses are mainly ligand dependent and full activation 
of both receptor types requires ligand-dependent interaction between AF-1 and AF-2 
domains. It was demonstrated that an agonist ER ligand stimulates fully activation of the 
ER while antagonist agents have the opposite effect by preventing the interaction 
between these domains as a result of inducing conformational changes in receptor 
structure (Kumar and Thompson, 2003). 
1.3.2. Estrogen receptor isoforms 
Several isoforms of both ERα and ERβ result from use of alternative promoters or 
alternative splicing (Moore et al., 1998; Ascenzi et al., 2006). Approximately, 20 isoforms 
of ERα (Poola et al., 2000) and 5 isoforms of ERβ (Moore et al., 1998) have been detected. 
Among ERα isoforms ERα66, ERα46 and ERα39 are well-characterised (Reid et al., 2002; 
Chen et al., 2014). ERα46 is distinguished from the wild type by lacking the AF-1 domain 
(Li et al., 2003) while ERα36 is devoid  of both AF (AF-1 and AF-2) regions (Wang et al., 
2005). ERβ isoforms (ERβ 2, 3, 4, and 5) are characterised by having a shorter C-terminus 
compared with ERβ1. Functionally, they are inactive on their own but they become active 
upon dimerization with ERβ1 (Leung et al., 2006). Furthermore, ERβ2 can form a 
heterodimer with ERα to confer a negative regulatory function (Omoto et al., 2003). 
The expression of these isoforms appears to be cell type and cell condition 
dependent. For instance, ERβ3 was expressed only in testis, and ERβ1 was absent or its 
expression was reduced in liver and colon tumor (Moore et al., 1998; Campbell-Thompson 
et al., 2001; Thomas and Gustafsson, 2011).  
1.3.3. Distribution of estrogen receptors 
ERα and ERβ are present together in several tissues including brain, the 
reproductive system, the skeletal system, heart and adipose tissues. However, their 
expression ratio varies in different tissue types and under different conditions (Paech et 
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al., 1997; Pearce and Jordan, 2004; Böttner et al., 2014). For example, it was 
demonstrated that ERβ is the predominant ER in colon tissue while in hepatic tissue ERα 
is the prominent receptor (Pearce and Jordan, 2004; Böttner et al., 2014). The expression 
profiles of ERs can be disturbed under pathophysiological conditions. For instance, the 
expression of ERβ was dramatically reduced in colon adenocarcinoma (Konstantinopoulos 
et al., 2003) and prostate cancer (Leav et al., 2001). 
1.3.4. Mechanism of estrogen receptor responses 
In the classical pathway, ER ligands enter the cell through simple or facilitated 
diffusion (Tsai and O'Malley, 1994). Upon binding to the receptor, they induce a structural 
change (Beekman et al., 1993) causing the receptor to translocate from the cytoplasm 
into the nucleus of the cell (Beato, 1989) where it binds directly to the estrogen response 
element (ERE) (Tsai and O'Malley, 1994) as a dimer (Schwabe et al., 1990). The core ERE 
consensus sequence occurs frequently as a series of repeats separated by three 
nucleotide intervals (Glass, 1994; Schwabe et al., 1995; Vanacker et al., 1999).  In the 
absence of the activating ligand, ERs can bind with heat-shock proteins (heat-shock 
protein-90 and heat-shock protein-70) and in this form, they appear to be inactive (Tsai 
and O'Malley, 1994; Ascenzi et al., 2006). It has recently been shown that in the absence 
of estrogen,  ERα (unliganded) can bind to several sites within the genome where it 
appears to have a role in controlling and stabilizing the expression of these genes (Caizzi 
et al., 2014). 
In the non-classical pathway the action of the activated ER does not involve 
binding to the ERE but it is through the ER binding with other transcription factors 
including activator protein-1 (AP-1) and specificity protein-1 (SP-1). The activated ER and 
AP1/or SP1 complex then binds to sequences including AP-1 and GC-rich SP1 sites to 
regulate gene expression (Kim et al., 2003; DeNardo et al., 2005; Burek et al., 2014). There 
is evidence that the AF-1 and AF-2 ER motifs are crucial for this non-classical pathway 
response (Kim et al., 2003; Achari et al., 2009). 
ERs can function as heterodimers  or homodimers (Paulmurugan et al., 2011). As 
heterodimers, ERα and ERβ can activate different sets of estrogen responsive genes 
(Monroe et al., 2005) and can have opposite effects to homodimers. For example, an ERα 
homodimer stimulated proliferation of normal murine mammary epithelial cells (HC11) 
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(Helguero et al., 2005) whereas the ERα/ERβ heterodimer was seen to have the opposite 
effect (Powell et al., 2012). Homodimers of ERs appear to have agonist and/or antagonist 
action on estrogen responsive genes depending on the type of the ligand and the 
promoter elements. For instance, binding of 17β-estradiol with ERα activated 
transcription of a reporter plasmid construct that included an AP1 (activated protein 1) 
element, whereas ERβ had the opposite effect. In contrast, ERβ with a tamoxifen ligand 
enhanced the transcriptional activity of the same construct (Paech et al., 1997).  
ERs can also be activated via ligand-independent pathways that involve their 
phosphorylation in the nucleus by kinase enzymes including mitogen activated protein 
kinase (MAPK) and protein kinase A (PKA) (Marino et al., 2006; Morani et al., 2008; Cao et 
al., 2013b). There is evidence that activation of this pathway can be through the epidermal 
growth factor receptor (Nilsson et al., 2001) or membrane bound estrogen receptors 
(Razandi et al., 2004).  
17β-estradiol and other agents with estrogenic action may have classical nuclear 
ER-independent actions by activating G-protein-coupled receptor-30 (GPR30), which is a 
non-classical membrane G-protein-coupled ER, within the plasma and endoplasmic 
reticulum membranes (Filardo et al., 2002; Revankar et al., 2005; Chevalier et al., 2012; 
Wei et al., 2014) and mostly associated with non-genomic estrogen signalling (Olde and 
Leeb-Lundberg, 2009).  .  
1.3.5. Estrogen receptors and cancer 
ERs status can provide important prognostic information about some types of 
cancer (Herynk and Fuqua, 2004; Dunnwald et al., 2007). Based on epidemiological 
studies, ERβ was identified as an important indicator to classify severity and stage of colon 
cancer (Rudolph et al., 2012). A substantial reduction and/or absence of ERβ is 
characteristic of some forms of cancer including colon adinocarcinoma (Foley et al., 2000; 
Campbell-Thompson et al., 2001; Konstantinopoulos et al., 2003), ovarian cancer 
(Rutherford et al., 2000; Bossard et al., 2012), breast cancer (Skliris et al., 2003; Huang et 
al., 2014), prostate cancer (Leav et al., 2001) and lung cancer (Kawai et al., 2005).  
Overexpression of ERβ can inhibit proliferation of both ERα positive and negative 
human ovarian cancer cell lines (BG1 and PEO14) (Bossard et al., 2012). Similarly, 
overexpression of ERβ reduced cell proliferation and induced cell cycle arrest at G1 in 
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colon cancer cell models (SW480 and HCT-116) (Hartman et al., 2009). Human breast 
cancers expressing high levels of ERβ have been shown to respond better to hormonal 
therapy than ERβ negative breast cancers (Murphy et al., 2002). Furthermore, ERβ was 
found to counteract the proliferative effects of ER-α in the breast cancer cell model T47D 
and in rat prostate cancer (Ström et al., 2004; Attia and Ederveen, 2012). However, the 
ERβ knockout mouse showed abnormal growth of breast and prostate epithelial tissue 
cells, which is a predisposing factor in neoplasia formation (Gustafsson and Warner, 2000; 
Weihua et al., 2001). Again, ERβ knockdown by siRNA in a prostate cancer cell model 
(LNCaP) increased the proliferative rate of the cells in association with a sharp increase in 
the expression level of  ER-α (Stettner et al., 2007). 
In contrast to ERβ, ERα appears to be highly expressed by cancer cells and 
approximately 70% of breast cancer cases are diagnosed as ER-α positive (DeSantis et al., 
2011). Unlike to ERβ, ERα seems to play a role in the onset (Hewitt et al., 2002) and 
progression of cancer (McPherson et al., 2008; Attia and Ederveen, 2012). Recently it has 
been shown that ERα dependent action inhibited P53/P21 expression and stimulated 
proliferative cell nuclear antigen (PCNA) and proliferation-related Ki-67 antigen 
expression in MCF-7 breast cancer cells (Liao et al., 2014). A low level of ERα expression 
was measured in normal human breast tissue but its expression was higher in some forms 
of breast cancer including invasive ductal carcinoma (Gustafsson and Warner, 2000) and 
in lobular cancer (Huang et al., 2014). ERα was consistently expressed in patients with  
non-small cell lung cancer where ERβ expression was variable (Kawai et al., 2005). 
However, in colon cancer ERα expression was reported to be similar to the surrounding 
normal tissue, and appeared to have no influence in colon carcinogenesis (Foley et al., 
2000; Campbell-Thompson et al., 2001),  
1.3.6. Estrogen receptors and obesity 
There is evidence that both ERα and ERβ may have functions that protect against 
obesity. For example, with high fat feeding ERβ knockout mouse accumulated more lipid 
in gonadal adipose tissue compared with wild type. Effects of ERβ on lipid biogenesis may 
be mediated through PPARγ (Foryst-Ludwig et al., 2008) which interacts with ERβ in a 
ligand-independent manner (Wang and Kilgore, 2002). In contrast, however, work in the 
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ovariectomized mouse indicated that ERβ has no role in diet-induced obesity (Roesch, 
2006).  
An ERα knockdown mouse model was obese and developed obesity related 
disorders including insulin resistance, glucose intolerance and lower energy expenditure 
compared with wild type (Heine et al., 2000). Another study showed a reduction in the 
expression of ERα in obese female subjects compared with lean subjects (Nilsson et al., 
2007). In contrast to ERβ, ERα was found to be important in reducing food intake and 
preventing diet-induced obesity in ovacriectomized rats (Roesch, 2006). 
1.3.7.  The effect of estradiol/or genistein on estrogen receptor expression 
It appears that the expression of ERs can be influenced by the presence of their 
activating ligands. 17β-Estradiol, the common endogenous mammalian ER ligand, was 
demonstrated to have differential effects on the expression of ERα versus ERβ. In vitro it 
was uncovered that 17β-estradiol treatment (1-20 nM) caused down-regulation of ERα in 
different cell models including M6 breast cancer cells (Yoshidome et al., 2000), MCF-7 
breast cancer cells (Hall et al., 2008) and ZR-75-1 cells (Kousidou et al., 2008). However, 
ERβ expression was not affected by 17β-estradiol in SW480 intestinal cells (Hartman et 
al., 2009). Moreover, in sheep foetal primary endothelial cells 17β-estradiol (0.1-10 nM) 
was found to have time dependent effects on ER expression. Short exposure (2 h) to 17β-
estradiol down regulated ER-α and had no effect on ERβ. However, a longer (6 h) exposure 
time caused ERα up-regulation and ERβ down-regulation (Ihionkhan et al., 2002). 
As a ligand, genistein has a higher affinity toward ERβ than ERα (Zhu et al., 2006; 
Chrzan and Bradford, 2007). At the expression level it was shown that giving genistein to 
mice (50-200 mg/kg) downregulated both ERs in epididymal adipocytes (Penza et al., 
2006). A low dose of genistein (1 µM) was found to have no effect on ERβ expression in 
MCF-7 cells but upregulated ERβ in T47D breast cancer cells. These differences were 
suggested to be related to the lower ERα/ERβ ratio in T47D compared with MCF-7 cells 
(Pons et al., 2014). In a study in 3T3-L1 and MCF-7 cells genistein (50-200 µM) was shown 
to down-regulate ERα dose and time dependently (Choi et al., 2014). Other 
phytoestrogens including tectorigenin (100 µM) upregulated ER-β in the LNCaP prostate 
cancer cell line (Stettner et al., 2007). Similarly, Belamcanda chinensis extract, which is a 
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mixture of around 13 different phytoestrogens, was also found to up-regulate ER-β in the 
same cell line (Thelen et al., 2007).  
1.4. Chromatin 
1.4.1. Chromatin structure 
Humans have 46 chromosomes comprising approximately 6.5 billion base pairs of 
DNA. Each chromosome consists of a double stranded DNA molecule wrapped around 
sequential histone protein octamer cores. 145-147 base pairs of DNA coils around each 
histone protein octamer to form the basic unit of chromatin, the nucleosome (Mariño-
Ramírez et al., 2005). The DNA between nucleosomes (linker-DNA) comprises 160-240 
base pairs (McGhee and Felsenfeld, 1980). Linker histone proteins (histone H1) are 
located outside the nucleosome in association with the linker DNA (McBryant et al., 2010; 
Harshman et al., 2013). This structural arrangement of the chromatin is crucial for 
genomic stability and transcriptional control of the genome (Jiang and Pugh, 2009). This 
structural arrangement is shown schematically in Figure 11. 
 
Figure 1. 11: Chromatin structure and arrangement of histone core proteins in association with the DNA 
and linker histone (Karp 2008). 
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1.4.2. Histone proteins 
Histone proteins can be divided generally into core and linker histone proteins. 
The core histone proteins are highly organised and essential for nucleosome assembly. 
The core of each nucleosome is an octamer of histone proteins comprising two copies of 
each of H2A, H2B, H3 and H4 (Jiang and Pugh, 2009). The N-terminal regions of core 
histone proteins and the H2A C-terminal region extend out of the nucleosome and 
interact with other proteins via covalent modifications of these histone tails structures to 
regulate gene expression activity and other functions (Karp, 2008). Histone H1, the linker 
histone, does not participate in nucleosome formation but is bound to the linker DNA in 
close proximity to the nucleosome (Bustin et al., 2005). Figure 12 shows relationship 
between DNA and histones. 
 
Figure 1. 12:  Nucleosome structure consists of an octamer of histone proteins comprising two copies of 
each of H2A, H2B, H3 and H4 which is associated with linker DNA and histone H1. Histone proteins 
properties including the number of amino acid residues and mass is also shown.  
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1.4.3. Organization of histone genes 
Cell division and proliferation requires the production of large quantities of 
histone proteins. This requirement is met by the presence of multiple copies of histone 
genes, which in higher eukaryotes cluster in tandem repeats or jumbled clusters of 
between 10 and 100 genes. In the human genome most histone gene clusters are on the 
short arm of chromosome 6. Other histone genes are scattered on chromosome 1, 4, 11, 
17 and 22. There is a small cluster on chromosome 1 whereas the other chromosomes 
accommodate only single histone genes (Albig and Doenecke, 1997; Marzluff et al., 2002; 
Marzluff et al., 2008). The arrangement of the human histone genes is shown in Figure-13 
 
Figure 1. 13: Chromosomal distribution of the human histone genes (Albig and Doenecke, 1997) 
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1.4.4. Histone mRNA and protein synthesis 
Approximately 90% of histone proteins synthesis occurs during S-phase of the cell 
cycle. This process is termed replication-dependent histone biogenesis. The remaining 
10% is replication-independent and is the process through which canonical histone 
proteins are replaced and that keeps specific loci of the genome in the inactive 
heterochromatin or active euchromatin configuration state as required by cellular 
functional demands (Wu and Bonner, 1981; Chen et al., 2013a).  
Specific proteins including stem-loop binding proteins (SLBP), the U7 small nuclear 
ribonucleic proteins (U7 snRNP) and heat labile factor participate in histone mRNA 
stabilization (Allard et al., 2005; Marzluff et al., 2008).  
The mRNAs of the canonical replication-dependent histones in vertebrates are 
characterized by two main features that distinguish them from replication-independent 
histones: a hairpin-loop at the 3` end of the mature mRNA and lack of an intron (Marzluff 
et al., 2008). In addition to their translation into histone proteins, they require SLBP and 
stem loop binding protein interacting proteins 1 SLIP1 in order to interact with eukaryotic 
translation initiation factor-4γ (EIF4G) (Marzluff et al., 2008). 
1.4.5. Histone variants 
Histones H1, H2A and H3 have multiple variants, whereas in contrast to H2B and 
H4 show less variability (Kamakaka and Biggins, 2005). Specialised and distinct functions 
of histone variants are assumed to be through their interactions with different chromatin 
assembling factors which direct them to specific chromatin loci (Ahmad and Henikoff, 
2002). Histone H3 variants appear to have vital roles in determining either euchromatin 
or heterochromatin formation. There are five main histone H3 variants in mammals, 
which comprise two replication-dependent (canonical) histones H3.1 and H3.2, and three 
non-canonical variants comprising a transcription-dependent histone variant (histone 
H3.3), the centromere specific histone variant (CENP-A) and testis specific histone H3 
(H3t) (Loyola et al., 2006; Loyola and Almouzni, 2007; Szenker et al., 2011). There are very 
few differences in sequence especially between histone H3.1, H3.2 and H3.3 proteins 
(H3.1/H3.2, 99%, and H3.1/H3.3, 96%). In contrast, CENP-A is much more divergent and 
shares only 47% amino acid sequence identity with H3.1 (Loyola and Almouzni, 2007). 
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It was demonstrated that presence of histone H3.3 and/or its post-translational 
modifications, especially at specific gene promoter and enhancer regions, was associated 
with transcriptional activity (Ahmad and Henikoff, 2002; Hake and Allis, 2006; Chen et al., 
2013a). Expression of this variant was found to be crucial for DNA replication during the 
S-phase of the cell division (Frey et al., 2014) and to be associated with the 
transcriptionally active sites of the genome in the chicken erythroid cell models HD24 and 
6C2 (Jin and Felsenfeld, 2006). Abundance of this variant marks highly active and fully 
differentiated cells such as nerve cells (Das and Tyler, 2013). Histone H3.3 knockdown in 
mouse resulted in abnormal chromosomal segregation (Bush et al., 2013) and in defective 
decondensation of the pericentromeric chromatin (Lin et al., 2013).  
Histone H3.2 on the other hand appears to be associated preferentially with 
silenced loci and with heterochromatin formation, whereas histone H3.1 is likely to have 
bidirectional (activation and/or silencing) effects on transcriptional regulation (Hake and 
Allis, 2006). Replacement of histone H3.3 with histone H3.1 prevented C2C12 
differentiation into myocytes and prevented lineage specific gene expression (Harada et 
al., 2014). Also histones H3.1 and H3.2 were found to be associated with heterochromatin 
formation during fertilization and embryogenesis in the mouse (Akiyama et al., 2011).  
1.4.6. Histone modification 
Another mechanisms through which histones control transcriptional activity is 
through their extensive post translational modifications (PTM), especially at the N-
terminus (Strahl and Allis, 2000; Zhou et al., 2011). These modifications tend to be 
conserved among cell types and possibly among species (Roh et al., 2007; Ryba et al., 
2010).  
The most common histone modifications include acetylation, methylation, 
phosphorylation, poly ADP rybosylation and ubiquitination. These post translational 
modifications can cause either activation or repression of their associated genes (Martin 
and Zhang, 2007; Ruthenburg et al., 2007; Bannister and Kouzarides, 2011). For example 
H4k16 acetylation is generally associated with gene activation while H4K20 with inhibition 
(Nishioka et al., 2002; Shogren-Knaak et al., 2006). 
Histone variants appear to be susceptible to specific forms of modification. For 
instance, histone H3.3 but not H3.1 was found to undergo extensive trimethylation at 
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lysine 4 and 27 (H3K4m3) which is a hallmark of active chromatin, and to be less 
susceptible to lysine 9 and 27 dimethylation (H3K9m2 and H3K27m2) which are 
associated with heterochromatin formation (McKittrick et al., 2004; Harada et al., 2014). 
1.4.7. Histone proteins and lifespan 
It has been posited that histone proteins and their posttranslational modification 
can be important in modulating life expectancy (Feser et al., 2010b; Khan and Khan, 2010). 
There is a view supporting the idea that abundance of histone proteins can positively 
affect life expectancy (O'Sullivan et al., 2010). Substantiate evidences include that 
overexpression of histone proteins in yeast increased lifespan (Feser et al., 2010b). It also 
reduced global histone protein expression and/or loss of histone proteins at specific 
regions of the genome correlated with genome instability and aging in yeast and in human 
foetal lung fibroblast cells (IMR90) (Dang et al., 2009; O'Sullivan et al., 2010; Hu et al., 
2014). The expression of histone H3 and H4 was specifically lower in fibroblasts of old 
versus young human individuals, and at late passage (P75) compared with early passage 
(P30) of fibroblasts (O'Sullivan et al., 2010). The ratio of histone variants including H2A 
and H3 variants was also found to be reduced compared with total histone expression 
level during aging in human lung embryonic fibroblast cells (Rogakou and Sekeri–Pataryas, 
1999). In contrast to a reduction in histone protein abundance with age, histone protein 
level was found to be increased in aged versus young mice (Alatawi, 2012).  
Histone modifications have also been correlated with life expectancy. The level of 
histone H3 lysine 9 tri-methylation (H3K9m3), histone H3 lysine 9 di-methylation 
(H3K9m2), and histone H3 lysine 56 acetylation (H3K56ac) decreased with age in human 
fibroblast cells and aged yeast (Dang et al., 2009; O’Sullivan et al., 2010). However, histone 
H4 lysine 16 acetylation (H4K16ac) increased in aged yeast (Dang et al., 2009).  
1.4.8. Effects of genistein on histone expression 
Histone protein expression can be affected by environmental and dietary factors 
(Ford et al., 2011; Dik et al., 2012; Suter et al., 2014). 1µM genistein or 0.1-2 µM 17β-
estradiol treatment for 6 days was found to upregulate expression of the canonical 
histone proteins (H2A, H2B, H3 and H4) in MCF-7 cells but not in the ERα and/or ERβ 
negative cell lines MDA-MB-231, MCF-10F, MCF-10A (Zhu et al., 2009). Another study in 
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MCF-7 cells showed that long term (40-60 day) genistein treatment (10 µM) reduced 
acetylated histone H3 expression (Jawaid et al., 2010).  
1.5. DNA methylation 
DNA methylation is the addition of a methyl group at Position C5 of cytosine where 
followed by a guanidine for example, at CpG sites. The DNA methylation status varies 
depending on cell phenotype and stage of differentiation (Morgan et al., 1999; Chong et 
al., 2007). The process is controlled by the DNA methyltransferase enzymes (DNMTs). 
DNMT1 maintains the DNA methylation pattern between daughter cells (Chong et al., 
2007), whereas DNMT3a and DNMT3b establish de novo DNA methylation (Okano et al., 
1999).  DNA methylation status is very susceptible to modifications by environmental and 
dietary factors including stress and diet (Junien and Nathanielsz, 2007; Daxinger and 
Whitelaw, 2010; Ford et al., 2011; Uriarte et al., 2013). For example, maternal exposure 
to ethanol (Kaminen-Ahola et al., 2010) led to changes in in the coat colour of the agouti 
mouse as a result of changes in the DNA methylation at the methylation-sensitive 
promoter element that determines this phenotype (Morgan et al., 1999). In humans, folic 
acid (0.4 mg/day) supplementation for 10 weeks also increased DNA methylation in both 
colonic mucosa and leukocytes (Pufulete et al., 2005). DNA methylation is considered to 
be an important likely contributor to the process of aging (Maegawa et al., 2010). Older 
individuals generally have lower global DNA methylation than younger individuals (Gomes 
et al., 2012). DNA methylation also appears to be involved in the control of lipogenesis. 
For example, DNA methylation of leptin gene varies among different cell types and stages 
of cell differentiation (Stöger, 2006), being hypermethylated in preadipocytes then 
hypomethylated  in mature adipocytes (Melzner et al., 2002). In mice Ucp1 gene had 
higher DNA methylation in white adipocytes compared with brown adipocytes (Kiskinis et 
al., 2007). Furthermore, DNA methylation of the FAS and SREBP1 promoters was 
decreased in mice in response to a high caloric diet (Uriarte et al., 2013).  
1.5.1. Effects of resveratrol on DNA methylation 
Resveratrol was found to stimulate an increase in the DNA methylation of genes 
encoding pro-inflammatory cytokines including IL1β, IL-6, TNF-α and IFN-γ, associated 
with lower level of  expression in rats (Lou et al., 2014). Effect of resveratrol on DNA 
59 
 
methylation is likely to be through affecting DNMT expression and activity (Paluszczak et 
al., 2010). In the support of this view, resveratrol was observed to down-regulate DNMT1 
(Qin et al., 2005; Stefanska et al., 2012) and DNMT3b expression (Qin et al., 2005; Qin et 
al., 2014). Additionally,  
Recently, it has been demonstrated that a high caloric diet can stimulate a reduction 
in the DNA methylation of genes involved in the process of lipogenesis including Fasn and 
Srebp1 (Uriarte et al., 2013; Gracia et al., 2014). The dietary induced changes in the DNA 
methylation status, especially that of FAS, was prevented by pterostilbene (30 
mg/kg/day), which is a dimethyl ether derivative of resveratrol. However, in spite of  its 
effects to reduce diet-induced obesity in rats, resveratrol (30 mg/kg/day) was found to 
have no effect on FAS promoter DNA methylation, showing that antiobesogenic effects of 
resveratrol occur through mechanisms which are alternative or additional to DNA 
methylation (Gracia et al., 2014). 
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Aims and objectives 
This study arose from previous work in the laboratory that had uncovered novel 
actions of resveratrol, specially that treatment of mouse 3T3-L1 adipocytes with 
resveratrol reduced mRNA for two key enzymes involved in lipogenesis – fatty acid 
synthase (FAS; Fasn gene) and acetyl Co-A carboxylase (ACC; Acaca gene)- and that 
resveratrol evoked a reduction in histone protein expression.  The aim was initially to 
investigate these responses in more detail, in particular to determine details of the 
underlying molecular mechanism.  A second major aim was to determine if genistein had 
similar actions, predicated on the fact that these two compounds are structurally similar.  
However, I discovered that actions of genistein were potentially of more interest and 
importance.  In particular I observed that treatment of 3T3-L1 cells with genistein 
appeared to induce a beige adipocyte phenotype.  Thus, the objectives of the wok evolved 
to be as follows 
1. Determine if genistein affects the expression of genes that characterise both white 
(Acaca, Fasn, Fabp4, Lipe, Rarres2, Retn) and brown (Ucp1, Tnfrsf9) adipocytes, and/or 
affects the expression of genes that have been recognised as mediators of white to brown 
adipocyte interconversion (Sirt1, Cebpb, Ppargc1a) in 3T3-L1 cells. 
2. Determine if genistein affects mitochondrial function in 3T3-L1 cells in a manner 
commensurate with a change in phenotype from white to beige adipocytes. 
3. Determine if the effects of genistein that suggest conversion of white to beige adipocytes 
are a function of genistein binding to the ER. 
4. Investigate the involvement of Sirt1 in the process of white into brown adipocyte 
interconversion. 
5. Determine if genistein, like resveratrol, affects histone protein expression through effects 
on histone gene transcription and determine if such action is mediated through the ER.  
6. Measure the effect of genistein on the expression of both ER subtypes, and compare this 
action with that of 17β-estradiol, based on evidence that expression of the ER can be auto-
regulatory. 
7. Investigate the effect of resveratrol on DNA methylation of Acaca and Fasn promoters, to 
address the hypothesis that this is the basis of the reduction in the corresponding mRNA 
species observed in 3T3L1 cells. 
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Chapter 2 
2. Materials and Methods 
2.1. Cell culture  
Cell culture and preparation of media was carried out under aseptic conditions 
using a class-II laminar flow hood cabinet. Ethanol (70%) was used to clean all working 
area. Disposable plastic ware was purchased sterile. All reusable glassware and other 
equipment was sterilized by autoclaving.   
2.1.1.  3T3-L1 Cells 
3T3-L1 cells, which model adipocytes after differentiation under suitable 
conditions and were derived from disaggregated Swiss 3T3 mouse embryos (Green and 
Kehinde, 1975), were purchased from American Type Culture Collection (ATCC)].   
2.1.1.1. Culture and differentiation of 3T3-L1 cells 
Cryovials containing 3T3-L1 cells were removed from storage in liquid nitrogen and 
thawed in a waterbath (37°C/ 3-4 min). Cells were washed with 10 ml pre-warmed 
preadipocyte medium [Dulbecco’s modified Eagle’s medium containing Glutamax plus 
4500mg/l glucose (Life Technologies), supplemented with 10% calf serum (Sigma), 1% 
penicillin/streptomycin]. Cells were collected by centrifugation at 100 g for 5 min. The 
supernatant fluid was discarded and the cell pellet was re-suspended in pre-warmed 
(37°C) preadipocyte medium. Cells were then seeded in 75 cm2 flasks at 0.2 X 105/ml 
(Greiner Bio-one), then incubated at 37°C in 5% CO2 in air. 
Cells proliferation was monitored regularly after seeding using a phase contrast 
microscope (Olympus CK2) and cells were passaged when approximately become 70-80% 
confluent, after removing the spent medium, cells were washed with pre-warmed 1x 
Phosphate Buffered Saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM NaHPO4.7H2O, 1.4 
mM KH2PO4, pH 7.3) (Sigma, D8538). Cells were detached from the flask by adding 2-3 ml 
of 0.05% trypsin plus 0.02 M EDTA (Sigma) and then incubating (37°C) for approximately 
5 min. The detached cells were washed with 10 ml of pre-warmed preadipocyte medium 
and centrifuged (100 g for 5 min) to pellet the cells. Following re-suspension of the cell 
pellet in 10 ml of freezing medium (90% preadipocyte medium plus 10% DMSO) cells were 
aliquoted into cryovials (Corning) (1 ml/tube). Cells were held overnight at -80°C in a 
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freezing box (Nalgene®) containing isopropyl alcohol to reduce the temperature of the 
cells gradually then transferred into liquid nitrogen for long-term storage. 
Fresh cells were used for each experiment. Thus all measurements were made on 
cells at the same passage number. Cells were passaged at the ratio of 1:10 in 75 cm2 flasks 
and counted using a haemocytometer chamber slide (Neubauer) after mixing 15 µl of cell 
suspension with an equal volume of 0.4% Trypan blue dye solution (Sigma). 
For differentiation, 3T3-L1 cells were grown in preadipocyte medium in 6-well 
plates (Griener). Forty eight hours after cells reached confluence, taken as day 0, cells 
were induced to differentiate by using preadipocyte medium supplemented with a 
differentiation cocktail containing 500 μM 3-isobutyl-1-methylxanthine (IBMX), 10µg/ml 
insulin (Sigma, I9278) and 250 nM dexmethasone (Sigma, D4902), 8 µg/ml biotin (Sigma, 
B4639) and 4 µg/ml pantothenic acid (Sigma, P5155). After a further 48 h, cells were fed 
with preadipocyte medium fortified with 10 µg/ml insulin, 8 µg/ml biotin and 4 µg/ml 
pantothenic acid and incubated for another 48 h. Thereafter, cells were maintained in 
mature adipocyte medium (0.2 µg/ml insulin, 8 µg/ml biotin and 4 µg/ml pantothenic 
acid), which was replaced every 2 days until the end of the experiment. Normally lipid 
droplets began to appear 5-6 days after inducing differentiation. 
2.1.1.2. Staining 3T3-L1 cells with oil red-O 
Oil Red O (Sigma, O1391, 0.5% w/v), which is a lipid specific stain, was diluted 3:2 
in double distilled water to make up the working solution then sterilised by filtration 
through a sterile syringe filter (Biotech, 0.2µm pore size) after standing at room 
temperature for 30 min. Cells were washed with warm PBS, then fixed with 10% neutral 
formaldehyde for 2-3 h at room temperature then rinsed quickly with 60% isopropanol 
diluted in double distilled water and allowed to dry at the room temperature for 
approximately 10 min. cells were overlaid with freshly prepared Oil Red O and incubated 
for 2-3 h at room temperature. Cells were then washed 3-4 times with double distilled 
water and photographed under a light microscope. 
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2.1.2.  Culture of Caco-2 and MCF-7 cells  
2.1.2.1. Preparation of medium 
Caco-2 complete medium was prepared by supplementing Dulbecco’s modified 
Eagle’s medium (DMEM, Life Technologies), which includes Glutamax plus 4.5 g/L glucose, 
with 10% v/v fetal bovine serum (FBS, Sigma), 60 µg/ml gentamycin (Sigma, G1397-10ml) 
and 1% v/v non-essential amino acids (NEAA) (Sigma, M7145). 
MCF-7 complete medium was prepared by supplementing modified Eagle’s 
medium (MEM, Sigma, M2279), with 2% Glutamax-100X (Life Technologies, 35050-038), 
10% v/v fetal bovine serum (FBS, Sigma), 1% v/v non-essential amino acids (Sigma, 
M7145), 1% V/V sodium pyruvate (Life Technologies, 11360-039) and 60 µg/ml 
gentamycin (Sigma, G1397). 
Phenol-free medium, for use when treating cells with phytoestrogens, was 
prepared by supplementing DMEM (Dulbecco’s Modified Eagle Medium, Life 
Technologies), with 2% Glutamax (Life Technologies), 10% v/v fetal bovine serum (FBS, 
Sigma) and 1% sodium pyruvate (Life Technologies, 11360-039). 
2.1.2.2. Passaging and seeding Caco-2 and MCF-7 cells 
Routine culture of Caco-2 and MCF-7 cells was as described for 3T3-L1 cells 
(section, 2.1.1.1) but with the specific media described above. Caco-2 cells and MCF-7 
cells were seeded at a density of 3.5×105 cells/ml - 4.5×105 cells/ml for experiments and 
cells were passaged at a 1:10 ratio for routine subculturing. 
2.2. Treatment of cells with test substances 
Stock solutions were prepared under sterile conditions and stored in aliquots at -
20°C to avoid multiple freezing and thawing. Stock solutions of 100 mM resveratrol 
(Sigma, R5010), 100 mM genistein (Sigma, G6776), 0.5 mM fulvestrant (Sigma, 14409), 50 
mM EX-527 (Sigma, E7034) and 10 mM TTNPB (Sigma, T3757), were prepared by 
dissolving them separately in dimethyl sulfoxide (DMSO, Sigma, D4540), while 1 µM β-
estradiol (Sigma, E4389) was prepared in double distilled water. Stock solutions were 
added in the required volumes to the cell culture medium and the same volume of solvent 
only was added to control medium to ensure that DMSO concentration was constant 
under all experimental conditions. Solutions were then filtered through a sterile filter 
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syringe (Biotech, 0.2 µm pore size). Cells were treated for specific periods of time with 
test substances, which were added to the medium and replaced every 2 days until the end 
of the experiment, and at specific times after seeding and/or transfection as specified in 
relation to particular experiments. There was no decline in RNA yield with increasing 
concentration of genistein indicating that there were no toxic effects (table 1). 
2.3. Primer design 
Oligonucleotide primers were designed manually based on mRNA sequences as 
identified through NCBI (http://www.ncbi.nlm.nih.gov/). Primers were designed to be 18-
25 nucleotide long with CG content 50-60% and where possible with melting temperature 
greater than 55°C. Sequences were assessed to check for chance of hairpin/self-
dimerization or self-complementary using online software 
(http://www.basic.northwestern.edu/biotools/OligoCalc.html). Primers were 
synthesized by Eurofins MWG.  
2.4. RNA measurement 
2.4.1. RNA extraction 
Cells were washed with 1 x PBS (1 ml/well), then TRIzol® Reagent (Life 
Technologies, 15596018) was added (1ml/well) and the mixture was then collected in a 
microfuge tube then stored at -80C°. Total RNA was then extracted using the PureLinkTM 
RNA Mini Kit (Life Technologies, 12183018A), following the manufacturer’s protocol. 
Briefly, 0.2 ml chloroform was added to the TRIzol cell preparation, then the mixture was 
shaken vigorously for 15 s then incubated for 2-3 min at room temperature then 
centrifuged (12000 g for 15 min at 4°C) to separate the cell components. The clear upper 
phase containing RNA (approximately 0.4 ml) was transferred into a sterile microfuge 
tube, an equal volume of 70% ethanol was added and the reagents were combined by 
pulse vortexing then transferred to the spin-cartridge, centrifuged (12000 g/15 s at room 
temperature) and the flow through was discarded. The cartridge was then washed with 
0.7 ml and 0.5 ml wash buffer I and II respectively. After drying the membrane by 
centrifuging at 12000 g for 1 min at room temperature, RNA was eluted using 30 µl RNase 
free water as provided in the kit. Concentration was measured using a Nanodrop 
spectrophotometer and RNA was stored at -80°C.    
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2.4.2. Measurement of RNA and DNA concentration 
RNA and DNA concentrations were measured routinely using a Nanodrop-1000 
spectrophotometer (Thermo Fisher Scientific). Absorbance ratios 260/280 nm and 
260/230 nm of 1.8-2.2 were considered to indicate acceptably pure preparations. RNA 
integrity was not measured (eg. By measuring RIN value) because the cost would be 
prohibitively high for the large number of samples analysed. However, the same 
procedure for preparing RNA for analysis by hybridization to DNA measurements carried 
out in the laboratory yielded RNA with RIN values of ˃7  (Ions, 2011). Moreover RNA 
integrity is much smaller potential confounding factor for the measurement of specific 
mRNAs by RT-qPCR to amplify short (˂200 bp) region than for analysis using DNA 
microarray. 
 
Table 1: an example of the RNA concentrations obtained from 3T3-L1 cells treated with different 
concentrations of genistein. 
2.4.3. Reverse transcription of RNA to cDNA 
RNA (0.5-1 µg) from cells (3T3-L1, Caco-2 cells or MCF-7) was reverse transcribed 
to cDNA using Superscript™ III RNase H- Reverse Transcriptase (Life Technologies) in two 
steps. First, RNA (approximately 1 µg) was added to 0.4 μl of 0.5 mM dNTPs (Bioline), 1 µl 
random primers (150 ng/µl; Promega) and RNase free water in a final volume of 13 μl. The 
reaction was held at 65 ºC for 5 min then samples were transferred onto ice. Second, 1 µl 
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RNase Inhibitor (40 U/μl; Promega), 1 μl Superscript™ III RT (200 U/μl), 4 μl 5x first strand 
buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2) and 1 μl DTT (0.1 M) were 
mixed into the reaction by pipetting. The reaction was then heated to 25 ºC for 5 min, 50 
ºC for 45 min, and then 70 ºC for 15 min using a Thermohybaid PX2™ thermal cycler. 
Samples prepared in an identical manner but omitting the addition of Superscript™ III 
were used as negative controls in downstream PCR to detect/ensure absence of DNA 
contamination. 
2.4.4. RT-qPCR 
The relative quantification method was used for RT-qPCR:  Reactions were set up 
in LightCycler® 96 well plates (Starlab, I1402-9909), to contain 1 μl cDNA (RTR-reaction), 
5 μl SYBR Green I Master Mix (Roche), 1 µl (0.5 μM) sense and antisense primers (Eurofins 
MWG; Tables 1 and 2) made up to total of 10 µl using sterile nucleic acid free water 
(Roche). Cycling parameters were 95˚C/5 min initial denaturation, 95˚C/10 s denaturation, 
followed by 45-55 cycles of 55-60˚C/10 s annealing, 72˚C/15 s elongation.  
Each sample was measured in duplicate. Fluorescence was detected for each PCR 
cycle and the threshold crossing points (Ct values) determined. At the end of all reactions 
a melting curve was generated to ensure the specificity of target gene amplification.  
Expression of all target and reference genes were calculated for each sample using 
2∆∆Ct. Each target cDNA concentration was then expressed in relation to the average value 
of the reference gene from the same cDNA preparation. Two reference genes were used 
for all measurements. 
2.5. Agarose gel electrophoresis 
Agarose gels (1% or 2%) were prepared by boiling 0.5 or 1 g agarose in 50 ml of 1 
x TBE buffer (Tris base 10.8 g, Boric Acid 5.5 g, EDTA 0.93 g, 1 L double distilled water pH 
8.3). Before pouring the gel, 2 μl of Safe View nucleic acid stain (NBS Biologicals Ltd, NBS-
SV) was added. Samples were mixed with loading dye (50 mM Tris-HCl pH 8, 5 mM EDTA, 
20 % glycerol and 0.1 % Bromophenol Blue) in a ratio of 1:5 (1 µl of the dye and 5 µl of 
sample), and loaded onto the gel in parallel with a molecular weight marker mixture 
(Ladder I-V, Bioline). Gels were run at 60 V for 50 min then DNA bands were visualised 
using a UV transilluminator (Uvitec BTS-26M). 
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2.6 . Measurement of mitochondrial function 
2.6.1. Cell seeding on Seahorse V7 cell plates 
Mitochondrial function was measured using the Seahorse XF-24 analyser 
(Seahorse Bioscience), 3T3-L1 cells were cultured in Seahorse V7 cell plates (Seahorse 
Bioscience). Cells were induced to differentiate and maintained to grow in the presence 
and absence of genistein as described in section 2.1.1.2. 
2.6.2. Pre-test plate preparation 
The Seahorse V7 cell plate cartridge was hydrated with Seahorse calibration buffer 
(Seahorse Bioscience) and incubated without CO2 at 37°C for approximately 4-5 h before 
use.  Solutions for injection were prepared from stock solutions and assay medium, then 
loaded into the injection ports. Briefly, 50 µl of oligomycin (10 µg/ml) (Sigma, O4876) was 
added to port A, 55 µl TTNPN (10 µM) (Sigma, T3757) was added to port B, 60 µl of FCCP 
(2.5 µM) (Sigma, C2920) was added to port C, 65 µl antimycin A (2.5 µM) (Sigma, A8674) 
was added into port D. After loading solutions the cartridge was loaded into the Seahorse 
XF-24 analyser for calibration. 
2.6.3. Preparation of the assay medium 
On the day of the assay, 35.l ml of assay medium was prepared from 33.6 ml of 
pre-warmed DMEM (Sigma, D5030) by adding 31.5 mg D-glucose (Sigma, G8270), 2% L-
Glutamax (Life Technologies), 3% calf serum (Sigma, C8056-500ML), 1% sodium pyruvate 
(Life Technologies). 
2.6.4. Washing and replacing cell culture medium with the assay medium 
Carefully and gently 400 µl of the cell culture medium (from a total of 450 µl) was 
removed and replaced with assay medium (400 µl), a further volume of 400 µl/well was 
then replaced  again with another 450 µl/well, giving a final volume of 500 µl per a well. 
The plate was incubated in the absence of CO2 at 37°C for 1 h before use. Finally the plate 
was installed into XF-24 analyser to measure mitochondrial function. All data were 
expressed relative to total protein (section; 2.9.2), which was measured by preparing cell 
lysate at the end of the experiment. 
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2.7. Generation and manipulation of promoter-reporter plasmid DNA 
constructs 
2.7.1. Identifying gene promoter sequences 
The region 1000-1500 base pairs upstream to the transcription start site was taken 
as the promoter region for each gene. Sequences were retrieved in FASTA format by 
searching NCBI (http://www.ncbi.nlm.nih.gov/). Promoter sequences identified in this 
way were confirmed by alignment against the transcript sequence using Clustal software 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
2.7.2. Amplification of DNA products by PCR   
Required region of DNA were isolated and amplified by PCR. Reactions of 50 µl were 
prepared by mixing 25 µl of HotStart Taq master mix (Qiagen), 1 µl (10 µM) each of sense 
and antisense primers (Table 3), approximately 50-200 ng of template (the volume 
dependent on the concentration and type of the template) and double distilled water to 
make up the volume. To check for DNA contamination negative control reactions were 
prepared by adding water instead of the template. Generally the following PCR program 
was used:  
                                           95°C for 15 min (to activate Hot Start polymerase) 
                                           95°C for 30 s denaturation 
35 Cycles                           50-60°C for 30 s annealing temperature 
                                          72°C for 1 min elongation 
                                         72°C for 10 min final elongation 
                                           4°C holding temperature 
 
For subcloning PCR products were analysed by agarose gel electrophoresis to confirm 
successful amplification then purified using the Qiamp PCR purification kit (Qiagen). 
2.7.3. Digestion of DNA with restriction enzymes 
Plasmid vector and DNA inserts (PCR products) were digested by mixing 1µl 
(10u/μl) Hind III (Promega, R604A), 1µl (12u/μl) EcoR1 (Promega, R601A), 2.5 µl buffer E 
(Promega, R005A), 0.25 µl of acetylated bovine serum albumin (BSA; Promega, R396E), 
500-1000 ng template in a total volume 25 µl, made up with double distilled water. 
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Reactions were incubated at 37 °C for 1-2 h. Products were resolved by agarose gel 
electrophoresis then purified by using the Qiaquick PCR purification kit (Qiagen, 28104). 
2.7.4.  Subcloning PCR product into pSF-pA-PromMCS-BetaGal 
For subcloning into pSF-pA-PromMCS-BetaGal (Oxford genetics, OG239) ligation 
reactions comprised 30-60 ng vector with 90-180 ng DNA (1:3 molar ratio), 1 µl 10X T4 
DNA ligase buffer (Promega, C126B), 4 µl double distilled water and 1 μl (1-3u/μl) T4 DNA 
ligase (Promega, M180A). The reaction was left to stand at 4°C/overnight, then used for 
bacterial transformation. 
2.7.5. Bacterial transformation and preparation of plasmid DNA 
Approximately 5 µl of ligation reaction was added to competent DH5α E. coli cells 
(Invitrogen) in a microfuge tube. After mixing gently the tube was incubated on ice for 30 
min, then cells were heat-shocked at 42°C for 45 s, and incubated on ice for further 5 min. 
After addition of 250 µl of Luria Bertani (LB) medium (1% peptone, 0.5% yeast extract and 
1% NaCl) cells were incubated for 1-2 h in a shaking incubator at 37°C/250 rpm, then the 
cells were spread on LB agar plates that contained either 100 µg/ml ampicillin or 50 µg/ml 
kanamycin, depending on the plasmid vector, and incubated at 37°C overnight. A starter 
culture (LB containing ampicillin or kanamycin) from a well isolated colony was grown for 
6-7 h in a shaking incubator (37°C/250 rpm) then used to inoculate 200 ml of LB medium 
containing 100 µg/ml ampicillin or 50 µg/ml kanamycin at a ratio of 1:100. The culture 
was grown overnight in a shaking incubator at 37°C/250 rpm. Finally, cells were harvested 
by centrifugation at 5000 g for 15 min at 4°C and DNA was extracted using the Endotoxin-
free plasmid maxiprep kit (Qiagen) following the manufacturer`s protocol. 
2.7.6. Preparation of plasmid DNA for sequencing 
A well isolated colony was selected and grown in LB containing 100 µg/ml 
ampicillin or 50 µg/ml kanamycin for 14-16 h in a shaking incubator (37C°/250 rpm). The 
Qiaprep® Spin Miniprep-Kit (Qiagen, 27104) was used to prepare plasmid DNA, following 
the manufacturer`s protocol. 
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2.8. Transient transfection of mammalian cells and reporter gene assay 
2.8.1. Transient transfection 
Before transfection, cells were seeded (3.5×105 cells/ml) in six-well plates 
(Greiner) in complete medium. Twenty four hours later when the cells reached 50-60% 
confluence, cells were transfected with plasmid constructs. Briefly, for each well, 4 µl 
GeneJammer transfection reagent (Agilent technologies, 204130) was mixed with 100 µl 
of Opti-MEM medium (with no additions) (Invitrogen, 51985-026) and the mixture was 
incubated at room temperature for 5 min before adding 1.7-2 µg of plasmid DNA. This 
mixture was incubated at room temperature for further 15-20 min. The mixture was 
prepared in one single volume, scaled up as appropriate depending on the number of 
wells for transfection. During this time, spent medium was replaced with 900 µl of fresh 
phenol free medium in six-well plates then 100 µl of the transfection mixture was added 
drop-wise with gentle swirling. Cells were then incubated at 37°C/5% CO2 for 4 h then 
wells were topped up with 500 µl phenol free medium. Cells were treated with test 
compounds 24 h after transfection. 
2.8.2. Whole cell lysate preparation 
After removing medium cells were washed with cold 1X-PBS (1ml/well) (Sigma) 
then 200 µl of cold lysis buffer (0.25 M Tris-HCl (pH 7.4), 0.25% (v/v) NP-40, 2.5 mM EDTA) 
was added to each well. Cells were then frozen at -20°C for 30 min then thawed at room 
temperature and the cell lysates were transferred into microfuge tubes using a sterile 
disposable cell scraper (Fisherbrand® Disposable Cell Lifters, Fisher Scientific). Cell lysates 
were then centrifuged at 12000 g for 5 min at 4°C. Supernatant fluids were transferred 
into new clean microfuge tubes, kept on ice and used on the same day for reporter gene 
assay by measuring beta-galactosidase activity. 
2.8.3. Measurement of protein concentration 
Protein concentration was measured using the Bradford assay. Briefly, protein 
samples were diluted 1:50, and standards were prepared using 0.1 mg/ml BSA serum 
albumin (BSA) which was diluted to give standards ranging from 0 to 0.1 mg/ml. Two 
hundred microliters protein solution was mixed with 800 µl of Bradford reagent (Bio-Rad), 
which was diluted 1:5 with double distilled water then volume of 250 µl were loaded in 
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triplicate into 96 well microplate. Absorbance at 595 nm was measured using a plate 
reader (ThermoLab Systems Multiscan Acent). 
2.8.4. Measurement of Beta-galactosidase enzyme activity 
β-galactosidase activities were determined based on a colorimetric assay involving 
the hydrolysis of the substrate chlorophenol red–β-D-galactopyranoside (CPRG) to release 
chlorophenol red. Twenty microliters of cell lysate was mixed with 130 µl of substrate (1.2 
mg/ml chlorophenol red-β-D-galactopyranoside (CRPG, Sigma), which was diluted in 
buffer A (25 mM MOPS, 100 mM NaCl, 10 mM MgCl2, pH 7.5), in 96-well plates. The plate 
then was incubated at 37°C and the reactions were allowed to progress until the colour 
had changed from yellow to red. The reaction was stopped by adding 80 µl of stop solution 
(0.5 M Na2CO3) and the incubation time was recorded. β-galactosidase specific activities 
were calculated as nmoles of chlorophenol red formed per min per mg of protein 
(nmoles/min/mg). 
2.9. Western blot analysis 
2.9.1. Antibodies 
Primary antibodies used were anti-histone H2B (Abcam, ab1790; 1:10000), Anti-
histone H3 (Abcam, H0164; 1:5000), anti-histone H4 (Abcam, ab10158; 1:1000), anti-α 
tubulin (Sigma, T6074; 1:2000) and anti-β-actin (Santa cruz, SC-1615; 1:5000). Infra-red 
labelled secondary anti-bodies were used to visualise protein bands and were either 
donkey anti-Rabbit IgG (Li-Cor, 926-32223; 1:1000) or goat anti-mouse IgG (Li-Cor, 926-
32220; 1:1000). All antibodies were diluted in a solution prepared by combining wash 
solution (0.1% tween-20 plus 1X PBS) with Odyssey blocking buffer (Li-Cor, 927-40000) in 
a 1:1 ratio.  
2.9.2. Preparation of cell lysates 
Cells were re-suspended using a sterile cell scraper in a mixture of 1X PBS and 
protease inhibitor cocktail (Roche, 11836153001) (1 ml/well) which was prepared by 
dissolving 1 tablet of protease inhibitor cocktail tablet in 10 ml PBS. Cells were placed in 
microfuge tubes and centrifuged at 13000 g for 15 min at 4C°. The supernatant fluid was 
discarded and cell pellets were resuspended in 50 µl of RIPA lysis buffer (Sigma, R0278-
50ml) plus protease inhibitor cocktail then frozen at -80°C. Lysates were thawed and then 
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centrifuged at 13000 g for 20 min to remove cell debris. The supernatant fluid was 
transferred into new sterile microfuge tubes. Protein concentration was measured using 
the Bradford assay as described in section 2.8.3. 
2.9.3. Preparation of SDS polyacrylamide gels  
Separating gel (12.5%) was prepared using 2.19 ml 40% bis acrylamide (37.5:1), 
2.8 ml 2.5X separating gel buffer (1.87 M Tris-HCl pH 8.9, 0.25 % SDS), 6 µl of TEMED, 65 
µl of 10% ammonium persulfate (APS) in a total volume of 7 ml. Stacking gel (10%) was 
prepared using 0.25 ml 40% bis acrylamide (37.5:1), 0.4 ml 5X stacking gel buffer (0.3 M 
Tris-HCl pH 6.7, 0.5% SDS), 2.5 µl TEMED, 18 µl 10% APS in a total volume of 2 ml. The 
separating gel was poured between assembled glass plates (Bio-Rad) and overlaid with 2 
ml of isopropanol to remove air then left for approximately 25 min to polymerise.  
Isopropanol overlaid was removed then stacking gel was added, inserting the comb to 
create wells. The gel was allowed to stand for further 20 min before use.  
2.9.4. Preparation and electrophoresis of protein samples 
Protein samples (5-10 µg) were mixed with protein loading buffer  (45 mM Tris-
HCl pH 6.8, 10% glycerol, 1% SDS, 0.01% bromophenol blue, 50 mM DTT, and 5% β-
mercapto-ethanol), and heated at 95°C for 4-6 min then loaded onto acrylamide gels in 
parallel with a molecular weight marker (ColorBurst Marker MW 8-220 kDa, (Sigma). 
Electrophoresis was at 100-120 V for 1-2 h in 1X protein electrophoresis running buffer 
(0.5 M Tris-HCl pH 8.8, 1.9 M glycine, 0.1% SDS. 
2.9.5. Transfer of protein onto PVDF membrane  
Proteins were transferred from gels onto PVDF membrane (Hybond P, Amersham) 
by semi-dry transfer using an electroblotting cassette (TE22, GE Life Science). Briefly, a 
PVDF membrane was pretreated with 100% methanol for 30 s. Membranes were then 
rinsed with double distilled water for 2 min on a shaker at room temperature. Membranes 
were then incubated in transfer buffer (0.04 Tris-HCl pH 8.8, 1.5 M glycine, 0.08% SDS, 
20% methanol) for 10-12 min at room temperature. Gels and membranes were then 
placed in contact and sandwiched in cassette between Whatman paper blotting paper. 
Transfer was at 15V for 50 min. 
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2.9.6. Probing membranes with antibodies  
Membranes were cut into two pieces before being probed with primary antibodies 
against target (one half of the membrane) or reference proteins (other half). Membranes 
were allowed to air dry completely and incubated in membrane blocking solution (1 
volume of Odyssey Blocking Buffer plus 1 volume of 1X-PBS) for one hour at room 
temperature with shaking. After blocking, membranes were incubated with primary 
antibodies for 1 h at room temperature with gentle shaking. Following washing (4 x 15 
min) with membrane washing solution (0.1% Tween-20 in 1X-PBS), infra-red labelled 
secondary antibodies, protected from direct exposure to light, were applied for another 
hour on a shaker at room temperature, then membranes were washed again (4 x 15 min) 
with membrane washing solution. Membranes were rinsed with 1X-PBS and scanned 
using the Odyssey infra-red imaging system (LI-COR). Odyssey densitometry software was 
used to quantify protein bands.  
2.10.Measurement of DNA methylation  
2.10.1. DNA extraction 
After removing spent medium, cells were washed and collected into pre-warmed 
1X-PBS (1ml/well) in microfuge tubes using a disposable cell scraper. Genomic DNA was 
extracted from cells using the QIAamp® DNA Mini Kit (Qiagen, 51306) following the 
manufacturer`s protocol. Briefly, the cell suspension was centrifuged at 500 g for 5 min 
and the cell pellet was re-suspended in 200 μl 1X-PBS then 20 µl of proteinase K (Qiagen) 
and 200 µl of buffer AL (Qiagen) were added, and the reagents were mixed by pulse-
vortexing for 15 s. Following incubation at 56°C for 10 min and brief centrifugation, 200 
µl ethanol (100%) was added. After thorough mixing samples were applied onto mini-spin 
columns and centrifuged for 1 min at 6000 g. After washing with buffers AW1 then AW2 
(Qiagen) the spin column was dried by high speed centrifugation (10000 g/1min). DNA 
was eluted into DNase-free tubes using double distilled water. 
2.10.2.  Bisulfite conversion of DNA 
200-500 ng of genomic DNA was bisulfite modified using the EZ DNA Methylation-
Gold™ Kit (Zymo Research Corp, D5006) following the manufacturer’s protocol to convert 
non-methylated cytosine to uracil. Briefly, 130 µl of CT conversion reagent (900 µl double 
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distilled water, 300 µl M-Dilution Buffer, and 50 µl M-Dissolving Buffer) was mixed with 
20 µl of DNA in a 0.5 µl microfuge tube. The samples were then incubated at 98°C for 10 
min then 64°C for 2.5h. M-Binding Buffer (600 µl) was added to each sample then samples 
were applied to Zymo-SpinTM IC Columns. Columns were then washed with 100 µl M-Wash 
Buffer (with centrifugation at 10000 g for 30 s). M-Desulphonation Buffer was then added 
(200 µl per tube) and incubated with sample at room temperature for 15-20 min. Samples 
were centrifuged again (10000 g for 30 s) then columns were washed twice with 200 µl of 
M-Wash Buffer and DNA was eluted into DNase-free tubes using 10 µl of M-Elution Buffer 
with centrifugation (10000 g/30 s).  
4 µl of the bisulfite modified DNA was used in a PCR reaction (see section 2.7.2) to 
amplify the required region using specific biotinylated primers (Table 4) then run on an 
agarose gel (section 2.5) to confirm successful amplification.  
2.10.3. Pyrosequencing using the Qiagen PyroMark MD system 
Pyrosequencing was carried out using biotinylated PCR product (section 2.10.2). The 
biotinylated DNA strand was separated then used as template in the pyrosequencing 
reaction. Briefly, 10 µl of biotinylated DNA was incubated with 80 µl binding master mix 
(containing 2 µl streptavidin-coated sepharose beads (GE Healthcare), 38 µl binding buffer 
(Qiagen) and 40 µl H2O) on a shaker for 10 min. At the same time 12 µl sequencing primer 
(diluted in annealing buffer; Qiagen) was added into each well of the Pyromark MD 96 
well plate (Qiagen). The PyroMark Vacuum Prep Workstation vacuum tool (Qiagen) was 
prepared in double distilled water for 25 s and then the biotinylated PCR product/binding 
master mix was applied. Sequential washing followed (5 s/each solution) using 70 % 
ethanol, 0.2 mol/L NaOH solution (denaturing buffer) and wash buffer (Qiagen). The 
vacuum pump was switched off, and the vacuum pump probes were submerged into the 
Pyromark MS 96 well plate containing sequencing primer which led to release of the biotin 
tagged, single stranded DNA into the wells. The plate was then incubated at 80ºC for 2 
min, cooled to room temperature and transferred to the PyroMark MD™ system (Qiagen). 
The principle of pyrosequencing depends on detecting pyrophosphate (PPi) released as a 
result of deoxribonucleotide triphosphate (dNTP) incorporation into the complementary 
DNA strand. The released PPi is used by ATP sulfurylase to synthesise ATP in the presence 
of adenosine 5 phosphosulfate (APS). The ATP generated is used for luciferase-mediated 
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conversion of luciferin into oxylucifirin, which is accompanied by emission of light. The 
amount and the intensity of the generated light is proportional with the quantity of ATP. 
Unincorporated ATP and nucleotides are degraded by apyrase, which is a nucleotide 
degrading enzyme (Qiagen).  
 
2.11.Statistical analysis 
SPSS software (one way ANOVA and Student`s unpaired T-test) was used for statistical 
analysis. Data are presented as mean ± standard error (SE) or standard deviations (SD). 
P≤0.05 was considered statistically significant. 
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Table 2: Oligonucleotide sequences and thermal cycling parameters used for RT-q PCR in samples from Mus musculus. Sequences are in the 5’-3’ 
direction as indicated below. Times are given in the order denaturing, annealing and extension. 
Gene product Purpose Transcript Genbank 
accession number 
Primer sequence (5’---> 3’) Anneal 
temp. (oC) 
Cycling 
parameters 
No. of cycles 
FAS RT-qPCR NM_007988.3 Forward primer: 
GTGGACATGGTCACAGATG 
Reverse primer:  
CATAGCTGACTTCCAACAGC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
ACC RT-qPCR NM_133360.2 Forward primer: 
ATGTCCTGGATAACCTGGTC 
Reverse primer:  
GATATCCTGCAGCTCTAGCA 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
AP2 RT-qPCR NM_024406.2 
 
Forward primer: 
GACAGGAAGGTGAAGAGCAT 
Reverse primer:  
GTGGAATGTGTTATGAAAGGC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
HSL RT-qPCR NM_010719.5 Forward primer: 
GTCAGTGCCTATTCAGGGAC 
Reverse primer:  
AGTTGAGCCATGAGGAGGC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
Chemerin RT-qPCR NM_027852.2 Forward primer: 
CTGTGCAGTTGGCCTTCCAAG 
Reverse primer:  
GGTTTGATTGTGCACTCCGG 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
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Resistin RT-qPCR NM_022984.4 
 
Forward primer: 
CAGAACTGAGTTGTGTCCTGC 
Reverse primer:  
CTTGTCGATGGCTTCATCGATG 
55 95oC, 10 s 
56oC,   5 s 
72oC, 10 s 
 
45 
Sirt1 RT-qPCR NM_001159589 Forward primer: 
GCTGTGAAGTTACTGCAGG 
Reverse primer:  
GCAAGGCGAGCATAGATAC 
56 95oC, 10 s 
56oC,   5 s 
72oC, 10 s 
45 
C/EBPβ RT-qPCR NM_009883.3 Forward primer:  
CAAGGCCAAGATGCGCAAC 
Reverse primer:  
GCAGCTGCTTGAACAAGTTC 
56 95oC, 10 s 
56oC,   5 s 
72oC, 10 s 
45 
UCP1 RT-qPCR NM_009463.3 Forward primer: 
CCTGCCTCTCTCGGAAACAA 
Reverse primer:  
TGTAGGCTGCCCAATGAACA 
60 95oC, 10 s 
60oC,   5 s 
72oC, 10 s 
55 
CD-137 RT-qPCR NM_011612.2 
NM_001077508.1 
NM_001077509.1 
Forward primer: 
TCATTGTGCTGCTGCTAGTGG 
Reverse primer:  
CTGCACACACTCTGCAGATGT 
55 
 
 
95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
PGC1α RT-qPCR 
 
NR_027710.1 
NM_008904.2 
Forward primer: 
CAATTGAAGAGCGCCGTGTG 
Reverse primer:  
GTCACAGGTGTAACGGTAGGTG 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
ERα 
 
RT-qPCR 
 
 
NM_007956.4 
 
 
Forward primer:(Wang et al., 2012) 
TGGGCTTATTGACCAACCTAGCA  
Reverse primer:  
AGAATCTCCAGCCAGGCACAC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
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ERβ RT-qPCR 
 
NM_207707.1 
NM_010157.3 
NR_104386.1 
Forward primer: (Wang et al., 2012) 
GACTGTAGAACGGTGTGGTCATCAA 
Reverse primer:  
CCTGTGAGGTAGGAATGCGAAAC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3  
(H3.1, 
H3.2, 
H3.3) 
RT-qPCR 
 
NM_178203.1 
NM_178216.3 
NM_178205.2 
NM_178204.2 
NM_013548.4 
NM_145073.2 
NM_178206.2 
U62670.1 
Forward primer: 
ACCAGAAGTCGACCGAGCTG 
Reverse primer:  
ATGGCGCACAGGTTGGTGTC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
TOPO1 
 
RT-qPCR 
 
 Primer mix (Primerdesign, 26690) 
 
60 95oC, 10 s 
60oC,   5 s 
72oC, 10 s 
45 
GAPDH RT-qPCR NM_008084.2 
 
Forward primer: 
TGGAGTCTACTGGTGTCTTC 
Reverse primer:  
GCTGACAATCTTGAGTGAGT 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
NONO RT-qPCR NM_023144.2 Forward primer:(Arsenijevic et al., 2012) 
TGCTCCTGTGCCACCTGGTACTC 
Reverse primer:  
CCGGAGCTGGACGGTTGAATGC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
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Table 3: Oligonucleotide sequences and thermal cycling parameters used for RT-qPCR in samples from homo sapiens. Sequences are in the 5’-3’ 
direction as indicated below. Times are given in the order denaturing, annealing and extension. 
Gene product Purpose Transcript Genbank 
accession number 
Primer sequence (5’---> 3’) 
 
Anneal 
temp (°C) 
Cycling 
parameters 
No. of cycles 
ERα RTqPCR 
 
 
 
NM_000125.3 
NM_001122740.1 
NM_001122741.1 
NM_001122742.1 
Forward primer: 
CTAGAAGGTGGACCTGATCATGG 
Reverse primer:  
GATGGTCAGTGCCTTGTTGGATG 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
 
 
 
 
ERβ RTqPCR 
 
NM_001437.2 
NM_001040275.1 
NM_001214902.1 
NM_001271876.1 
NM_001214903.1 
Forward primer: 
GATGCGTAATCGCTGCAGACA 
Reverse primer:  
TGGTGTGAAGCAAGATCGCTAG 
 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
Sirt1 RTqPCR 
 
NM_012238.4 Forward primer: 
GGCAAAGGAGCAGATTAGTAGG 
Reverse primer:  
CATCAGGCTCATCTTCTAAGCC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3a RTqPCR NM_003529.2 Forward primer: 
GCTCGGAAGTCTACTGGTG 
Reverse primer:  
GGACTTCTGATAACGGCGG 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3b RTqPCR NM_003537.3 Forward primer:  
ACCGATCTTCGCTTCCAGAGCTC 
Reverse primer:  
GTCACTCGCTTAGCATGGATGGC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
 
45 
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Histone H3c RTqPCR NM_003531.2 Forward primer: 
GTCGCTACCAGAAGTCCAC 
Reverse primer:  
GTGTCTTCGAAGAGTCCCAC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3d RTqPCR NM_003530.4 Forward primer: 
ATCCGCAACGACGAGGAG 
Reverse primer:  
GTGGACTTGCGAGCAGTC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3e RTqPCR NM_003532.2 Forward primer: 
GTACTAAGCAGACGGCTCG 
Reverse primer:  
CTTCTGGTAGCGACGGATC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
 
Histone H3f RTqPCR NM_021018.2 Forward primer: 
CAGCTCGTAAGTCCACTGG 
Reverse primer:  
GCGAATCAGTAGCTCAGTCG 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3g RTqPCR NM_003534.2 Forward primer: 
CAAGCAGACTGCACGCAAG 
Reverse primer:  
CTGATAGCGGCGAATCTCG 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3h RTqPCR NM_003536.2 Forward primer: 
CTCGGTGGACTTCTGGTAG 
Reverse primer:  
CGTACGAAGCAGACTGCTC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3i RTqPCR NM_003533.2 Forward primer: 
CTACCAGAAGTCGACCGAG 
Reverse primer:  
CGCACAGGTTGGTATCCTC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
81 
 
Histone H3j RTqPCR NM_003535.2 Forward primer: 
GACAGCTCGCAAGTCTACC 
Reverse primer:  
GAGCAGCTCAGTCGACTTC 
55 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3.2 RTqPCR NM_021059.2 Forward primer: 
CTAAGCAGACTGCTCGCAAGTC 
Reverse primer:  
GATCAGCAGCTCCGTGGACTT 
 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
Histone H3.3 RTqPCR NM_002107.4 Forward primer: 
GCTTCCAGAGCGCAGCTATC 
Reverse primer:  
CTTAAGCACGTTCTCCACGTATG 
 95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
TOPO1 RTqPCR  Primer mix (Primerdesign, 26690)  95oC, 10 s 
55oC,   5 s 
72oC, 10 s 
45 
GAPDH RTqPCR  Forward primer: 
TGAAGGTCGGAGTCAACGGATTTG 
Reverse primer:  
CATGTAAACCATGTAGTTGAGGTC 
 95oC, 5 s 
 55oC, 5 s 
  72oC, 10 s 
 
45 
 
 
 
 
 
82 
 
Table 4: Oligonucleotide sequence and thermal cycling parameters used for amplification of human ERβ and histone H3.1 (variant H3b) promoter 
region by PCR. Sequences are in the 5’-3’ direction and restriction sites are highlighted in red as indicated below.  
Gene/ 
Product 
Purpose Transcript Genbank 
accession number 
Primer sequence (5’---> 3’) Anneal 
temp (°C) 
Cycling 
parameters 
No. of cycles 
ERβ 
promoter 
region 
PCR 
amplificati
on 
NC_018925.2 Forward primer: 
CTCAAGCTTGTGGTGTATGCCTGTAATC 
Primer Reverse: 
GAGGAATTCGGAAGGTATGTATATGGAGC 
55 See section 
2.7.2 
30 
Histone H3 
promoter 
region (H3b) 
 
PCR 
amplificati
on 
M26150 Forward primer: (2)(Alatawi, 2012) 
GTGGGAGAAGTGCCATGCAGCAC 
Reverse primer:  
CTTGCCTGCAGAGACGTCTGTG 
57 See section 
2.7.2 
40 
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Table 5: oligonucleotide sequences and thermal cycling parameters used for PCR and pyrosequencing in samples from mus musculus. Sequences 
are in the 5’-3’ direction as indicated below. Times are given in the order denaturing, annealing and extension. 
Gene Sequence ID Primer sequence (5’---> 3’) Anneal 
temp (°C) 
Cycling 
parameters 
No. of cycles 
Acaca NT_096135.6 Forward primer:  
Bio-TGGAATTAATGGAAATGGGATAGG 
Reverse primer:  
AACTCAACACAACCCTTCATCCT 
50 95oC, 30 s 
50oC, 30 s 
72oC, 90 s 
72oC, 120 s 
50 
Fasn NT_096135.6 Forward primer:  
Bio-GGATAGGAGGGAAGGGAATAATT 
Reverse primer:  
AACTCCCACCCTCTATAACCAC 
50 95oC, 30 s 
50oC, 30 s 
72oC, 90 s 
72oC, 120 s 
50 
Sequenced region 
Acaca  
Pyrosequencing primer:   TTTTTTTGGTGGTATATATG 
Sequenced part: 
TTTGC/TGTTAGGGAGTAGTGTTTC/TGTATAGGTGTTTGTC/TGTTGGGTAGGC/TGTTAGTTGTTAAATAC/TGGTTGTTTTTAGTTTGTGTAGTTTTTAGAAA 
Fasn  
Pyrosequencing primer:   GGTATTTAGTTAGTTAGATG            
Sequenced part: GTC/TGC/TGTTTGGATATTGAGC/TGGATTTC/TGGAGGTC/TGTTATAC/TGC/TGTTC/TGTTAGTGTTTTTTATTTTGTTTATTGTTT 
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                                Chapter 3  
3. The induction of a beige adipocyte phenotype by genistein 
3.1. Introduction 
Published observations indicate that genistein can affect cell differentiation into 
adipocytes and also lipid metabolism. For example, a relatively low dose (up to 10 µM) of 
genistein was found to prevent lipogenesis while at a higher dose (>10 µM) genistein 
induced lipogenesis in primary mouse bone marrow cells (Dang et al., 2003) and primary 
human synovial fibroblasts (Relic et al., 2009). In contrast to these in vitro studies, 
observations made in mice were that at a low dose (50 mg/Kg per day) genistein induced 
lipogenesis, while at a higher dose (200 mg/Kg per day) genistein inhibited lipogenesis 
(Penza et al., 2006). Overall, however, it appears that genistein has the potential to affect 
adipose tissue physiology in a beneficial manner either by inhibiting the production of 
new adipocytes and/or through effects on adipocyte fat metabolism. In support of this 
view both in vivo and in vitro studies showed that genistein inhibited the expression of 
key transcription factors and their downstream genes involved in the process of lipid 
biogenesis, including peroxisome proliferator-activated receptor-γ (PPARγ), sterol 
regulatory element-binding protein-1 (SREBP-1) and fatty acid synthase (FASN) (Zhang et 
al., 2009; Kim et al., 2010) but increased the expression of genes involved in fat 
catabolism, including PPARα and its downstream genes including carnitine 
palmitoyltransferase 1 (CPT1) (Kim et al., 2004).  
Genistein appears to have pleiotropic cellular actions mediated through different 
molecular targets. It is thus difficult to attribute physiological effects to specific actions at 
the molecular level. However, there is good evidence that genistein can act as an estrogen 
receptor (ER) ligand. At lower concentrations (up to 3.7 µM) genistein appears to have 
estrogen-like effects (Chen and Donovan, 2004; Magee and Rowland, 2004) while the 
action of genistein at higher concentrations seems to be via other cellular pathways, 
including inhibition of tyrosine kinase and topoisomerase activities (Schmidt et al., 2008). 
Genistein has also been shown to have epigenetic actions including effects on DNA 
methylation and histone modification (Zhang et al., 2013a; Xie et al., 2014). In summary, 
many molecular actions of genistein have been demonstrated and many of these actions 
are possible actions that may underlie some of the physiological manifestations of 
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genistein consumption. However, further research in this area is merited to attribute 
unequivocally specific beneficial outcomes to particular molecular actions.  
White adipocytes synthesize and store fat in the form of triglycerides and release 
it as a source of energy as required (Lafontan, 2005) depending on nutritional status. 
When energy availability is high white adipocytes store energy in the form of triglycerides 
and release it in the form of free fatty acids during periods of energy deprivation (Sorisky, 
1999). White adipocytes are highly active and responsive (Kim and Moustaid-Moussa, 
2000). They actively communicate with other cells by receiving, synthesizing and sending 
biological signals in the form of biologically active peptides and proteins, which are known 
as adipokines. Through adipokines, adipocytes play important roles in integrating and 
regulating the overall physiological and metabolic activity of adipose tissue and other 
organs (Frühbeck et al., 2001; Ali et al., 2013).  
In contrast to white adipose tissue, the presence of brown adipose tissue reduces 
fat storage. Brown adipose tissue functions metabolically to dissipate energy in the form 
of heat (Lowell and Spiegelman, 2000). Brown adipocytes are characterised by having 
small multi-locular fat droplets (Cinti et al., 1997; Ravussin and Galgani, 2011; Lee et al., 
2012c) and the cytoplasm of brown adipocytes is densely packed with mitochondria. The 
mitochondria of brown adipocytes can be distinguished from those of white adipocytes 
by the presence of uncoupling protein-1 (UCP1), which is responsible for dispersing stored 
energy as heat by uncoupling ATP synthesis from electron transport (Matthias et al., 2000; 
Cannon and Nedergaard, 2004; Frontini et al., 2007). Absence of or defects in UCP1 
activity in brown adipose tissue have been seen to be associated with obesity, metabolic 
disorders (Nedergaard et al., 2007; Cannon and Nedergaard, 2009) and defective adaptive 
thermogenesis (Golozoubova et al., 2001; Meyer et al., 2010) in humans and mice. 
Development of brown/beige adipose tissue within the white adipose tissue depots of the 
body may be considered one of the important approaches to reduce obesity and its 
related disorders including diabetes, cardiovascular disease and cancer. 
Brown adipocytes are characterised by expressing a distinct set of genes that are 
involved in the process of differentiation (SIRT1, C/EBPβ, PPARGC1A) or confer the 
specialised function of non-shivering thermogenesis (UCP1). Additionally, these genes are 
a useful research tool since they can be used to distinguish brown adipocytes from other 
cell types and to distinguish between classical brown and beige adipocytes.  
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Sirt1 appears to have pivotal roles in the development of beige adipocytes as an 
increase in the expression of Sirt1 in a transgenic mouse model increased the expression 
level of brown adipocyte marker genes, including Ucp1 and Cebpb, among white adipose 
tissue depots while the white adipocyte marker genes, Rarres2 (chemerin) and Retn 
(resistin), were found to be reduced (Qiang et al., 2012). The activities of Sirt1 and PGC1α 
are closely linked (Aquilano et al., 2010). An increase in the expression level of Sirt1 has 
been found to enhance the browning of white adipocytes coincident with PGC1α 
deacetylation in mouse and 3T3-L1 cells (Fu et al., 2014).  In addition, PGC1α is a key 
stimulating factor for mitochondrial biogenesis, which occurs at a high level during the 
development of brown adipocytes (Rodgers et al., 2005; Guarente, 2007; Fernandez-
Marcos and Auwerx, 2011). PGC1α appears to have a stimulatory effect on UCP1 
expression through recruitment of PPARγ and the thyroid receptor onto the UCP1 
promoter (Puigserver et al., 1998; Tiraby et al., 2003). In the same way, PGC1α acts as a 
coactivator of PPARα to increase UCP1 expression (Barberá et al., 2001) and it also 
associates with the retinoic acid receptor to augment UCP1 expression (Liang and Ward, 
2006).   
Recently, C/EBPβ was recognised as a conspicuous player in the development of 
classical brown and beige adipocytes and has been used as a characteristic marker of 
brown adipocytes (Qiang et al., 2012). Its expression appears to be critical for 
differentiation of brown adipose tissue in mice (Tanaka et al., 1997).  In addition, 
overexpression of C/EBPβ in human skin fibroblasts, mouse skin fibroblasts and 3T3-L1 
cells was shown to be sufficient to convert these cells into brown adipocytes (Karamanlidis 
et al., 2007; Kajimura et al., 2009). Consistently, the C/EBPβ deficient mouse embryo was 
reported to have depleted brown adipose tissue and a reduction in the expression level 
of UCP1 (Kajimura et al., 2009). In addition, defective thermogenesis was observed in the 
C/EBPβ knockout mouse (Carmona et al., 2005).  
UCP1 appears to be the protein primarily responsible for the induction of non-
shivering thermogenesis and it is expressed selectively by brown adipocytes including 
both classical brown and beige adipocytes (Golozoubova et al., 2001; Golozoubova et al., 
2006). However, CD-137 has been discovered recently to be selectively expressed in beige 
rather than classical brown adipocytes (Wu et al., 2012; Fu et al., 2014) and its expression 
can be used to differentiate beige adipocytes from classical brown adipocytes. CD-137 has 
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been used to classify some brown adipocyte depots, including human epicardial and 
visceral paracardial fat depots, as beige rather than classical brown adipose tissue (Sacks 
et al., 2013). 
3.2. Objectives 
The initial objective of this research was to address the hypothesis that genistein 
may affect the expression of genes linked to the process of lipogenesis, specifically Fasn 
and Acaca, on the basis of previous observations made in the laboratory by Goiuri Alberdi 
Aresti who found a reduction in the mRNA levels of lipogenic enzymes comprising FAS and 
ACC in 3T3-L1 cells after treatment with resveratrol. I proposed that other polyphenols 
that, like resveratrol, resemble estrogen-in particular genistein-may enhance a similar 
change in gene expression. The approach was to treat the 3T3-L1 cell line, which can be 
induced to differentiate into adipocytes, with genistein then extract mRNA to measure 
transcript levels by RT-qPCR (primer sequences are stated in chapter 2, table 1). The work 
led to the serendipitous discovery that genistein appears to promote the appearance of 
brown/beige rather than white adipocytes, which may be through a process of either 
trans-differentiation or by promoting differentiation from pre-adipocytes with a brown 
adipocyte-like phenotype rather than cells with a white adipocyte phenotype. Thus the 
major objective was to investigate if genistein could regulate the expression of genes that 
characterise both white (Acaca, Fasn, Fabp4, Lipe, Rarres2, Retn) and brown (Ucp1, 
Tnfrsf9) adipocytes, and/or affect the expression of genes that have been recognised as 
mediators of white to brown adipocyte interconversion (Sirt1, Cebpb, Ppargc1a). 
To probe further the effect of genistein I observed and to gain an indication of 
functional consequence, mitochondrial function was also measured. 
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3.3. Results 
3.3. 1. Differentiation of 3T3-L1 cells   
 3T3-L1 cells were stimulated to differentiate into mature adipocytes using a 
standard published protocol used by other researchers (Caprio et al., 2007; Arsenijevic et 
al., 2012) as discussed in chapter 2, section 2.1.1. Staining of cells with oil red-O stain and 
measurement of mRNA levels of genes that characterise white adipocytes comprising 
Acaca, Fasn, Fabp4 and Lipe by RT-qPCR at day 0 and day 12 of differentiation determined 
that this procedure led to development of an adipocyte-like phenotype. Fat accumulation 
within the cells was markedly increased after 12 days of differentiation (Figure 3.1) and 
expression of Acaca, Fasn, Fabp4 and Lipe mRNA was increased by several fold at day 12 
in comparison to day 0 (Figure 3.2).  
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Figure 3. 1: Growth and differentiation of 3T3-L1 cells. Cells were cultured and grown to confluence in 6-
well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to 
differentiate. Cells were fixed in 10% neutral formaldehyde and stained with Oil Red-O stain on day 0 and 
day 12 to reveal fat droplets. Cells were photographed using a 40X objective lens. Initially 3T3 cells had a 
fibroblastic-shape (A), became rounded after reaching confluence (B), and on day 12 of differentiation 
showed a marked accumulation of fat droplets within the cytoplasm, indicating a mature white adipocyte 
phenotype (C).  
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Figure 3. 2: The mRNA levels of gene products that characterise white adipocytes (ACC, FAS, AP2 and HSL) 
in 3T3-L1 cells on day 0 and day 12 of differentiation. Cells were cultured and grown to confluence in 6-
well plates. Forty eight hours after cells reached confluence, taken as day-0, cells were induced to 
differentiate. Total RNA was extracted on day 0 and day 12. mRNA expression levels were measured by 
RT-qPCR. Data are expressed relative to TOPO1 and NONO and are normalised to the measurement for 
day 0. Values are means (n=6 “three separate wells for each of two independent experiments”), with 
standard errors represented by vertical bars. Statistical analysis was by Student’s unpaired T-test. ***P≤ 
0.001. Data were distributed evenly around the mean value, as established using Levene`s test for 
homogeneity of variant. 
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3.3.2. Effects of genistein in 3T3-L1 cells on gene expression and lipid 
accumulation 
When 3T3-L1 cells were treated with 50 μM genistein for 48 h beginning on day 
10 after inducing differentiation, the expression of genes corresponding to enzymes 
involved in lipogenesis (Acaca, Fasn) and genes expressed in maturing white adipocytes 
(Fabp4, Lipe, Rarres2 and Retn) were upregulated as indicated by measurement of mRNA 
levels by RT-qPCR. In contrast, 100 µM genistein applied in exactly the same way had an 
opposite effect and led to down-regulation of the expression of all of these genes with 
the exception of Acaca (Figure 3.3). Parallel effects of genistein on Sirt1 mRNA were very 
small, but there was a significant reduction with 50 µM genistein and a significant increase 
with 100 µM genistein (Figure 3.4). C/EBPβ mRNA was not affected by 50 µM genistein 
but was increased by 100 µM genistein. PGC1α mRNA was reduced by 50 µM genistein 
(Figure 3.4). UCP1 mRNA was not affected by treatment with either concentration of 
genistein (Figure 3.4). 
To obtain a more detailed and dynamic profile of the changes in gene expression 
induced by genistein, cells were induced to differentiate in the presence and absence of 
genistein (10 μM, 50 μM and 100 μM) and the expression of the same genes was 
measured at day 2, day 3, day 4, day 5, day 8 and day 12 by RT-qPCR. I found that effects 
of genistein on these mRNAs was dose and time dependent such that mRNAs 
corresponding to genes involved in lipogenesis (Fasn, Acaca) and genes expressed in 
maturing adipocytes (Fabp4, Lipe, Rarres2 and Retn) reached maximum levels at lower 
concentrations of genistein over a longer treatment period or at higher concentrations of 
genistein more quickly, and then declined. 
Observation of the cells after staining with Oil red-O stain revealed that higher 
doses of genistein or treatment over a long period of time led to an accumulation of small 
multilocular fat droplets within the cytoplasm of the cells, which contrasted with the 
typical large fat droplets observed in the control differentiated cells (Figure 3.5). The 
accumulation of small multilocular fat droplets is considered one of the characteristic 
features of brown adipocytes. 
Figures (3.6 to 3.16) and appendix (2) show the response to each concentration of 
genistein applied as mRNA measured at each time point. Genistein (10 μM) treatment 
caused the expression of genes involved in white adipocyte maturation (Fabp4, Lipe, 
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Rarres2, Rent) to increase at day 4. Expression of genes involved in lipogenesis (Acaca, 
Fasn) then increased, being evident at day 8, at which point expression of the genes 
involved in white adipocyte maturation (Fabp4, Lipe, Rarres2, Rent) had further increased. 
However, these differences were not observed at day-12, with the exception of the 
response of Lipe and Rent. The expression of genes involved in mediating white to brown 
adipocyte interconversion (Sirt1, Cebpb) was not affected, while there was a reduction in 
the expression of Ppargc1α on day 8 and day 12. 
Higher doses of genistein, specifically 50 μM genistein, were found to increase 
expression of genes involved in lipogenesis (Acaca, Fasn) and white adipocyte maturation 
(Fabp4, Lipe, Rarres2, Rent) at earlier time points of the treatment (day 2, day 3 and day 
5) these increase were followed by a dramatic reduction in expression (day 8 and day 12). 
Sirt-1 mRNA was significantly decreased (day 8 and day 12) after an initial increase (day 
2). There was a persistent increase in C/EBPβ and PGC1α mRNA, particularly after day 5 
of the treatment, while the mRNA of markers of beige adipocytes, Ucp1 and Tnfrsf9, 
fluctuated.    
The expression of genes involved in lipogenesis and white adipocyte maturation, 
specifically Fasn, Fabp4, Lipe, Rarres2 and Rent, was markedly decreased by 100 µM 
genistein at the earliest time point measured (day 2). In addition, there was a persistent 
increase in the mRNA of both Sirt1 and Cebpb. After a dramatic increase in the expression 
of Ppargc1a (between day 2 and day 4), there was a gradual decrease in its expression, 
especially after day 5 of the treatment. The mRNAs for uncoupling protein-1 (UCP1) and 
CD-137 were significantly increased following treatment with 100 µM genistein, 
particularly at the later time points.  
Figure 3.24 is a heat map that provides a visual overview of these response 
patterns. The overall relationship between these responses is consistent with genistein 
promoting the conversion of white adipocytes to beige adipocytes. As genistein 
concentration increased the observed reduction in the expression of genes involved in 
lipogenesis (Fasn) and/or characteristic of white adipocytes (Fabp4, Lipe, Rarres2 and 
Retn) occurred more rapidly. The observed increase in the expression of genes that 
mediate the conversion of white to beige adipocytes (Sirt1, Cebpb, Ppargc1a) peaked 
more rapidly. The expression of Sirt1 and Cebpb appears to be persistent throughout the 
treatment course while Ppargc1α was sharply reduced after a dramatic increase. The 
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increase in the expression of genes involved in mediating white to brown adipocyte 
interconversion was followed by a peak in the expression of genes characteristic of beige 
adipocytes including Ucp1 and Tnfrsf9. At each concentration of genistein applied a peak 
in the expression of genes that play a role in mediating the conversion of white to beige 
adipocytes (Sirt1, Cebpb, Ppargc1a) was followed by a reduction in the expression of 
genes characterise white adipocytes ( Fabp4, Lipe, Rarres2 and Retn). 
A notable exception to this pattern of genes responses consistent with genistein 
promoting a beige adipocyte gene expression profile was Acaca, which initially increased 
after the application of genistein, but were ultimately (like the other markers of white 
adipocytes) down-regulated.  Acetyl Co-A carboxylase (ACC) catalyses the carboxylation 
of acetyl Co-A to generate malonyl  Co-A, an early step in the process of lipogenesis. The 
metabolic rationale for this change is not clear, and a search of current literature was not 
revealed any evidence that ACC has a particular role in adipocyte browning, exploring this 
question in depth would be an interesting topic for future research and may lead to better 
understanding distinct metabolic activities of the different types of adipocyte tissue. 
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Figure 3. 3: The effect of genistein applied between days 10 and day 12 after inducing differentiation of 3T3-L1 cells on mRNAs corresponding to gene products that are involved in 
lipogenesis (ACC and FAS) or maturation of white adipocytes (AP2, HSL, chemerin and resistin). Cells were cultured and grown to confluence in 6-well plates. Forty eight hours after 
cells reached confluence, taken as day 0, cells were induced to differentiate. On day 10 cells were treated with genistein (50 μM or 100 μM) for 48 h. Total RNA was extracted on 
day 12 and mRNA expression levels were measured by RT-qPCR. Data are expressed relative to the reference genes Topo1 and NONO and normalised to control. Values are means 
(n=6 “three separate wells for each of two independent experiments”), with standard errors represented by vertical bars. Statistical analysis was by Student’s unpaired T-test.  *P≤ 
0.05, **P≤ 0.01, ***P≤ 0.001. Data were distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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Figure 3. 4: The effect of genistein applied between days 10 and day 12 after inducing differentiation 3T3-L1 cells on mRNAs corresponding to gene products that are involved in 
interconversion of white to beige adipocytes Sirt1, C/EBPβ and PGC1α) or marks of beige adipocytes (UCP1). Cells were cultured and grown to confluence in 6-well plates. Forty 
eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate. On day 10 cells were treated with genistein (50 μM or 100 μM) for 48 h. Total RNA 
was extracted on day 12 and mRNA levels were measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are 
means, n=6 groups based on 3 technical replicates (wells from the same experiment) for 2 biological replicates (independent experiments), with standard errors represented by 
vertical bars. Statistical analysis was by Student’s unpaired T-test.  *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001. Data were distributed evenly around the mean value, as established using 
Levene`s test for homogeneity of variant.
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Figure 3. 5: Growth and differentiation of 3T3-L1 cells in the presence and absence of genistein (50 µM or 
100 µM). Cells were cultured and grown to confluence in 6-well plates. Forty eight hours after cells 
reached confluence, taken as day 0, cells were induced to differentiate. Cells were fixed in 10% neutral 
formaldehyde, and stained with Oil Red-O stain on day 0 and day 12 to reveal fat droplets. Cells were 
photographed using a 40X objective lens. On day 12 of differentiation showed a marked accumulation of 
fat droplets within the cytoplasm, indicating a mature white adipocyte phenotype (A). In contrast, cells 
treated with 50 µM or 100 µM genistein had smaller multilocular fat droplets (B, C). 
 E)  100 µM genistein 
 
D)  50 µM genistein C. 100 µM genistein, day 12 
 
B. 50 µM genistein, day 12 
 
A. Control, day 12 
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Figure 3. 6: The effect of genistein (10 µM 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to ACC. Cells were cultured and grown 
to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein.  Total 
RNA was extracted. mRNA was measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means n=3-15 
groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical bars. 
Statistical analysis was by Student’s unpaired T-test.  *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test for 
homogeneity of variant. 
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Figure 3. 7: The effect of genistein (10 µM 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to FAS. Cells were cultured and grown 
to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. Total 
RNA was extracted. mRNA expression levels were measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are 
means n=3-15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented 
by vertical bars. Statistical analysis was by Student’s unpaired T-test.  *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using 
Levene`s test for homogeneity of variant. 
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Figure 3. 8: The effect of genistein (10 µM 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to AP2. Cells were cultured and grown 
to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. Total 
RNA was extracted. mRNA levels were measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means n=3-
15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical 
bars. Statistical analysis was by Student’s unpaired T-test.  *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test 
for homogeneity of variant. 
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Figure 3. 9: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to HSL. Cells were cultured and grown 
to confluence in 6-well plates, Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein.  Total 
RNA was extracted and mRNA levels were measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means 
n=3-15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical 
bars. Statistical analysis was by Student’s unpaired T-test. **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test for 
homogeneity of variant. 
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Figure 3. 10: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to chemerin. Cells were cultured and 
grown to confluence in 6-well plates, Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. 
Total RNA was extracted and mRNA levels were measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are 
means n=3-15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented 
by vertical bars. Statistical analysis was by Student’s unpaired T-test. **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s 
test for homogeneity of variant. 
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Figure 3. 11: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to resistin. Cells were cultured and 
grown to confluence in 6-well plates, Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. 
Total RNA was extracted and mRNA levels were measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are 
means n=3-15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented 
by vertical bars. Statistical analysis was by Student’s unpaired T-test. **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s 
test for homogeneity of variant. 
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Figure 3. 12: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to Sirt1. Cells were cultured and grown 
to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. Total 
RNA was extracted. mRNA was measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means n=3-15 
groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical bars. 
Statistical analysis was by Student’s unpaired T-test. *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test for 
homogeneity of variant.  
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Figure 3. 13: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to C/EBPβ. Cells were cultured and 
grown to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. 
Total RNA was extracted. mRNA was measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means n=3-
15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical 
bars. Statistical analysis was by Student’s unpaired T-test. *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test 
for homogeneity of variant.  
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Figure 3. 14: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to PGC1α. Cells were cultured and 
grown to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. 
Total RNA was extracted. mRNA was measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means n=3-
15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical 
bars. Statistical analysis was by Student’s unpaired T-test. *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test 
for homogeneity of variant.  
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Figure 3. 15: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to UCP1. Cells were cultured and 
grown to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. 
Total RNA was extracted. mRNA was measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means n=3-
15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical 
bars. Statistical analysis was by Student’s unpaired T-test. *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test 
for homogeneity of variant. 
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Figure 3. 16: The effect of genistein (10 µM, 50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 cells on mRNA corresponding to CD-137. Cells were cultured and 
grown to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein. 
Total RNA was extracted. mRNA was measured by RT-qPCR. Data are expressed relative to the reference genes Top1 and Nono and normalised to control. Values are means n=3-
15 groups based on 3 technical replicates (wells from the same experiment) for 1-5 biological replicates (independent experiments), with standard errors represented by vertical 
bars. Statistical analysis was by Student’s unpaired T-test. *P≤0.05, **P≤0.01, ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test 
for homogeneity of variant. 
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Figure 3. 17: A heat map to summarise data on effects of genistein at different concentrations as indicated 
on the expression of a panel of genes that are involved in lipogenesis (Acaca, Fasn), or white adipocyte 
maturation (Fabp4, Lipe, Rarres2, Retn), involved in mediating white to brown adipocyte interconversion 
or genes that characterise beige adipocytes (Ucp1, Tnfrsf9). Cells are coloured depending on the response 
size according to the key. For each gene the maximum increase or reduction in mRNA was determined 
and responses are shown as a portion. Numerical values normalised to control. 
≤ 2/3 of maximum 
reduction 
Between 1/3 and 2/3 
of maximum reduction 
No response Between 1/3 and 2/3 
of maximum increase 
≥ 2/3 of maximum increase 
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3.3.3. The effect of an ER antagonist on the responses of genes to 
genistein in 3T3-L1 cells  
  To test the hypothesis that the effects of genistein to apparently promote the 
conversion of white to beige adipocytes are a function of genistein binding to the ER 3T3-
L1 preadipocytes were induced to differentiate in the presence and absence of genistein 
(50 µM and 100 µM) and fulvestrant (0.1 µM), which is a potent estrogen receptor 
antagonist with the ability to block both AF1 and AF2 domains of the estrogen receptor 
with no agonistic effects. On binding with the ER fulvestrant prevents receptor 
dimerization and translocation into the nucleus and promotes receptor degradation 
(Howell, 2006; Hutcheson et al., 2011). The chemical structure of fulvestrant is shown in 
Figure 3.25. 
Measurement of the panel of mRNAs corresponding to genes characteristic of 
white adipocytes (Acaca, Fasn, Fabp4, Lipe, Rarres2 and Retn) revealed that fulvestrant 
did not interfere with the effect of genistein to reduce expression of these genes 
indicating that these responses are an action of genistein that is independent of binding 
to the ER. Likewise, measurement of mRNAs corresponding to genes that mediate the 
conversion of white to beige adipocytes (Sirt1, Ppargc1a) and of Ucp1, which is 
characteristic of beige adipocytes, showed that fulvestrant did not attenuate the effect of 
genistein to decrease expression of these genes indicating that these responses are an 
action of genistein that is independent of binding to the ER (Figures 3.26 and 3.27). 
An exception was C/EBPβ, for which fulvestrant reduced the size of the response 
to genistein consistent with this being a response mediated through the ER (Figure 3.28). 
Fulvestrant alone did not affect the mRNAs of this panel of genes. 
 
Figure 3. 18: Chemical structure of fulvestrant 
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Figure 3. 19: The effect the ER antagonist fulvestrant (0.1 µM) on the response of mRNA corresponding to gene products involved in lipogenesis (ACC and FAS) or maturation of 
white adipocytes (AP2, HSL, chemerin and resistin) to 50 µM genistein applied on induction of differentiation of 3T3-L1 cells. Cells were cultured and grown to confluence in 6-well 
plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein and fulvestrant. Total RNA was 
extracted on day 12 and mRNA expression levels were measured by RT-qPCR. Data are expressed relative to the reference genes Topo1 and NONO and normalised to control. Values 
are means (n= 3; three separate samples of one experiment), with standard errors represented by vertical bars. Statistical analysis was by one-way ANOVA followed by Bonferroni’s 
multiple comparisons test. ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant.  
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 Figure 3. 20: The effect the ER antagonist 0.1 µM fulvestrant on the response of mRNA corresponding to gene products involved in lipogenesis (ACC and FAS) or maturation of white 
adipocytes (AP2, HSL, chemerin and resistin) to 100 µM genistein applied on induction of differentiation of 3T3-L1. Cells were cultured and grown to confluence in 6-well plates. 
Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein and fulvestrant. Total RNA was extracted 
on day 12 and mRNAs expression levels were measured by RT-qPCR. Data are expressed relative to the reference genes Topo1 and NONO and normalised to control. Values are 
means (n= 3; three separate samples of one experiment), with standard errors represented by vertical bars. Statistical analysis was by one-way ANOVA followed by Bonferroni’s 
multiple comparisons test. ***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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Figure 3. 21: The effect the ER antagonist 0.1 µM fulvestrant on the response of mRNA corresponding to gene products involved in interconversion of white to beige adipocytes 
(Sirt1, C/EBPβ and PGC1α) or marking beige adipocytes (UCP-1) to 100 µM genistein applied on induction of differentiation of 3T3-L1 cells. Cells were cultured and grown to 
confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein and 
fulvestrant on day 0 to day 12. Total RNA was extracted on day 12 and mRNA expression levels were measured by using RT-qPCR. Data are expressed relative to the reference genes 
Topo1 and NONO and normalised to control. Values are means (n= 3; three separate samples of one experiment), with standard errors represented by vertical bars. Statistical 
analysis was by one-way ANOVA followed by Bonferroni’s multiple comparisons test. ***P≤0.001, **P≤0.01, *P≤0.05. Data were distributed evenly around the mean value, as 
established using Levene`s test for homogeneity of variant.  
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3.3.3. The effect of a Sirt1 inhibitor on the responses of genes to genistein 
in 3T3-L1 cells  
We hypothesised that Sirt1, which was increased in response to treatment of 3T3-
L1 cells with the higher concentrations of genistein, was a mediator of the effect of 
genistein on other genes measured. To test this hypothesis cells were treated with 
genistein in the presence of Ex-527, which is a specific and potent Sirt1 inhibitor. Ex-527 
has been seen to have low cytotoxic effects compared with other Sirt-1 inhibitors such as 
sirtinol, nicotinamide and salarmide (Napper et al., 2005; Solomon et al., 2006; Peck et 
al., 2010). It appears to inhibit Sirt-1 by binding in the nicotinamide pocket of the Sirt-1 
protein (Gertz et al., 2013), and its inhibitory effects on Sirt1 activity have been confirmed 
in several cell models including rat H4IIEC3 hepatoma cells (Caton et al., 2011), primary 
human mammary epithelial cells (HMEC),  and MCF7 breast cancer cells (Solomon et al., 
2006). The chemical structure of EX-527 is shown in Figure 3.29. 
3T3-L1 cells were induced to differentiate in the presence and absence of 100 µM 
genistein and 10 µM EX-527. Total RNA was extracted at day 12 and mRNA corresponding 
to the target genes was measured by RT-qPCR. The results showed that the genistein-
stimulated down-regulation of genes that characterise white adipocytes (Acaca, Fasn, 
Fabp4, Lipe, Rarres2 and Retn) was not reversed in the presence of EX-527 (Figure 3.30). 
However, the expression of this panel of genes was increased significantly when the cells 
were induced to differentiate in the presence of EX-527 alone (Figure 3.30), which 
indicates the involvement of Sirt1 activity in regulating the process of lipogenesis.  
However, inhibition of Sirt1 activity reduced the genistein-mediated up-regulation of 
UCP1 and C/EBPβ but Sirt1 inhibition alone did not affect these mRNAs (Figure 3.31) 
revealing that at least a component of these responses is via Sirt1.  
 
Figure 3. 22: Chemical structure of EX-527
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Figure 3. 23: The effect of Sirt1 inhibitor EX-527 (10 µM) on the response of mRNA corresponding to gene products involved in lipogenesis (ACC and FAS) or maturation of white 
adipocytes (AP2, HSL, chemerin and resistin) to 100 μM genistein applied on induction of differentiation of 3T3-L1 cells. Cells were cultured and grown to confluence in 6-well plates. 
Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein EX-527. Total RNA was extracted on 
day 12 and mRNA expression levels were measured by RT-qPCR. Data are expressed relative to the reference genes Topo1 and NONO and normalised to control. Values are means 
(n= 6; three separate wells for each of two independent experiments), with standard errors represented by vertical bars. Statistical analysis was by one-way ANOVA followed by 
Bonferroni’s multiple comparisons test. ***P≤0.001, **P≤0.01. Data were distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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Figure 3. 24: The effect of Sirt1 inhibitor EX-527 (10 µM) on the response of mRNAs corresponding to gene products involved in white to beige adipocyte interconversion (Sirt1, 
C/EBPβ) or gene characterises brown adipocytes (UCP-1) to 100 µM genistein applied on induction of differentiation of 3T3-L1 cells. Cells were cultured and grown to confluence in 
6-well plates. 48 h after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein and EX-527. Total RNA was extracted 
on day 12 and mRNA expression levels were measured by RT-qPCR. Data are expressed relative to the reference genes Topo1 and NONO and normalised to control. Values are 
means (n= 6; three separate wells for each of two independent experiments), with standard errors represented by vertical bars. Statistical analysis was by one-way ANOVA followed 
by Bonferroni’s multiple comparisons test. ***P≤0.001, **P≤0.01, *P≤0.05. Data were distributed evenly around the mean value, as established using Levene`s test for homogeneity 
of variant. 
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3.3.4. The effect of genistein on mitochondrial function in 3T3-L1 cells 
I determined if the observed effects of genistein on lipid accumulation and gene 
expression in 3T3-L1 cells that were consistent with a switch in phenotype from white to 
beige adipocytes were accompanied by the predicted uncoupling of mitochondrial 
respiration from oxygen consumption. To do this I measured oxygen consumption under 
conditions where action of the mitochondrial electron transport chain was manipulated 
following treatment of cells with genistein. 
The seahorse XF-24 analyser was used for these experiments. After inducing the 
cells to differentiate in the presence and absence of genistein in Seahorse V7 cell plates, 
cellular respiration was measured at day 12. A baseline rate of oxygen consumption, 
including both oxidative phosphorylation and uncoupled oxygen consumption, was 
measured. Oxidative phosphorylation was then blocked using oligomycin (an ATP 
synthase inhibitor) (Symersky et al., 2012). UCP1 activity was then stimulated using TTNBP 
(Figure 3.32) (Tomás et al., 2004) a retinoid (Mercadera et al., 2007) that induces 
thermogenesis through UCP1 activation (Rial et al., 1999; Tomás et al., 2004). The potent 
mitochondrial uncoupler FCCP was then added, allowing free movement of protons from 
intermembrane space into the mitochondrial matrix through inner mitochondrial 
membrane (Brennan et al., 2006). Finally, oxygen consumption was blocked using 
antimycin A, which is a complex III inhibitor (Huang et al., 2005).   
Concomitant with the marked increase in UCP1 expression observed in response 
to genistein there was a significant increase in basal and uncoupled oxygen consumption 
rate compared with control (Figure 3.33A, 3.33B). In addition, the proportion of the total 
oxygen consumption that was uncoupled before FCCP addition and after activation of 
UCP1 by TTNBP was increased (Figure 3.33C). Together these measurements are 
consistent with a higher level of uncoupled oxygen consumption in cells treated with 
genistein consistent with the induction of a beige adipocyte phenotype.  
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Figure 3. 25: Chemical structure of oligomycin, TTNBP, FCCP and antimycin A 
(https://www.sigmaaldrich.com/united-kingdom.html) 
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Figure 3. 26: The effect of genistein on mitochondrial function measured as oxygen consumption in 3T3-
L1 maturing preadipocytes. Cells were cultured and grown to confluence Seahorse V7 cell plates. Forty 
eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate in the 
presence and absence of genistein (100 μM). Oxygen consumption was measured on day 12 using 
Seahorse XF-24 analyser. Data are expressed relative to total protein, measured in the same samples. 
Values are means (n= 10), with standard errors represented by vertical bars. Statistical analysis was by 
unpaired Student`s T-test. ***P≤0.001.  
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3.3.5. The effect of genistein on Sirt1 protein abundance in 3T3-L1 cells 
Sirt1 is a focus of other complementary research in the laboratory. Thus I 
investigated further the effect of genistein on Sirt1 in 3T3-L1 cells by determining how 
genistein affected the abundance of Sirt1 protein. 3T3-L1 cells were induced to 
differentiate in the presence and absence of 100 µM genistein then total protein was 
extracted at day 10 of differentiation and abundance of Sirt1 protein was measured by 
western blotting. The results showed that despite the increase in Sirt1 mRNA induced by 
genistein being only moderate Sirt1 protein abundance was increased by several fold 
(Figure 3.34).   
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Figure 3. 27: The effect of 100 µM genistein applied on induction of differentiation on Sirt1 protein 
abundance in 3T3-L1 cells. Cells were cultured and grown to confluence in 6-well plates. Forty eight hours 
after cells reached confluence, taken as day 0, cells were induced to differentiate in the presence and 
absence of 100 µM genistein. On day 10 total protein was extracted. Histone H3 expression was measured 
by western blotting. Panel A shows representative western blots. Bands were quantified using Odyssey 
densitometry software to generate the data shown in panel B. Data are expressed relative to the 
corresponding α-tubulin then normalised to control. Values are means (n=5; three and two separate wells 
for each of two independent experiments), with standard errors represented by vertical bars. Statistical 
analysis was by Student`s unpaired T-test.  ***P≤0.001. 
A 
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3.3.6. The effect of genistein on Sirt1 expression in other cell models 
 I investigated if the effect of genistein on Sirt1 expression is cell and/or species 
specific and also determined if the response is mediated through the ER or through the 
GPR30 receptor for estrogen action (Hutchens et al., 2012; Luo et al., 2014). To do this 
MCF-7 cells were treated with 100 µM genistein 24 h after seeding in the presence and 
absence of the ER antagonist fulvestrant (0.1 µM) or G-15 (1 µM) for 48 h. G-15 (1 µM) is 
a specific GPR30 antagonist (Dennis et al., 2009; Prossnitz and Barton, 2011) and thus 
inhibits the GPR30 mediated estrogen response pathway (Hutchens et al., 2012; Luo et 
al., 2014). 
As observed in 3T3-L1 cells Sirt1 mRNA measured by RT-qPCR (primer sequences 
are stated in chapter 2, table 2) was increased and neither ER antagonist affected the 
response to genistein (Figures 3.35 and 3.36), showing that the effect of genistein on Sirt1 
is ER-independent and not cell type and/or species specific.  
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Figure 3. 28: The effect of the ER antagonist fulvestrant on the response of Sirt1 to 100 µM genistein in 
MCF-7 cells. Cells were cultured and grown in 6-well plates. Twenty four hours after seeding cells were 
treated with 100 µM genistein in the presence and absence of 0.1 µM fulvestrant for 48 h. Total RNA was 
extracted and Sirt1 mRNA level was measured by RT-qPCR. Data are expressed relative to the reference 
genes TOPO1 and GAPDH and normalised to control. Values are means (n=6; three separate wells for each 
of two independent experiments), with standard errors represented by vertical bars. Statistical analysis 
was by one-way ANOVA followed by Bonferroni’s multiple comparisons test. ***P≤0.001. Data were 
distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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Figure 3. 29: The effect of the ER antagonist G-15 on the response of Sirt1 to 100 µM genistein in MCF-7 
cells. Cells were cultured and grown in 6-well plates. Twenty four hours after seeding cells were treated 
with 100 µM genistein in the presence and absence of 1 µM G-15 for 48 h. Total RNA was extracted and 
Sirt1 mRNA level was measured by RT-qPCR. Data are expressed relative to the reference genes TOPO1 
and GAPDH and normalised to control. Values are means (n=6; three separate wells for each of two 
independent experiments), with standard errors represented by vertical bars. Statistical analysis was by 
one-way ANOVA followed by Bonferroni’s multiple comparisons test. ***P≤0.001. Data were distributed 
evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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3.3.7. The effect of genistein on the expression of reference genes in 3T3-
L1 cells 
 The expression of reference genes sued as an internal control for RT-qPCR may 
vary considerably under experimental conditions to select suitable reference genes that 
were not affected by genistein I measured the effect of genistein in 3T3-L1 cells on the 
RNA correspondent to Topo1, Nono and Gapdh, which are commonly used as reference 
genes. For Top1 and Nono mean Ct value measured over 3 samples were within 0.2 cycles 
for control cells and cells exposed to 50 µM genistein using the standard experimental 
protocol and within 0.4 cycles for cells exposed to 100 µM genistein (Figure 3.31). 
However, the mean Ct value for GAPDH increased substantially at both concentration of 
genistein (˃1.4 cycles at 50 µM and ˃1.8 cycles at 100 µM), indicating that the treatment 
caused a reduction in GAPDH in the order of 2.6 and 3.5 folds. Thus Nono and Topo1 were 
used as reference genes in all experiments involving treatment of 3T3-L1 cells.  
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Figure 3. 30: The effect of genistein (50 µM or 100 µM) applied on induction of differentiation of 3T3-L1 
cells on mRNA corresponding to TOPO1, NONO and GAPDH. Cells were cultured and grown to confluence 
in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to 
differentiate in the presence and absence of genistein. Total RNA was extracted at day 12. mRNA was 
measured by RT-qPCR. Data are expressed as mean CT values for n=3 separate wells from the same 
experiment. 
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3.4. Discussion 
The work presented in this chapter developed from the observation that 
treatment of 3T3-L1 preadipocyte cells with genistein induced a change in appearance 
suggestive of a beige rather than white adipocyte phenotype. This observation was made 
when performing experiments to determine if genistein had effects similar to the 
polyphenol resveratrol on the expression of genes involved in lipogenesis including Acaca 
and Fasn in 3T3-L1 cells. These effects of resveratrol had been observed in previous 
experiments in the laboratory. To determine if genistein promoted a beige adipocyte 
phenotype, the morphological changes of 3T3-L1 cells were monitored by staining cells 
with oil-red-O, which is a lipid specific stain. I also determined if there was a change in the 
expression of a panel of marker genes selected on the basis that they were involved in; (I) 
lipid biogenesis (Acaca, Fasn) or white adipocyte maturation (Fabp4, Lipe, Rarres2, Retn), 
which I predicted to be down-regulated, (II) involved in mediating white to brown 
adipocyte interconversion (Sirt1, Cebpb, Ppargc1α), which I expected to be upregulated, 
(III) genes that can be used as markers of beige adipocytes (Ucp1, Tnfrsf9), which I also 
predicted would be up-regulated. I also determined if the change in gene expression 
profile was accompanied by the predicted uncoupling of mitochondrial oxygen 
consumption from ATP synthesis.  
In support of our hypothesis there was an accumulation of small multilocular lipid-
droplets within the cytoplasm of genistein treated cells, which contrasted with the typical 
large fat droplets observed in the control differentiated cells. Consistent with this 
morphological change, there was a large reduction in the expression of genes that are 
expressed exclusively by white adipocytes (Acaca, Fasn, Fabp4, Lipe, Rarres2 and Retn), 
which was associated with a marked increase in the expression of genes mediating white 
to brown interconversion (Sirt1, Cebpb, Ppargc1a), and an increase in the expression of 
those genes characterise brown adipocytes, specifically Ucp1 and Tnfrsf9. Concomitant 
with a marked increase in UCP1 expression observed in response to genistein there was a 
dramatic increase in basal and uncoupled oxygen consumption rate. In addition, the 
proportion of the total oxygen consumption rate that was uncoupled before FCCP 
addition and after activation of UCP1 by TTNBP was markedly increased. Together these 
measurements are consistent with increased uncoupling of mitochondrial oxygen 
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consumption from ATP synthesis and thus with the induction of a beige adipocyte 
phenotype.  
Previous studies in rodents have shown that genistein alone or as a crude extract 
with other polyphenols can have an effect on energy expenditure and UCP expression. For 
example, genistein (5000-50,000 µg/Kg per a day) was found to upregulate UCP1 
expression in white adipose tissue depots in mice (Penza et al., 2006). Also the obesogenic 
effect of a high caloric diet in mice was prevented by genistein (0.2%, 0.4% genistein in 
the diet for 12 weeks) concomitant with an increase in the expression of PGC1α, 
mitochondrial medium chain acyl Co-A dehydrogenase, UCP2, and mitochondrial 
biogenesis  (Lee et al., 2006). Dietary soya protein containing isoflavones given to rats for 
14 d or 180 d reduced body weight and energy expenditure and increased UCP expression 
in brown and white adipose tissue (Takahashi and Ide, 2008; Torre-Villalvazo et al., 2008). 
Similarly, soya protein alone and/or in combination with exercise in rats stimulated the 
expression of PGC1α and  PPARα lipid content of the liver and epididymal adipose tissue 
(Morifuji et al., 2006). Higher UCP1 expression and oxygen consumption rate was 
measured in rodents fed an isoflavone rich plant extract (Puerariae thomsonii) or a soya 
based diet compared with the control group (Lephart et al., 2004; Kamiya et al., 2012). It 
has also been shown that other polyphenols, including diadzein and resveratrol can 
increase UCP1 expression and mitochondrial biogenesis. For example, diadzein increased 
UCP1 expression in brown adipose tissue and reduced body weight in dietary induced 
obese rats (Crespillo et al., 2011). Resveratrol increased UCP expression and 
mitochondrial biogenesis in rat brown adipose tissue and muscle (Alberdi et al., 2013).  
To the best of our knowledge this study is the first in vitro study to show the 
modulatory effect of genistein on white to brown adipocyte interconversion in 3T3-L1 
cells. The establishment of this in vitro model had provided a valuable research tool with 
which to probe in detail mechanisms of diet induced white to beige adipocyte 
interconversion at a level of molecular detail that cannot be readily achieved using in vitro 
model. In addition, this observation indicates that the parent compound genistein rather 
than its metabolites is the active stimulator of this response. Here a caveat is that to draw 
such a conclusion unequivocally I would need to show that genistein is not metabolised 
in this cell culture system. The model thus also provide the opportunity to test individual 
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metabolite of genistein, as well as other dietary agents and their metabolite for activity. 
Our observations also confirm the fact that beige adipocytes have the same precursor as 
white adipocytes, which is distinct from that of classical brown adipocytes.  
The fact that effects observed at the higher concentrations of genistein used (50 
and 100 µM) mirrored effects also achieved at a lower concentrations (10 µM), but 
occurred over a shorter time scale, indicates that the responses to the higher 
concentrations were not the result of toxic action. The expectation would be that toxic 
effects would be distinct. However, I also saw a more direct indication that the higher 
concentrations of genistein were not toxic to the cells in that there was no decline in RNA 
yield as reported in section 2.4.2.2.  
Since genistein resembles 17β-estradiol structurally and is, therefore, described as 
a phytoestrogen I determined if the responses I observed in 3T3-L1 cells were mediated 
through the ER. In the presence of the ER antagonist fulvestrant the observed change in 
cell appearance induced by genistein was not reversed and the changes in expression of 
our test gene panel was not abolished, with the exception of the response of Cebpb to 
genistein, which was significantly attenuated by fulvestrant. Thus the effect of genistein I 
observed appears to be not mediated via the ERs. A caveat to this conclusion is that I were 
unable to identify a suitable marker gene to measure as a positive control to confirm that 
the fulvestrant applied was effective in blocking all ER-mediated action. However, the 
attenuated response of Cebpb to genistein by fulvestrant is evidence of activity. The 
concentration of fulvestrant (0.1 µM) used has been shown in other work to be effective 
(Howell, 2006; Hutcheson et al., 2011), and in parallel work (chapter 5) I observed an 
effect of the same concentration of fulvestrant on ERs in MCF-7 cells (see section 5.3.2). 
The ER-independent effects of genistein at the concentration I used are consistent with 
previous studies that have shown dose-dependent effects of genistein with respect to 
action at the ER or through other pathways, Lower concentrations of genistein (up to 3.7 
µM) appear to have estrogen-like effects (Chen and Donovan, 2004; Magee and Rowland, 
2004; Pons et al., 2014) in different cell models including MCF-7 breast cancer cells, 
human cervical epithelial cells (HeLa), Caco-2 human intestinal cells, murine 
preosteoblastic cells (KS483) and mouse bone marrow cells (Maggiolini et al., 2001; Dang 
et al., 2003; Chen and Donovan, 2004). The action of genistein at higher concentrations, 
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however, appears to be via other cellular pathways (Dang et al., 2003). These actions 
measured at higher concentrations include inhibition of tyrosine kinase and 
topoisomerase activities (Salti et al., 2000; Chen and Donovan, 2004; Kasai and Kikuchi, 
2010). Whether there are other pathways are conduits for genistein action to affect the 
response I observed requires further investigation. 
I proposed that key initiating steps in the process of beige adipocyte 
differentiation induced by genistein would be reflected as changes in gene expression that 
occurred early in the sequence of effects I observed. I also proposed that genes reported 
to play an active role in the process of differentiation, as opposed to bystander marker 
genes, were prime candidates as pivotal initiating mediators. Our gene panel, Sirt1 met 
these criteria. Moreover, Sirt1 is a focus of other complementary research in the 
laboratory. Thus, I investigated if Sirt1 was necessary for genistein to affect the changes 
observed. In support of this hypothesis, the responses of Ucp1 and Cebpb genes to 
genistein were significantly attenuated when the activity of Sirt1 was inhibited by EX-527, 
which is a specific and potent Sirt1 inhibitor with the ability to bind in the nicotinamide 
pocket of the Sirt-1 protein (Gertz et al., 2013).  The increase in Sirt1 mRNA I observed in 
response to treatment of 3T3-L1 cells with genistein was very moderate (2 fold). However, 
I measured an increase of approximately 12 fold in Sirt1 protein providing a further 
indication that increased Sirt1 action is a key mediator in the change I observed. 
I also showed that the effect of genistein on Sirt1 expression was shown to not be 
unique to adipocytes. Genistein also was found to promote an increase in the expression 
of Sirt1 in MCF-7 breast cancer cells and the effect was ERs-independent similar to the 
observations made in 3T3-L1 cells. The stimulatory effect of genistein on Sirt1 expression 
may be one of the reasons behind the pleiotropic effects of genistein. Sirt1 is a class III 
histone deacetylase but has a diverse substrate range.  Sirt1 thus affects fundamental 
processes including inflammatory and metabolic pathways (Revollo and Li, 2013; 
Davenport et al., 2014). Sirt1 has been proposed as a mediator of the lifespan extension 
observed in response to dietary restriction, consistent with observations such as extended 
life expectancy when pharmacologically activated in mice (Mitchell et al., 2014) and a 
decrease with age in the liver of old mice (Jin et al., 2011). Pharmacological activation of 
Sirt1 has been reported to have several health-beneficial actions including improvement 
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in the blood lipid profile and decreasing the risk of non-alcoholic fatty liver (Mitchell et al., 
2014) and diabetes (Qiao and Shao, 2006).  
It has been shown that Sirt1 has a key regulatory role especially in mediating beige 
adipocyte development. An increase in Sirt1 expression or its activation by resveratrol was 
followed by an increase in the expression of genes that characterise brown adipocytes 
including UCP1 and C/EBPβ in white adipose tissue depots of transgenic mice and 3T3-L1 
cells, while there was a marked reduction in the expression of genes that characterise 
white adipocyte cells including Rarres2 and Retn (Qiang et al., 2012; Fu et al., 2014). 
However, in classical brown adipocytes the function of Sirt1 appears to not be important 
in the regulation of UCP1 and C/EBPβ expression as an increase in Sirt1 expression or its 
knock-down in transgenic mice was found to have no effect on UCP1 and C/EBPβ 
expression  (Qiang et al., 2012).  
The increase in C/EBPβ expression induced by genistein in the present study is also 
likely to be important in the process of beige adipocyte development in response to 
genistein. C/EBPβ has emerged as a conspicuous player in the development of classical 
brown and beige adipocytes (Qiang et al., 2012). Expression of C/EBPβ appears to be 
crucial for differentiation of brown adipose tissue in mice (Tanaka et al., 1997).  
Furthermore, overexpression of C/EBPβ in human skin fibroblasts, mouse skin fibroblasts 
and 3T3-L1 cells was reported to be sufficient to convert these cells into brown adipocytes 
(Karamanlidis et al., 2007; Kajimura et al., 2009).  
The observed large increase in PGC1α expression by genistein, especially during 
the first few days of the treatment, is also likely to be important in the process of white 
to brown adipocyte interconversion. PGC1α has been recognised as a key stimulating 
factor for mitochondrial biogenesis, which occurs at a high level during the development 
of brown adipocytes (Rodgers et al., 2005; Guarente, 2007; Fernandez-Marcos and 
Auwerx, 2011). Also a strong correlation between PGC1α and Sirt1 activity has been 
suggested, activation of PGC1α by Sirt1 via deacetylation appears to be important in 
modulating white to brown adipocyte interconversion (Aquilano et al., 2010; Fu et al., 
2014).  
In conclusion the work presented in this chapter shows for the first time in a 
malleable in vitro adipocyte model that genistein can mediate the process of white to 
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beige adipocyte conversion. Important conclusions I draw from the finding are that beige 
adipocytes can differentiate from the same cell lineage as white adipocytes. However, 
further work is required to determine if the process of interconversion is 
transdifferentiation of mature white adipocytes or denovo differentiation of precursor 
cells induced by genistein. The in vitro system affords the opportunity to address this 
fundamental question through approaches such as genetically marking the mature white 
adipocytes (for example, with β-galactosidase under the control of white-adipocyte-
specific promoter) thus observing the distribution of marked cells after induction of the 
phenotypic change by genistein. Another important outcome of the presented study is 
the role of Sirt1 in mediating white to brown interconversion. A better understanding of 
this process may allow ultimately for the development of new dietary or pharmacological 
strategies to promote beige adipocyte tissue development and thus protect against 
metabolic diseases.   
 
 
 
 
 
 
 
 
 
 
 
 
132 
 
                                           Chapter 4 
4. Effects of genistein and resveratrol on histone expression 
4.1. Introduction 
Histone proteins and their posttranslational modifications can be important in 
modulating life expectancy (Feser et al., 2010b; Khan and Khan, 2010). There is a view 
supporting the idea that abundance of histone proteins can positively influence life 
expectancy (O'Sullivan et al., 2010). Supporting evidence includes that overexpression of 
histone proteins in yeast increased lifespan (Feser et al., 2010b) and decreased global 
histone protein expression and/or loss of histone proteins at specific regions of the 
genome was associated with genome instability and aging in yeast and in human foetal 
lung fibroblast cells (IMR90) (Dang et al., 2009; O'Sullivan et al., 2010; Hu et al., 2014). The 
expression of histone H3 and H4 was lower in fibroblasts of old versus young human 
individual, and at late passage (P75) compared with early passage (P30) of fibroblasts 
(O'Sullivan et al., 2010). Also the ratio of histone variants including H2A and H3 variants 
was found to be reduced compared with total histone expression level during aging in 
human lung embryonic fibroblast cells (Rogakou and Sekeri–Pataryas, 1999).  
Specific histone protein variants appear to be important in gene regulation. For 
example, presence of histone H3.3 and/or its post-translational modifications, particularly 
at specific gene promoter and enhancer regions, was associated with transcriptional 
activity (Ahmad and Henikoff, 2002; Hake and Allis, 2006; Chen et al., 2013a). Expression 
of this variant was found to be crucial for DNA replication during the S-phase of the cell 
division (Frey et al., 2014) and to be associated with the transcriptionally active sites of 
the genome in the chicken erythroid cell models HD24 and 6C2 (Jin and Felsenfeld, 2006). 
Abundance of this variant marks highly active and fully differentiated cells such as nerve 
cells (Das and Tyler, 2013). Histone H3.3 knockdown in mouse resulted in abnormal 
chromosomal segregation (Bush et al., 2013) and defective decondensation of the 
pericentromeric chromatin (Lin et al., 2013). Histone H3.2, on the other hand, appears to 
be associated preferentially with silenced loci and with heterochromatin formation, 
whereas histone H3.1 seems to have bidirectional (activation and/or silencing) effects on 
transcription (Hake and Allis, 2006). Replacement of histone H3.3 with histone H3.1 
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prevented C2C12 differentiation into myocytes and prevented lineage specific gene 
expression (Harada et al., 2014). Also, histones H3.1 and H3.2 were found to be associated 
with heterochromatin formation during fertilization and embryogenesis in the mouse 
(Akiyama et al., 2011).  
4.2. Objective 
Initial objective of this study was to replicate experiments to attempt to confirm 
observations made previously in the laboratory (Alatawi, 2012). These observations were 
a reduction in the level of histone protein abundance and in the activity of a histone H3.1 
(variant H3b)-promoter reporter plasmid construct induced in Caco-2 human intestinal 
cells by 10 µM resveratrol. In the earlier work these effects were abolished in the presence 
of the ER-antagonist fulvestrant, indicating that this action of resveratrol was via the ERs. 
Thus, a subsidiary aim was to confirm this effect. A second aim was to investigate if 
genistein produced similar effects and also to determine if genistein modifies (either 
increases or reduces) the response to resveratrol. The rationale for this approach was that 
genistein and resveratrol are both polyphenols and have both been shown to have actions 
mediated via ERs. Secondly, in the natural diet, resveratrol and genistein can occur 
together, hence their interacting effects are worthy of investigation. 
4.3. Results 
4.3.1. The effect of genistein and resveratrol on a histone H3.1 promoter-
reporter plasmid construct  
To repeat and attempt to replicate earlier work in the laboratory, Caco-2 cells were 
transfected with a plasmid comprising the region -18 to -826 relative to the transcription 
start site of the human histone H3.1 (variant H3b) gene upstream of a β-galactosidase 
reporter gene. The transfected cells were then treated with 10 µM resveratrol in either 
the presence or absence of the ER antagonist fulvestrant (0.1 µM). In agreement with the 
earlier observations, lower levels of β-galactosidase activity in extracts from transfected 
Caco-2 cells were observed after treatment of cells with resveratrol compared with 
controls. However, in contrast to the earlier work, the response was not affected by 
fulvestrant (Figure 4.1). 
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Subsequent experiments investigated if genistein affected expression of the 
reporter gene from the same construct in Caco-2 cells. The effect observed was similar to 
that seen with resveratrol and also was not affected by fulvestrant (Figure 4.2). These data 
indicate that both resveratrol and genistein act on the human histone H3.1 (variant H3b) 
promoter to repress transcription and that the mechanism of action is independent of 
ERs. I also investigated the effect of resveratrol and genistein in combination on histone 
H3 gene transcription using the same experimented model. Reduced reporter gene 
expression was observed after treatment with the combined compounds but the effect 
was not greater than that observed with either compound separately. Also, as predicted 
based on the lack of effect on the responses to the single compounds, this response was 
not affected by fulvestrant (Figure 4.3). These data indicate that resveratrol and genistein 
act through the same ER-independent mechanism to affect histone H3.1 (variant H3b) 
promoter activity.  
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Figure 4. 1: The effect of resveratrol in the presence and absence of the ER antagonist fulvestrant (0.1 
µM) on the response of a human histone H3.1 (variant H3b) promoter reporter plasmid to resveratrol. 
Data are derived from Caco-2 cells transfected with a histone H3.1 promoter-reporter-construct 
comprising the region -18 to -826 relative to the transcription start site of the human histone H3.1 (variant 
H3b) gene. Cells were treated with 10 µM resveratrol with or without 0.1 µM fulvestrant 24 h after 
transfection and reporter gene activity was measured after further 48 h. Data are expressed relative to 
total protein and normalised to control values. Values are means n=12-21, with standard errors are 
represented by vertical bars. Statistical analysis was by one-way ANOVA followed by Bonferroni’s 
multiple comparisons test. ***P≤0.001. 
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Figure 4. 2: The effect of genistein in the presence and absence of the ER antagonist fulvestrant on the 
response of a human histone H3.1 (variant H3b) promoter reporter plasmid to resveratrol. Data are 
derived from Caco-2 cells transfected with a histone H3.1 promoter-reporter-construct comprising the 
region -18 to -826 relative to the transcription start site of the human histone H3.1 (variant H3b) gene. 
Cells were treated with 50 µM genistein with or without 0.1 µM fulvestrant 24 h after transfection and 
reporter gene activity was measured after further 48 h. Data are expressed relative to total protein and 
normalised to control values. Values are means (n=12-21), with standard errors are represented by 
vertical bars. Statistical analysis was by one-way ANOVA followed by Bonferroni’s multiple comparisons 
test. ***P≤0.001. 
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Figure 4. 3: The effect of genistein and resveratrol in the presence and absence of the ER antagonist 
fulvestrant on the response of a human histone H3.1 (variant H3b) promoter reporter plasmid to 
resveratrol. Data are derived from Caco-2 cells transfected with a histone H3.1 promoter-reporter-
construct comprising the region -18 to -826 relative to the transcription start site of the human histone 
H3.1 (variant H3b) gene. Cells were treated with 50 µM genistein and 10µM resveratrol with or without 
0.1 µM fulvestrant 24 h after transfection and reporter gene activity was measured after further 48 h. 
Data are expressed relative to total protein and normalised to control values. Values are means (n=6; 
three separate wells for each of two independent experiments), with standard errors are represented by 
vertical bars. Statistical analysis was by one-way ANOVA followed by Bonferroni’s multiple comparisons 
test. ***P≤0.001. 
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4.3.2. The effect of genistein on histone protein abundance 
The reduced expression of the β-galactosidase reporter gene driven by the human 
histone H3.1 (variant H3b) promoter observed after treatment with resveratrol and 
genistein in combination was not greater than that observed with either compound 
separately. Hence further experiments focused on the effect of genistein alone, since this 
was the polyphenol of primary interest in the current work. The effect of genistein on 
histone protein abundance was measured in different cell models-MCF-7 (human breast 
cancer), Caco-2 (human intestinal) and 3T3-L1 (mouse preadipocytes) to determine if the 
action of genistein on the histone H3.1 (Variant H3b) promoter in Caco-2 cells was 
manifest as a reduction in abundance of the corresponding protein and if a similar effect 
was seen in other cell types.  
In contrast to the predicted effect, genistein (100 µM) increased histone H3 and 
histone H4 protein in both Caco-2 and MCF-7 cell lines as measured by western blotting 
(Figures 4.4 and 4.5). I also measured the effect of genistein on histone H2B in MCF-7 cells 
and saw no change (Figure 4.6). Also, similar to the observations made in Caco2 and MCF-
7 cells, histone H3 protein in 3T3-L1 cells increased in response to genistein applied on 
induction of differentiation (Figure 4.7).  
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Figure 4. 4: The effect of genistein on histone H3 protein abundance in MCF-7 and Caco-2 cells. Forty eight 
hours after treatment total protein was extracted and histone H3 protein abundance was measured by 
western blotting. Panel A shows a typical representative western blot. Bands were quantified using 
Odyssey densitometry software to generate the data shown in panel B. Data are expressed relative to β-
actin and normalised to control. Values are means (n=6; three separate wells for each of two independent 
experiments), with standard deviations are represented by vertical bars. Statistical analysis was by 
Student`s unpaired T-test.  **P≤0.01. 
A 
B 
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Figure 4. 5: The effect of genistein on histone H4 protein abundance in MCF-7 and Caco-2 cells. Forty eight 
hours after treatment total protein was extracted and histone H4 protein abundance was measured by 
western blotting. Panel A shows a typical representative western blot. Bands were quantified using 
Odyssey densitometry software to generate the data shown in panel B. Data are expressed relative to β-
actin and normalised to control values. Values are means (n=6; three separate wells for each of two 
independent experiments), with standard deviations are represented by vertical bars. Statistical analysis 
was by Student`s unpaired T-test.  *P≤0.05. 
A 
B 
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Figure 4. 6: The effect of genistein on histone H2B protein abundance in MCF-7 cells. Forty eight hours 
after treatment total protein was extracted and histone H2B protein abundance was measured by 
western blotting. Panel A shows a typical representative western blot. Bands were quantified using 
Odyssey densitometry software to generate the data shown in panel B. Data are expressed relative to β-
actin and normalised to control values. Values are means (n=6; three separate wells for each of two 
independent experiments), with standard deviations are represented by vertical bars. Statistical analysis 
was by Student`s unpaired T-test.  *P≥0.05. 
B 
A 
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Figure 4. 7: the effect of genistein on histone H3 protein abundance applied on induction of differentiation 
of 3T3-L1 cells. Cells were cultured and grown to confluence in 6-well plates. Forty eight hours after cells 
reached confluence, taken as day 0, cells were induced to differentiate in the presence and absence of 
genistein. On day 2 and day 10 total protein was extracted. Histone H3 protein abundance was measured 
by western blotting. Panel A shows a typical representative western blot. Bands were quantified using 
Odyssey densitometry software to generate the data shown in panel B. Data were expressed relative to 
α-tubulin and normalised to control values. Values are means (n=5; three separate wells for each of two 
independent experiments), with standard deviations are represented by vertical bars. Statistical analysis 
was by Student`s unpaired T-test.  **P≤0.01. 
B 
A 
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4.3.3. The effect of genistein on histone mRNA levels 
I reasoned that a possible explanation for the discordant effects of genistein on 
histone H3 protein and activity of the histone H3.1 (variant H3b) promoter was differential 
action on different histone variants. H3 variants differ by only a few amino acids and 
commercially available antibodies such as the antibody used in this work do not 
differentiate between these variants and thus detect the whole pool of histone H3 
variants. I thus used RT-qPCR (primer sequences are stated in chapter 2, tables 1 and 2) 
to measure the effect of genistein on specific H3 variants. The effect of genistein on 10 
individual histone H3.1 variants was measured in MCF-7 and Caco-2 cells using variant 
specific primers. Concurring with the action of genistein on the H3.1 (Variant H3b) 
promoter-reporter plasmid construct, most of the histone H3.1 variants measured were 
down-regulated by genistein (Figures 4.8 and 4.9). However, in agreement with our 
hypothesis, histone H3.1 variants differed in their response to genistein. In particular in 
contrast to the other variants histone H3d was upregulated in both cell lines. 
I also measured the effect of genistein on histone H3.2 and H3.3 mRNAs in MCF-7 
cells and observed a reduction in histone H3.2 mRNA and an increase in histone H3.3 
mRNA (Figure 4.10), further showing that genistein has histone H3 variant-specific 
actions.  
  The Effect of genistein on the pool of histone H3 variants was also investigated in 
3T3-L1 adipocytes using primer that annealed to a region of conserved sequence. In 
overall agreement with the effect I observed on histone H3 protein, genistein (100µM) 
applied on induction of differentiation, induced an increase in this H3 mRNA pool, 
measured at day 12 of differentiation (Figure 4.11). 
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Figure 4. 8: The effect of genistein applied for 48 h on histone H3.1 mRNA levels in Caco-2 cells. Cells were cultured in 6-well plates. Twenty four hours after seeding, cells 
were treated with genistein (100 μM) for 48 h. Total RNA was extracted and mRNA levels of histone H3.1 variants were measured by RT-qPCR. Data were expressed 
relative to the reference genes TOPO-1 and GAPDH and normalised to control values. Values are means (n=3; three separate wells for one experiment), with standard 
errors are represented by vertical bars. Statistical analysis was by Student`s T-test.  *P≤0.05, ***P≤0.001. Data were distributed evenly around the mean value, as 
established using Levene`s test for homogeneity of variant.
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Figure 4. 9: The effect of genistein applied for 48 h on histone H3.1 mRNA levels in MCF-7 cells. Cells were cultured in 6-well plates. Twenty four hours after seeding, 
cells were treated with genistein for 48 h. Total RNA was extracted and mRNA levels of histone H3.1 variants were measured by RT-qPCR. Data were expressed relative 
to the reference genes TOPO-1 and GAPDH and normalised to control values. Values are means (n=6; three separate wells for each of two independent experiments), 
with standard errors are represented by vertical bars. Statistical analysis was by Student`s T-test.  *P≤0.05, ***P≤0.001. Data were distributed evenly around the mean 
value, as established using Levene`s test for homogeneity of variant. 
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Figure 4. 10: The effect of genistein applied for 48 h on histone H3.2 and H3.3 mRNA levels in MCF-7 cells. 
Cells were cultured in 6-well plates. Twenty four hours after seeding, cells were treated with genistein 
(100 µM) for 48 h. Total RNA was extracted and mRNA levels of histones H3.2 and H3.3 were measured 
by RT-qPCR. Data are expressed relative to the reference genes TOPO-1 and GAPDH and normalised to 
control values. Values are means (n=6; three separate wells for each of two independent experiments), 
with standard errors are represented by vertical bars. Statistical analysis was by Student`s T-test.  
*P≤0.05, **P≤0.01.  Data were distributed evenly around the mean value, as established using Levene`s 
test for homogeneity of variant. 
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Figure 4. 11: The effect of genistein on histone H3 (H3.1, H3.2 and H3.3) mRNA level applied on induction 
of differentiation of 3T3-L1 cells. Cells were cultured and grown to confluence in 6-well plates. Forty eight 
hours after cells reached confluence, taken as day 0 and were induced to differentiate in the presence 
and absence of genistein (100 µM). Total RNA was extracted at day 12 and the mRNA levels of histone H3 
were measured by RT-qPCR. Data were expressed relative to the reference genes TOPO-1 and NONO and 
normalised to control values. Values are means (n=6; three separate wells for each of two independent 
experiments), with standard errors are represented by vertical bars. Statistical analysis was by Student`s 
unpaired T-test.  ***P≤0.001. Data were distributed evenly around the mean value, as established using 
Levene`s test for homogeneity of variant. 
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4.3.4. The effect of an ER antagonist on the response of histone mRNA 
levels to genistein 
Having found no evidence that genistein action on the histone H3.1 (Variant H3b) 
promoter was through the ER, since the ER-antagonist fulvestrant did not influence this 
response, I determined if other elements of action that affected the net abundance of 
histone H3.1 (variant H3b) mRNA (which could be effects on mRNA stability, translation 
or protein degradation) were via the ER. MCF-7 cells were treated in the presence and 
absence of 100 µM genistein and the estrogen receptor antagonist fulvestrant (0.1 µM) 
or G-15 (1 µM). G-15 (1 µM) is a specific GPR30 antagonist (Dennis et al., 2009; Prossnitz 
and Barton, 2011) and thus inhibits the GPR30 mediated estrogen response pathway 
(Hutchens et al., 2012; Luo et al., 2014). Concurring with the data obtained using the 
histone H3 promoter reporter plasmid construct, the down regulatory effect of genistein 
on histone H3.1 (variant H3b) mRNA was not attenuated by either of the estrogen 
receptor antagonists. However, both fulvestrant and G-15 reduced the mRNA levels of 
histone H3.1 (variant H3b) (Figures 4.12 and 4.13), suggesting that endogenous levels of 
antagonist compounds usually maintained baseline level.  
Similarly in 3T3-L1 cells the response of histone H3 (H3.1, H3.2 and H3.3 combined) 
mRNA levels to genistein was not reversed by fulvestrant (Figure 4.14). 
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Figure 4. 12: The effect of genistein applied for 48 h on histone H3.1 (variant H3b) mRNA in the presence 
and absence of the ER antagonist fulvestrant in MCF7 cells. Cells were seeded in 6-well plates. Twenty 
four hours after seeding, cells were treated with genistein (100 μM) with or without fulvestrant (0.1 µM) 
for 48 h. Total RNA was extracted and mRNA levels of histone H3.1 (variant H3b) was measured by RT-
qPCR. Data are expressed relative to the reference genes TOPO-1 and GAPDH and normalised to control 
values. Values are means (n=6; three separate wells for each of two independent experiments), with 
standard errors are represented by vertical bars. Statistical analysis was by one-way ANOVA followed by 
Bonferroni’s multiple comparisons test. ***P≤0.001. Data were distributed evenly around the mean 
value, as established using Levene`s test for homogeneity of variant. 
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Figure 4. 13: The effect of genistein applied for 48 h on histone H3.1 (variant H3b) mRNA in the presence 
and absence of the ER antagonist G-15 in MCF7 cells. Cells were seeded in 6-well plates. Twenty four 
hours after seeding, cells were treated with genistein (100 μM) with or without G-15 (1 µM) for 48 h. Total 
RNA was extracted and mRNA levels of histone H3.1 (variant H3b) was measured by RT-qPCR. Data are 
expressed relative to the reference genes TOPO-1 and GAPDH and normalised to control values. Values 
are means (n=6; three separate wells for each of two independent experiments), with standard errors are 
represented by vertical bars. Statistical analysis was by one-way ANOVA followed by Bonferroni’s 
multiple comparisons test. ***P≤0.001. . Data were distributed evenly around the mean value, as 
established using Levene`s test for homogeneity of variant 
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Figure 4. 14: The effect of genistein on histone H3 (H3.1, H3.2 and H3.3) mRNA expression level in the 
presence and absence of estrogen receptor antagonist (fulvestrant) in 3T3-L1 cells. Cells were cultured 
and grown to confluence in 6-well plates. Fourty eight hours after cells reached confluence, taken as day 
0, cells were induced to differentiate in the presence and absence of 100 µM genistein and 0.1 µM 
fulvestrant. Total RNA was extracted on day 12 and mRNA levels of histone H3 were measured by RT-
qPCR. Data are expressed relative to the reference genes Top-1 and Nono and normalised to control 
values. Values are means (n=3; three separate wells for one experiment), with standard errors are 
represented by vertical bars, Statistical analysis was by one-way ANOVA followed by Bonferroni’s 
multiple comparisons test.  **P≤0.01, ***P≤0.001. . Data were distributed evenly around the mean value, 
as established using Levene`s test for homogeneity of variant 
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4.4. Discussion 
The results presented in this chapter reveal the effect of genistein and resveratrol 
alone and in combination on histone expression. Previous work in the laboratory (Alatawi, 
2012) revealed that resveratrol reduced the level of histone protein abundance and also 
the activity of a histone H3.1 (variant H3b) promoter-reporter plasmid in Caco-2 human 
intestinal cells. I proposed that genistein may produce similar effects because genistein 
and resveratrol are both polyphenols and have both been shown to have actions 
mediated via the ER. Secondly, in the natural diet, resveratrol and genistein can occur 
together, hence their interacting effects are worthy of investigation. I determined if 
adding both compounds together to the extracellular medium of cultured cells had an 
effect on histone protein expression or the activity of the histone H3.1 (variant H3b) 
promoter-reporter construct that was greater than the effect of the single compounds. 
Caco-2, MCF-7 and 3T3-L1 cell lines were used based on their use to acquire the previous 
data (Caco-2 and MCF-7 cell) and to investigate effects also in an adipocyte model (3T3-
L1), since effects of genistein on other aspects of adipose tissue physiology was the major 
focus of the work in this thesis. Data acquired during the present study showed that 
resveratrol and genistein alone and in combination decreased histone H3.1 (variant H3b) 
promoter activity in Caco-2 cells. These finding confirmed the effect of resveratrol 
observed previously and were a novel observation in the case of genistien alone and in 
combination with resveratrol.  
The effect of resveratrol and genistein in combination was not greater than that 
observed with either compound separately, indicating that the compounds probably 
affect histone H3 gene transcription through the same mechanism. Since both resveratrol 
and genistein have structural similarity to 17β-estradiol and have been shown to induce 
effects in some instances through the ER I determined if the action of either of both 
compound on the histone H3 promoter-reporter construct was via ERs. I thus determined 
if the ER-antagonist fulvestrant affected the response of the histone H3.1 (variant H3b) 
promoter-reporter construct to resveratrol and genistein. I found that the response to 
either resveratrol or genistein was not attenuated in the presence of fulvestrant. Thus, 
the likely common pathway through which both compounds repress the H3.1 (variant 
H3b) promoter is unlikely to be through the ER. Other effects of resveratrol reported in 
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the literature are ER-independent. For example, low (around 0.1 nM) and high (20- 170 
µM) concentrations of resveratrol inhibited cell proliferation in both the ER positive cell 
line MCF-7 and the ER negative cell line MDA-MB-231 (Mgbonyebi et al., 1998; Damianaki 
et al., 2000). Also the effect of resveratrol on growth inhibition was not reversed by the 
ER antagonist ICI 182,780 (Levenson et al., 2003). However, other actions of resveratrol 
appears to be via the ER. For example, resveratrol (0.1 µM) stimulated an increase in 
glucose uptake by C2C12 cells and the response was abrogated in the presence of the ER 
antagonist ICI 182,780 (Deng et al., 2008).  
Since I found no evidence for synergistic interaction of resveratrol and genistein 
with regard to action on the histone H3.1 (variant H3b) promoter, and because actions of 
genistein are the primary focus of the work presented in this thesis, effects of only 
genistein on histone expression were investigated further. This work comprised 
measurement of the effect of genistein on histone protein and mRNA in MCF-7, Caco-2 
and 3T3-L1 cells to confirm that the response of histone H3.1 (variant H3b) to genistein is 
ER-independent, the effect of genistein on histone H3.1 (variant H3b) mRNA was 
measured in the presence and absence of the ER antagonist fulvestrant and also G-15, 
which is GPR30 antagonist. Consistent with the data on histone H3.1 promoter activity, 
the response was not attenuated by fulvestrant, Similarly, G-15 had no effect on the 
action of genistein. These finding further indicate that the effect of genistein on histone 
protein expression is ER-independent. A limitation of this work is that I did not identify a 
robust positive control response to show that fulvestrant and G-15 were active 
antagonists in our experiment models. However, the fact that I observed a significant 
reduction in the mRNA of histone H3.1 (variant H3b) in response to fulvestrant and G-15 
alone (section, 4.3.4) indicated the compounds were active. Also the concentrations and 
exposure times used have been shown to be effective in published studies (Howell, 2006; 
Hutcheson et al., 2011; Hutchens et al., 2012; Luo et al., 2014).  
Our finding that genistein action was not through the ER is discordant with other 
reported findings (eg. Zhu et al, (2009). Such differences may relate to the concentrations 
of genistein used. Studies showing effects of genistein through the ER in different cell 
models including MCF-7, HeLa, Caco-2, KS483 and mouse bone marrow cells have typically 
used lower concentrations of genistein(≤3.7 µM) (Maggiolini et al., 2001; Dang et al., 
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2003; Chen and Donovan, 2004). The action of genistein at higher concentrations appears 
to be via other cellular pathways (Dang et al., 2003). Actions measured at higher 
concentrations include inhibition of tyrosine kinase and topoisomerase activities (Salti et 
al., 2000; Chen and Donovan, 2004; Kasai and Kikuchi, 2010).  
Surprisingly, genistein was found to increase histone H3 protein abundance in 
Caco-2 and MCF-7, which opposed the effect on histone H3 promoter activity. Similarly, 
genistein increased histone H3 protein abundance in 3T3-L1 cells. With respect to effects 
of genistein on other histone proteins I observed that histone H2B protein abundance did 
not respond to genistein treatment while like histone H3, histone H4 protein abundance 
was increased. An increase in histone protein abundance appears to have a physiological 
importance. For instance, reduced global histone protein expression and/or loss of 
histone proteins at specific regions of the genome is correlated with genome instability 
and aging. A sharp decrease in the level of histone expression has been observed in aged 
yeast and aged human foetal lung fibroblast cells (IMR90) (Dang et al., 2009; O'Sullivan et 
al., 2010; Hu et al., 2014) consistent with an association between higher levels of histone 
expression and longevity in yeast (Feser et al., 2010a). The expression of histone H3 and 
H4 particularly was lower in fibroblasts of old versus young human individuals, and at late 
passage (P75) compared with early passage (P30) of fibroblasts (O'Sullivan et al., 2010). 
The ratio of histone variants including H2A and H3 variants was also shown to be reduced 
compared with total histone expression level during aging in human lung embryonic 
fibroblast cells (Rogakou and Sekeri–Pataryas, 1999). In contrast to a decrease in histone 
protein abundance with age, histone protein level was found to be increased in aged 
versus young mice, while there was not any difference in histone protein level between 
aged and young human intestinal biopsy (Alatawi, 2012).  
Histone H3 exists as multiple variants. The antibody used to measure histone H3 
did not distinguish between these variants and would thus give only a global readout of 
net abundance. Histone H3 variants are transcribe from different promoter. Thus I 
hypothesised that the discordance between the effect of genistein on histone H3 
promoter activity and protein abundance may be due to differential effects on specific H3 
variants. To test our hypothesis mRNAs for the histone H3 variants including H3.1, H3.2 
and H3.3 were measured. In support of our hypothesis genistein was found to decrease 
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histone H3.2 and H3.1 subvariants with the exception of histone H3d, which was 
increased. Histone H3.3 mRNAs was also increased.  
The significance of this finding with respect to cell physiology is not yet clear. 
However, specific and distinct roles of histone H3 variants have been shown; thus the 
findings are likely to be important. For example, the presence of histone H3.3, especially 
at specific gene promoter and enhancer regions, was associated with transcriptional 
activity (Ahmad and Henikoff, 2002; Hake and Allis, 2006; Chen et al., 2013a). Expression 
of this variant was found to be crucial for DNA replication during the S-phase of the cell 
division (Frey et al., 2014) and to be associated with the transcriptionally active sites of 
the genome in the chicken erythroid cell models HD24 and 6C2 (Jin and Felsenfeld, 2006). 
Abundance of this variant marks highly active and fully differentiated cells such as nerve 
cells (Das and Tyler, 2013). Histone H3.3 knockdown in fertilized mouse zygote resulted in 
abnormal chromosomal segregation (Bush et al., 2013) and with decondensation of the 
pericentromeric chromatin (Lin et al., 2013).  
Histone H3.2, on the other hand, appears to be associated preferentially with 
silenced loci and with heterochromatin formation, whereas histone H3.1 seems to have 
bidirectional (activation and/or silencing) effects on transcriptional regulation (Hake and 
Allis, 2006). Replacement of histone H3.3 with histone H3.1 prevented C2C12 
differentiation into myocytes and prevented lineage specific gene expression (Harada et 
al., 2014). Also histones H3.1 and H3.2 were found to be correlated with heterochromatin 
formation during fertilization and embryogenesis in the mouse (Akiyama et al., 2011). 
Moreover, specific histone variants appear to be susceptible to specific forms of 
modification. For example histone H3.3 but not H3.1 was found to undergo extensive 
trimethylation at lysine 4 and 27, which is a hallmark of active chromatin, and to be less 
susceptible to lysine 9 and 27, dimethylation which are associated with heterochromatin 
formation (McKittrick et al., 2004; Harada et al., 2014).  
The present study is the first, to the best of our knowledge, to demonstrate 
selective regulatory and ER-independent effects of genistein on histone expression in 
different cell models comprising Caco-2, MCF-7 and 3T3-L1 cells. Thus, dietary intake of 
genistein may affect gene expression through specific alterations in chromatin structure 
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and this may be one of the mechanisms through which this compound has its reported 
beneficial effects.  
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Chapter 5 
5. Effects of genistein and 17β-estradiol on ER expression 
5.1. Introduction 
Estrogen receptors (ER) belong to the steroid/thyroid superfamily of intracellular 
receptors (Evans, 1988). They show wide distribution throughout the body tissues and are 
involved in physiological and pathophysiological process including growth, development, 
adipogenesis and cancer (Dunnwald et al., 2007; Lee et al., 2012a). The importance of ER 
expression in cancer has driven research in this direction. Thus, knowledge about the 
influence of ER action in this area is extensive. For example, based on epidemiological 
studies, ERβ was identified as an important marker  to classify severity and stage of colon 
cancer (Rudolph et al., 2012). A substantial reduction and/or absence of ERβ is 
characteristic of some forms of cancer including colon adinocarcinoma (Foley et al., 2000; 
Campbell-Thompson et al., 2001; Konstantinopoulos et al., 2003), breast cancer (Skliris et 
al., 2003; Huang et al., 2014) and prostate cancer (Leav et al., 2001). Overexpression of 
ERβ can inhibit proliferation of both ERα-positive and ERβ-negative human ovarian cancer 
cell lines (BG1 and PEO14) (Bossard et al., 2012). Human breast cancers expressing high 
levels of ERβ have been shown to respond better to hormonal therapy than ERβ negative 
breast cancers (Murphy et al., 2002). Furthermore, ERβ was found to counteract the 
proliferative effects of ER-α in the breast cancer cell model T47D and in rat prostate cancer 
(Ström et al., 2004; Attia and Ederveen, 2012). However, the ERβ knockout mouse showed 
abnormal growth of breast and prostate epithelial tissue cells, which is a predisposing 
factor in neoplasia formation (Gustafsson and Warner, 2000; Weihua et al., 2001). In 
contrast to ERβ, ERα appears to be highly expressed by cancer cells and approximately 
70% of breast cancer cases are diagnosed as ER-α positive (DeSantis et al., 2011). Unlike 
to ERβ, ERα seems to play a role in the onset (Hewitt et al., 2002) and progression 
(McPherson et al., 2008; Attia and Ederveen, 2012) of cancer.  
In contrast knowledge about the role of ER function in adipogenesis, which is of 
particular relevance to the work in this thesis, is relatively poor. However, there is 
evidence that both ERα and ERβ may have functions that protect against obesity. An ERβ 
knockout mouse model fed a high fat diet accumulated more lipid in gonadal adipose 
tissue compared with wild type (Foryst-Ludwig et al., 2008). In contrast, work in the 
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ovariectomized mouse indicated that ERβ has no role in diet-induced obesity (Roesch, 
2006). However, an ERα was found to be important in reducing food intake and preventing 
diet-induced obesity in ovacriectomized rats (Roesch, 2006). An ERα knockdown mouse 
model was obese and developed obesity-related disorders including insulin resistance, 
glucose intolerance and lower energy expenditure compared with wild type (Heine et al., 
2000). Another study showed a reduction in the expression of ERα in obese female 
subjects compared with lean subjects (Nilsson et al., 2007).  
As a ligand, genistein has a higher affinity toward ERβ than ERα (Zhu et al., 2006; 
Chrzan and Bradford, 2007). Previous published data regarding the effect of genistein on 
expression of ERs appears to be conflicting. For example giving genistein to mice (50-200 
mg/kg) downregulated both ERs in epididymal adipocytes (Penza et al., 2006). A low dose 
of genistein (1 µM) was found to have no effect on ERβ expression in MCF-7 cells but 
upregulated ERβ in T47D breast cancer cells. In a study in 3T3-L1 and MCF-7 cells genistein 
(50-200 µM) was shown to down-regulate ERα dose and time dependently (Choi et al., 
2014).  
5.2. Objectives 
Published work shows that genistein can mediate some of its effects through the 
ER in different cell models including rat primary neuronal cell culture (Adams et al., 2012), 
primary mouse bone marrow cells, murine preosteoblastic (KS483) cells (Dang et al., 
2003), Caco-2 cells (human intestinal adenocarcinoma cells) (Chen and Donovan, 2004) 
and MCF-7 cells (breast cancer cell model) (Maggiolini et al., 2001). However, in the 
present study, as shown by data presented in chapters 3 and 4, the effects of genistein on 
adipocyte phenotype and histone expression that I observed appeared to be ER-
independent. However, it was still possible that genistein influenced ER expression in our 
cell models under the experimental conditions applied. This view was based on the fact 
that genistein and 17β-estradiol are structurally similar and can have similar actions and 
because 17β-estradiol (1-20 nM) has been shown to down-regulate expression of ERα in 
different breast cancer cell lines including M6 cells (Yoshidome et al., 2000), MCF-7 cells 
(Hall et al., 2008) and ZR-75-1 cells (Kousidou et al., 2008). In contrast, ERβ expression was 
not affected by 17β-estradiol in SW480 intestinal cancer cells (Hartman et al., 2009). Our 
aim thus was to test the hypothesis that genistein, like 17β-estradiol, can differentially 
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regulate ERα and ERβ. The objective was to measure the effect of 100 µM genistein on 
the expression of both ER subtypes, and compare this action with that of 17β-estradiol. 
There is evidence that expression of the ER can be auto-regulatory (Cardone et al., 1998). 
The second objective was therefore to determine if any effects of genistein on ER 
expression I observed were themselves mediated via the ER. 
The approach was to treat MCF-7 and 3T3-L1 cells with genistein and 17β-estradiol 
including under conditions of ER blockade by antagonists fulvestrant and G-15, and then 
measure mRNAs of ERα and ERβ by RT-qPCR. Primer sequences are stated in chapter 2, 
tables 1 and 2. 
5.3. Results 
5.3.1. The effect of genistein or 17β-estradiol on ERα and ERβ expression 
Initially the effect of 17β-estradiol on ER mRNA levels was measured by RT-qPCR 
in MCF-7 cells, which express both ER subtypes. Twenty four hours after seeding, cells 
were treated with 2 nM 17β-estradiol for 48 h. I observed that 17β-estradiol decreased 
ERα mRNA but did not have any effect on ERβ mRNA (Figure 5.1). 
To determine if genistein has any effect on ER subtype expression, MCF-7 cells 
were treated with 100 µM genistein for the same length of time (48 h). The data revealed 
that the two ER subtypes were differentially regulated by 100 µM genistein. Similar to the 
observations we made using 17β-estradiol, genistein reduced ERα mRNA. However, unlike 
17β-estradiol, which had no effect, genistein increased ERβ mRNA (Figure 5.2). 
To investigate if these effects of genistein on ER subtypes were cell type specific 
or if they are observed in other cell types, the effect of genistein on ER mRNA was 
measured in 3T3-L1 adipocytes at day 12 after induction of differentiation in the presence 
and absence of 100 µM genistein. The effects of genistein on ER mRNAs in 3T3-L1 cells 
were consistent with those observed in MCF-7 cells; ERα mRNA was decreased and ERβ 
mRNA was increased (Figure 5.3). 
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Figure 5. 1: The effect of 17β-estradiol on the ER-α and ER-β mRNAs in MCF-7 cells. Cells were grown in 
6-well plates. Twenty four hours after seeding cells were treated with 17β-estradiol (2 nM) for 48 h, total 
RNA was extracted and mRNA levels of ER-α and ER-β were measured by RT-qPCR. Data are expressed 
relative to the reference genes Topo1 and GAPDH and normalised to control. Values are means (n=6; 
three separate wells for each of two independent experiments), with standard errors represented by 
vertical bars. Statistical analysis was by Student’s unpaired T-test. ***P≤0.001.  Data were distributed 
evenly around the mean value, as established using Levene`s test for homogeneity of variant 
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Figure 5. 2: The effect of genistein on ERα and ERβ mRNAs in MCF-7 cells. Cells were grown in 6-well 
plates. Twenty four hours after seeding cells were treated with genistein (100 µM) for 48 h. Total RNA 
was extracted and mRNA expression levels of ERα and ERβ were measured by RT-qPCR. Data are 
expressed relative to the reference genes Topo1 and GAPDH and normalised to the control. Values are 
means (n=6; three separate wells for each of two independent experiments), with standard errors 
represented by vertical bars. Statistical analysis was by Student’s unpaired T-test. ***P≤0.001. Data were 
distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant 
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Figure 5. 3: The effect of genistein on the ERα and ERβ mRNAs applied on induction of differentiation in 
3T3-L1 cells. Cells were grown to confluence in 6-well plates. Forty eight hours after cells reached 
confluence, taken as day 0, cells were induced to differentiate in the presence and absence of genistein 
(100 µM). Total RNA was extracted at day 12. mRNA levels were measured by RT-qPCR. Data are 
expressed relative to the reference genes Topo1 and NONO and normalised to control. Values are means 
(n=3; three separate wells for one experiment), with standard errors represented by vertical bars. 
Statistical analysis was by Student’s unpaired T-test. **P≤0.01, ***P≤0.01. Data were distributed evenly 
around the mean value, as established using Levene`s test for homogeneity of variant. 
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5.3.2. The effect of ER antagonists on the response of ERα and ERβ mRNAs 
to genistein or 17β-estradiol 
To investigate if the effect on ER mRNA was auto-regulatory (mediated through 
the ER), MCF-7 cells were treated for 48 h with genistein in the presence and absence of 
the ER-antagonists fulvestrant or G-15 (Figure 5.4). Fulvestrant (0.1 µM) is a potent ER 
antagonist that blocks both the AF1 and AF2 domains of the ER with no agonist effect. 
Upon binding it prevents ER dimerization and translocation into the nucleus and also 
promotes receptor degradation (Howell, 2006; Hutcheson et al., 2011).  G-15 (1 µM) 
(Hutchens et al., 2012; Luo et al., 2014) is a specific antagonist of the non-classical 
membrane G protein coupled ER GPR30 (Dennis et al., 2009; Prossnitz and Barton, 2011; 
Chakrabarti and Davidge, 2012; Chevalier et al., 2012).  
Measurement of ERα and ERβ mRNAs by RT-qPCR showed that neither ER 
antagonist affected the response to genistein (Figures 5.5 and 5.6) showing that these 
actions of genistein are independent of any binding to ERs. However, fulvestrant alone 
increased ERα mRNA (Figure 5.5), indicating that endogenous levels were repressed by 
the actions of compounds in the tissure culture medium  (possibly 17β-estradiol) whose 
actions were blocked by fulvestrant. To determine if genistein and 17β-estradiol differed 
with respect to potential auto-regulatory effects on ER expression, MCF-7 cells were 
treated with 2 nM 17β-estradiol in the presence and absence of 0.1 µM fulvestrant or 1 
µM G-15. In contrast to the action of genistein, the down-regulatory effect of 17β-
estradiol on ERα was attenuated in the presence of fulvestrant, indicating an auto-
regulatory action of ERα on its own expression (Figure 5.7). As in the earlier experiments 
we also observed that fulvestrant alone increased ERα mRNA (Figure 5.7). Consistent with 
the data obtained in the previous experiment (Figure 5.1), ERβ was not affected by 17β-
estradiol (Figures 5.7 and 5.8). Together, 17β-estradiol and fulvestrant induced a very 
small but statistically significant reduction in ERβ mRNA (Figure 5.7).   
G-15 had no effect on either the response of ERα mRNA to 17β-estradiol or on the 
levels of ERα or ERβ mRNA measured in the absence of 17β-estradiol indicating that the 
GPR30 pathway does not play a role in the action of 17β-estradiol on ER expression (Figure 
5.8).  
 
164 
 
 
Figure 5. 4: Chemical structure of fulvestrant and G-15 
 
Figure 5. 5: The effect the ER antagonist fulvestrant on the response of ERα and ERβ mRNA to genistein 
in MCF-7 cells. Cells were grown in 6-well plates. Twenty four hours after seeding cells were treated with 
genistein (100 µM) in the presence and absence of fulvestrant (0.1 µM) for 48 h. Total RNA was extracted 
and mRNA levels of ERα and ERβ were measured by RT-qPCR. Data are expressed relative to the reference 
genes Topo1 and GAPDH and normalised to control. Values are means (n=6; three separate wells for each 
of two independent experiments), with standard errors represented by vertical bars. Statistical analysis 
was by one-way ANOVA followed by Bonferroni’s multiple comparisons test. **P≤0.01, ***P≤0.001. Data 
were distributed evenly around the mean value, as established using Levene`s test for homogeneity of 
variant. 
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Figure 5. 6: The effect of the ER antagonist G-15 on the response of ERα and ERβ mRNA to genistein in 
MCF-7 cells. Cells were grown in 6-well plates. Twenty four hours after seeding cells were treated with 
genistein (100 µM) in the presence and absence of G-15 (1 µM) for 48 h. Total RNA was extracted and 
mRNA levels of ERα and ERβ were measured by RT-qPCR. Data are expressed relative to the reference 
genes Topo1 and GAPDH and normalised to control. Values are means (n=6; three separate wells for each 
of two independent experiments), with standard errors represented by vertical bars. Statistical analysis 
was by one-way ANOVA followed by Bonferroni’s multiple comparisons test. ***P≤0.001. Data were 
distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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Figure 5. 7: The effect of the ER antagonist fulvestrant on the response of ERα and ERβ mRNA to 17β-
estradiol in MCF-7 cells. Cells were grown in 6-well plates. Twenty four hours after seeding cells were 
treated with 17β-estradiol (2 nM) in the presence and absence of fulvestrant (0.1 µM) for 48 h. Total RNA 
was extracted and mRNA levels of ERα and ERβ were measured by RT-qPCR. Data are expressed relative 
to the reference genes Topo1 and GAPDH and normalised to control. Values are means (n=3; three 
separate wells for one experiment), with standard errors represented by vertical bars. Statistical analysis 
was by one-way ANOVA followed by Bonferroni’s multiple comparisons test. **P≤0.01, ***P≤0.001. Data 
were distributed evenly around the mean value, as established using Levene`s test for homogeneity of 
variant. 
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Figure 5. 8: The effect of the ER antagonist G-15 on the response of ERα and ERβ mRNA to 17β-estradiol 
in MCF-7 cells. Cells were grown in 6-well plates. Twenty four hours after seeding cells were treated with 
17β-estradiol (2 nM) in the presence and absence of G-15 (1 µM) for 48 h. Total RNA was extracted and 
mRNA levels of ERα and ERβ were measured by RT-qPCR. Data are expressed relative to the reference 
genes Topo1 and GAPDH and normalised to control. Values are means (n=3; three separate wells for one 
experiment), with standard errors represented by vertical bars. Statistical analysis was by one-way 
ANOVA followed by Bonferroni’s multiple comparisons test. ***P≤0.001. Data were distributed evenly 
around the mean value, as established using Levene`s test for homogeneity of variant. 
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5.3.3. Investigating if genistein increases ERβ mRNA by increasing 
transcription of ERβ gene 
The effect of genistein on ERβ mRNA was of particular interest because of the 
possible therapeutic benefits in cancer prevention or treatment of increasing ERβ 
expression (Murphy et al., 2002; Bossard et al., 2012). Thus, I probed the mechanism by 
addressing the hypothesis that the point of action is transcription of the ERβ gene. Also, 
despite the fact that I saw no evidence that the effect of genistein on ERβ was itself an ER-
mediated response (because ER antagonists had no effect), I tested the effect of ER 
antagonists because I identified likely EREs in the human ERβ promoter (Figure 5.9). I 
reasoned that measuring directly the action of genistein and the influence of ER 
antagonists by use of a promoter-reporter construct may be more sensitive than 
measurement of ERβ mRNA. I constructed an ERβ promoter-reporter construct 
comprising 1600 bp of the region of genomic DNA immediately upstream of the 
transcription start site of the ERβ gene upstream of a β-galactosidase reporter gene 
(Figure 5.9). The required promoter region was amplified from genomic DNA by PCR using 
primers (chapter 2, table 3) to add Hind III and EcoR1 restriction sites 5” and 3” of the 
sequence respectively. Then both vector (pSF-pA-PromMCS-BetaGal) and the amplified 
DNA insert were digested with Hind III and EcoR1, and the DNA insert was subcloned 
upstream to the β-galactosidase reporter gene as described in chapter 2 section 2.7.  After 
transforming DH5α E. coli then purifying the plasmid construct, successful subcloning of 
the DNA insert was confirmed by digesting the recombinant plasmid construct with Hind 
III and EcoR1 and observing the products after agarose gel electrophoresis. The plasmid 
construct was sequenced to further confirm correct identity of the cloned DNA insert.  
 Caco-2 cells were transfected transiently with the ERβ promoter reporter plasmid 
construct. Twenty four hours after transfection, cells were treated with 100 µM genistein 
then β-galactosidase activity was measured after 24, 48 or 72 h. Genistein did not affect 
the activity of the reporter gene measured after 24 h but at 48 and 72 h after addition 
genistein increased expression of the reporter gene as measured by an increase in β-
galactosidase activity (Figure 5.10). The data thus showed that genistein increases 
transcription of the ERβ gene. 
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Consistent with the lack of any effect on the genistein-induced increase in ERβ 
mRNA, neither fulvestrant nor G-15 attenuated the stimulatory effect of genistein on the 
ERβ promoter reporter gene construct, indicating that the effect was not an ER-mediated 
auto-regulatory action (Figures 5.11 and 5.12). 
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GTGGTGTATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGACATGATAATTGCTTGAACCTGGGAGGCAGAGATTG
CAGTGAGCTGATATGGCGCCATTGCACTCCAGCCTAGGCAACAAGAGTGAAACTCCATCTCAAAAAAAAAGATTTGC
CTGTAATCAGCCAGCACCCCCAGCCTTGTGCTCACTTTACATACAAAAATTCTGTTTTTTAGAGCATAAATTGAAGGG
CACATTCAAAACTGATACGTAGGCCAGGCATGGTGACTTATGCCTGTAATCCCAGCACTTTGGGAGACCGAGGCAGG
TGGATCACTCGAGATCAGGAGTTTGAGACCAGCCTGGCCAACGTGGTGAAACCCCATCCCTACTAAAAAATACAACA
AATTAGCCAGTCACAGTGGTGCGCACCCATAGTCTCAGCTACTCGTGAGGCTGAGGCAGGAGAATCACTAGAACCT
GGGAGGCAGGAGGTTGCAGTGAGCCGAGATCATGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGACCTTGTCTC
AAAAACAAAGACAAAACCAAAACAAAACAAAACTGAGAAGCAACAGATTGATAAGTGACACAGTTACACTGGTCAG
TCTCTTCAGCTAATACCCATTGTTTTTTATTATTGGAGATTCATAATGTGTTTTCTTTCTTTTAAAAACTTTTTTCGGAAA
TGGTAATTTCTCTCTTTTTTTTTTTTTTTTTTTTTTTTTGAGACAGGGTCTCACTCTATCACCCAGGCTGGAGCGCGGTG
GCACAATCTCTGCTCACTACAACCTCTGCCTCCTGGGCTTGAGCAATCACACCTCAGCCTCTTGAGTAGCTGGGACAA
CAGGCACATGCCACCATTCCTGGCTAATTTTTAGTAGAGACGGGGTTTCACCATGTTGCCCAGGCTGGTCTCGAACTC
CTGACCTCAAGTAATCTGCCCACCTCAGCCTCCCAAAGTATTGGGATTACAGGCGTGAGCCACTACGCTTGGCCTCA
TAGCGTATTTTAATATTGGTTGAGACTAGCCTTGCTCATTGATCTTCTCTTAGCGTTTACTTGGTTATTCTTGCTTATTT
TTCCATAAGAACTTTCATTTTTATTTAATCCTGTGTTTTTTGGTTTTAAAGACTATTTTATAATAAATTTTCGTGATTAAA
CTCTTGTGCTTAAACTCTTGATTAAACAAACAAGCAATGAAGAGATGAATGAAGCAGAAAATGTGAGTTTCATGCCT
CACATTCCCACTCCTCTGAGGTTAATATTTTCATGTATATTTTTCAGGATGTATTTGTAATCTCATACAAACGTATGTAT
TTTTTTAATGAAAATATTTAAATTTTCATAGTTAACAGCTGTAGCTCTAACTTGGCAATATCTTCTGTGTTTCTTTACAG
CCATTATACTTGCCCACGAATCTTTGAGAACATTATAATGACCTTTGTGCCTCTTCTTGCAAGGTGTTTTCTCAGCTGTT
ATCTCAAGACATGGATATAAAAAACTCACCATCTAGCCTTAATTCTCCTTCCTCCTACAACTGCAGTCAATCCATCTTA
CCCCTGGAGCACGGCTCCATATACATACCTTCC 
 
Figure 5. 9: Diagramatic representation of the human ERβ promoter sequence (NC_018925.2) in pSF-pA-
PromMCS-BetaGal vector highlighting the occurrence of multiple potential EREs (underlined and in red) 
in the promoter region. The yellow highlighting shows primers used to amplify the insert from human 
genomic DNA. 
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Figure 5. 10: The effect of genistein (100μM) on the response of the human ERβ promoter reporter 
plasmid. Data are derived from Caco-2 cells transfected with ERβ promoter-reporter plasmid construct 
comprising 1600 bp upstream to the ER transcription start site gene. Cells were treated with genistein 
(100 μM) 24 h after transfection and reporter gene activity was measured after further 24 h (n=3; three 
separate wells for one experiment), 48 h (n=9; three separate wells for each of three independent 
experiments)) or 72 h (n=9; three separate wells for each of three independent experiments)) of the 
treatment. Data are expressed relative to total protein and normalised to control. Values are means with 
standard errors represented by vertical bars. Statistical analysis was by Student’s unpaired T-test. 
***P≤0.001. Data were distributed evenly around the mean value, as established using Levene`s test for 
homogeneity of variant. 
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Figure 5. 11: The effect of the ER antagonist fulvestrant on response of the human ERβ promoter reporter 
plasmid to genistein. Data are derived from Caco-2 cells transfected with ERβ promoter-reporter plasmid 
construct comprising 1600 bp upstream to the ER transcription start site gene. Cells were treated with 
genistein (100 μM) in the presence and absence of fulvestrant (0.1 µM) 24 h after transfection and 
reporter gene activity was measured after further 48 h of the treatment. Data are expressed relative to 
total protein and normalised to control. Values are means (n=6; three separate wells for each of two 
independent experiments), with standard errors represented by vertical bars. Statistical analysis was by 
one-way ANOVA followed by Bonferroni’s multiple comparisons test. ***P≤0.001. Data were distributed 
evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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Figure 5. 12: The effect of the ER antagonist G-15 on response of the human ERβ promoter reporter 
plasmid to genistein. Data are derived from Caco-2 cells transfected with ERβ promoter-reporter plasmid 
construct comprising 1600 bp upstream to the ER transcription start site gene. Cells were treated with 
genistein (100 μM) in the presence and absence of G-15 (0.1 µM) 24 h after transfection and reporter 
gene activity was measured after further 48 h of the treatment. Data are expressed relative to total 
protein and normalised to control. Values are means (n=6; three separate wells for each of two 
independent experiments), with standard errors represented by vertical bars. Statistical analysis was by 
one-way ANOVA followed by Bonferroni’s multiple comparisons test. **P≤0.01, ***P≤0.001. Data were 
distributed evenly around the mean value, as established using Levene`s test for homogeneity of variant. 
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5.4. Discussion  
The aim of the work presented in this chapter was to investigate if there is functional 
similarity between 17β-estradiol, which is a mammalian endogenous female sex 
hormone, and genistein with respect to the effects of the two compounds on the 
expression of ERs. I determined if genistein affects the expression of ERs and if it has any 
auto-regulatory effect on ER expression such as has been observed for 17β-estradiol 
(Cardone et al., 1998). Thus, I measured the effect of genistein (100 µM) on the expression 
of both ER subtypes in MCF-7 cells, and compared this effect with that of 17β-estradiol. 
The experiment were then repeated under the inhibitory effects of the ER antagonists 
fulvestrant and G-15.  
I found that the two ER subtypes were differentially regulated by genistein. Similar 
to the action of 17β-estradiol, genistein decreased ERα mRNA. However, in contrast to 
17β-estradiol, which had no effect, genistein increased ERβ mRNA. The down-regulation 
of ERα concomitant with an increase in the expression of ERβ may be of benefit in cancer 
prevention or treatment. Based on epidemiological (Rudolph et al., 2012) and 
experimental studies, most cancers,  including colon adinocarcinoma (Foley et al., 2000; 
Campbell-Thompson et al., 2001; Konstantinopoulos et al., 2003), ovarian cancer 
(Rutherford et al., 2000; Bossard et al., 2012), breast cancer (Skliris et al., 2003; Huang et 
al., 2014), prostate cancer (Leav et al., 2001) and lung cancer (Kawai et al., 2005), have 
been associated with a substantial reduction and/or absence of ERβ. Moreover, 
overexpression of ERβ has been observed to inhibit proliferation of both ERα positive and 
negative human ovarian cancer cell lines (BG1 and PEO14) (Bossard et al., 2012). Similarly, 
overexpression of ERβ diminished cell proliferation and enhanced cell cycle arrest at G1 
in colon cancer cell models (SW480 and HCT-116) (Hartman et al., 2009). Also human 
breast cancers expressing high levels of ERβ have been shown to respond better to 
hormonal therapy than ERβ negative breast cancers (Murphy et al., 2002). Conversely, the 
ERβ knockout mouse showed abnormal growth of breast and prostate epithelial tissue 
cells, which is a predisposing factor in neoplasia (Gustafsson and Warner, 2000; Weihua 
et al., 2001). Again, ERβ knockdown by siRNA in a prostate cancer cell model (LNCaP) 
increased the proliferative rate of the cells in association with a sharp increase in the 
expression level of  ER-α (Stettner et al., 2007). 
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In contrast to ERβ, ERα appears to be highly expressed by cancer cells and 
approximately 70% of breast cancer cases are diagnosed as ER-α positive (DeSantis et al., 
2011). Unlike to ERβ, ERα seems to play a role in the onset (Hewitt et al., 2002) and 
progression of cancer (McPherson et al., 2008; Attia and Ederveen, 2012). Recently it was 
shown that an ERα dependent action inhibited P53/P21 expression and stimulated 
expression of proliferative cell nuclear antigen (PCNA) and proliferation-related Ki-67 
antigen in MCF-7 breast cancer cells (Liao et al., 2014). A low level of ERα expression was 
measured in normal human breast tissue but its expression was higher in some forms of 
breast cancer including invasive ductal carcinoma (Gustafsson and Warner, 2000) and in 
lobular cancer (Huang et al., 2014). ERα was consistently expressed in patients with  non-
small cell lung cancer were ERβ expression was variable (Kawai et al., 2005). However, in 
colon cancer ERα expression was reported to be similar to the surrounding normal tissue, 
and appeared to have no influence in colon carcinogenesis (Foley et al., 2000; Campbell-
Thompson et al., 2001). 
Our observations relating to probing the possible auto-regulatory actions of 
genistein and 17β-estradiol on ER expression also uncovered differences in action 
between the two compounds, whereas the effect of 17β-estradiol to reduce ERα mRNA 
was itself an ER-mediated response, being attenuated by the ER-antagonist fulvestrant, 
the response of neither ERα nor ERβ to genistein was reversed in the presence of 
fulvestrant, showing that both responses occur through a mechanism that does not 
involve ERs themselves. The response of the two ERs to neither genistein nor 17β-
estradiol was reversed in the presence of the GPR30 antagonist G-15, showing that the 
response of the ERs to these agents was not modulated through GPR30.  
Consistent with the data on effects of genistein and ER antagonists on ERβ mRNA, 
the ERβ promoter was activated by genistein and this action was not reversed in the 
presence of either ER-antagonist (fulvestrant and G-15). These observations, similar to 
those reported in chapters 3 and 4, uncovered effects of genistein that are ER-
independent and are consistent with previous studies showing that higher concentrations 
of genistein such as used in the present work act generally through other mechanisms. 
These alternative mechanisms of genistein action include inhibition of tyrosine kinase and 
topoisomerase activities (Salti et al., 2000; Dang et al., 2003; Chen and Donovan, 2004; 
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Kasai and Kikuchi, 2010). Further work is required to determine if either of these pathways 
is the mechanism through which genistein has the effects I report here. Lower 
concentrations of genistein (up to 3.7 µM) appear to mediate biological effects through 
ERs (Chen and Donovan, 2004; Magee and Rowland, 2004).  
In summary I observed that genistein reduced ERα mRNA and increased ERβ 
mRNA. Neither action appeared to be an auto-regulatory response mediated through ERs. 
In contrast, 17β-estradiol did not affect ERβ mRNA, while like genistein it reduced ERα 
mRNA. This was via an ER-mediated auto-regulatory mechanism. The most significant 
finding reported in this chapter is that genistein can simultaneously reduce ERα and 
increase ERβ, indicating that the therapeutic potential for prevention or treatment of 
hormone-dependent cancers may be worthy of future study.  
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                                                 Chapter 6  
6. An investigation into DNA methylation as a mechanism through which 
resveratrol affects d the expression of genes involved in lipid synthesis 
in 3T3-L1 cells.                                                                                                                                                                                                                                                         
6.1 Introduction 
DNA methylation status varies depending on cell phenotype and stage of 
differentiation (Morgan et al., 1999; Chong et al., 2007). The process is controlled by the 
DNA methyltransferase enzymes (DNMTs) (Okano et al., 1999; Chong et al., 2007).  DNA 
methylation status is very susceptible to modification by environmental and dietary 
factors including stress and diet (Junien and Nathanielsz, 2007; Daxinger and Whitelaw, 
2010; Ford et al., 2011; Uriarte et al., 2013). DNA methylation is considered to be an 
important likely contributor to the process of aging (Maegawa et al., 2010). Older 
individuals generally have lower global DNA methylation than younger individuals (Gomes 
et al., 2012). DNA methylation also appears to be involved in the control of lipogenesis. 
For example, DNA methylation of the leptin gene varies among different cell types and 
stages of cell differentiation (Stöger, 2006), being hypermethylated in preadipocytes then 
hypomethylated in mature adipocytes (Melzner et al., 2002). Furthermore, DNA 
methylation of the Fasn and Srebp1 promoters genes coding for the enzymes and 
transcription factor which have important functions in lipogenesis was decreased in mice 
in response to a high energy diet (Uriarte et al., 2013).  
Since there is already such an extensive body of research that shows the activity 
of genistein on DNA methylation, I selected the second polyphenol included in the work 
that forms the body of this thesis-resveratrol-for initial work to explore effects on DNA 
methylation in 3T3-L1 adipocytes. The focus on resveratrol also developed work carried 
out in the laboratory previously that uncovered effects of resveratrol on the expression 
of enzymes involved in lipid metabolism. 
Published evidence that resveratrol affects DNA methylation includes the 
observation that when given in the diet to rats it increased in the DNA methylation of 
genes encoding pro-inflammatory cytokines including IL1β, IL-6, TNF-α and IFN-γ, and 
reduced their expression (Lou et al., 2014). Resveratrol may alter DNA methylation 
through affecting DNMT expression and activity (Paluszczak et al., 2010). Resveratrol was 
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observed to down-regulate expression of DNMT1 (Qin et al., 2005; Stefanska et al., 2012) 
and DNMT3b (Qin et al., 2005; Qin et al., 2014).  
6.2. Objective 
Previous observations made in the laboratory by Goiuri Alberdi Aresti were that 
the mRNA of lipogenic enzymes including fatty acid synthase (FAS) and acetyl Co-A 
carboxylase (ACC) were reduced in 3T3-L1 adipocytes after treatment with resveratrol. 
This action may be the basis of a reported action of resveratrol to protect against obesity 
(Lin et al., 2012b; Jin et al., 2013; Andrade et al., 2014a). We thus proposed that 
resveratrol may induce changes in the expression of Acaca and Fasn genes through 
mediating changes in DNA methylation of Acaca and Fasn promoters.  
 The approach was to treat 3T3-L1 cells with resveratrol. Following extraction of 
DNA and RNA, DNA methylation of Acaca and Fasn promoters as well as corresponding 
mRNAs were measured by pyrosequencing and RT-qPCR respectively.  
6.3. Results  
To exclude a possible effect of cell differentiation on the methylation status of the 
Acaca and Fasn promoters prior to investigating the effects of resveratrol, DNA 
methylation of the promoter regions of these genes was measured at day 0 (before 
differentiation) and 12 days after initiating the process of differentiation by 
pyrosequencing. The assay for Fasn measured DNA methylation at 5CpG sites at positions 
-324, -328, -330, -337,-344, -351, -366, -368 relative to the transcription start site. The 
assay for Acaca measured DNA methylation at 5CpG sites at positions -1956, -1972, -1983, 
-1998, -1916 relative to the transcription start site. Primer sequences are stated in chapter 
2, table 4. I found that DNA methylation of neither gene at the CpG sites measured was 
changed when cells differentiated (Figure 6.1). Consistent with the earlier observations, 
treatment of cells with 10 μM resveratrol for 48 h (day 10 to day 12 of differentiation) 
decreased FAS and ACC mRNA (Figure 6.2). However, DNA methylation of the CpGs 
measured in Fasn and Acaca genes was not affected by resveratrol applied between day 
10 and 12 or applied on induction of differentiation until day 12 (Figures 6.3 and 6.4). The 
data thus indicate that resveratrol affects the expression of Fasn and Acaca genes in 3T3-
L1 cells by a mechanism other than DNA methylation of the promoters of corresponding 
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genes, at least at the CpG sites measured in the assay. It is possible that the treatment 
affected methylation of CpG sites not induced in the assay. 
180 
 
 
Figure 6. 1: DNA methylation at CpG sites in acetyl co-A carboxylase (ACC; Acaca) (paired A) and fatty acid synthase (FAS; Fasn) (paired B) gene promoter regions in 3T3-L1 cells. 
Cells were cultured and grown to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced to differentiate. Genomic DNA 
was extracted on day 0 and day 12 of differentiation. DNA methylation at specific CpG sites was measured by pyrosequencing. Values are means (n =5; A, n=4; B), with standard 
errors represented by vertical bars. Statistical analysis was by Student`s unpaired T-test. There were no differences between methylation at day 0 compared with day 12 at any 
of the CpG sites measured. P˃ 0.05. 
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Figure 6. 2: The effect of resveratrol (10 µM) on acetyl Co-A carboxylase (ACC) and fatty acid synthase 
(FAS) mRNA applied between days 10 to day 12 after inducing differentiation in 3T3-L1 cells. Cells were 
cultured and grown to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken 
as day 0, cells were induced to differentiate. Cells were treated with resveratrol (10 µM) from day 10 to 
day 12 for 48 h. Total RNA was extracted, and mRNA levels of FAS and ACC were measured by RT-qPCR. 
Data are expressed relative to the reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and normalised to control. Values are means (n=12), with standard errors represented by vertical bars. 
Statistical analysis was by Student`s unpaired T-test. *P≤0.05. 
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Figure 6. 3: The effect of resveratrol (10 µM) applied between days 10 to day 12 after induction of differentiation on DNA methylation at CpG sites in acetyl co-A carboxylase (ACC; 
Acaca) (panel A) and fatty acid synthase (FAS, Fasn) (panel B) gene promoter regions in 3T3-L1 cells. Cells were seeded and grown to confluence in 6-well plates. Forty eight hours 
after cells reached confluence, taken as day 0, cells were induced to differentiate and treated between day 10 and day 12 for 48 h. Genomic DNA was extracted on day 12. DNA 
methylation at specific CpG sites was measured by pyrosequencing. Values are means (n=12), with standard errors represented by vertical bars. Statistical analysis was by Student`s 
unpaired T-test. P˃ 0.05. 
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Figure 6. 4: Effect of resveratrol on methylation status of acetyl co-A carboxylase (ACC; Acaca) (panel A) and fatty acid synthase (FAS; Fasn) (panel B) promoter applied on induction 
of differentiation in 3T3-L1 cell. Cells were cultured and grown to confluence in 6-well plates. Forty eight hours after cells reached confluence, taken as day 0, cells were induced 
to differentiate in the presence and absence of resveratrol (10 µM). Genomic DNA was extracted on day 12. Assays measured percentage of DNA methylation at different CpG 
sites as indicated. Values are means (n= 11-12), with standard errors represented by vertical bars, compared by Student`s T-test. P˃0.05.
184 
 
6.4. Discussion 
In this chapter of the study I investigated the effect of resveratrol on DNA 
methylation of the genes coding for acetyl Co-A carboxylase (Acaca) and fatty acid 
synthase (Fasn), which are the key and rate limiting enzymes in the process of lipogenesis 
(Hellerstein et al., 1996; Ameer et al., 2014), We hypothesised that altered DNA 
methylation may be the mechanism underlying a previous observation made in the 
laboratory by Goiuri Alberdi Aresti, which was that resveratrol reduced the mRNA of these 
lipogenic enzymes in 3T3-L1 cells. This hypothesis was informed by previous studies where 
resveratrol was shown to regulate expression of genes via inducing changes in DNA 
methylation (Melzner et al., 2002; Stöger, 2006). I thus measured DNA methylation at 5 
and 8 sites in Acaca and Fasn promoter regions, respectively, before and after treating 
3T3-L1 cells with resveratrol.  
I first measured DNA methylation of Acaca and Fasn promoters before (day 0) and 
after induction of differentiation (day 12), and observed that DNA methylation of neither 
gene at the CpG sites measured changed when cells differentiated. The purpose of making 
these measurements was to be able to take into account any effects of resveratrol I might 
measure that were commensurate with effects on cell differentiation status. However, 
the fact that DNA methylation of the Acaca and Fasn genes remained constant throughout 
the differentiation process indicated that DNA methylation may not be an important 
factor in controlling the expression of the Acaca and Fasn genes, since both genes were 
observed to undergo large changes in expression as 3T3-L1 cells differentiate (see chapter 
3, section 3.3.1). Thus this initial observation suggested that DNA methylation may be an 
unlikely mechanism underlying the effect of resveratrol on expression of these genes.  
Indeed, resveratrol did not affected DNA methylation of Acaca and Fasn, yet in 
agreement with the previous work in the laboratory it reduced the corresponding mRNAs. 
Observations made in vivo have also shown a lack of action of resveratrol on DNA 
methylation of the Fasn gene. A dietary supplement of 30 mg/kg/day in rats was found to 
have no effect on Fasn promoter DNA methylation, yet it was effective in protecting 
against diet induced obesity (Gracia et al., 2014).  
To the best of our knowledge, this study is the first to investigate the effect of 
resveratrol on Acaca DNA methylation. The CpG content of the Acaca promoter is very 
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low and does not satisfy the following criteria for defining the CpG island: region ˃ 200 
bp; CpG content ≥ 50% (Deaton and Bird, 2011; Elango and Yi, 2011; Du et al., 2012). There 
is a general view that promoters that contain CpG islands are regulated by DNA 
methylation whereas it is a less important mechanism for controlling the expression of 
genes that lack CpG islands (Du et al., 2012; Rao et al., 2013). However, DNA methylation 
of genes with no CpG islands seems to have a role in controlling gene transcription (Han 
et al., 2011; Øster et al., 2013). Thus I considered it still worth investigating if resveratrol 
affected DNA methylation of the Acaca promoter. 
The effect of resveratrol on Acaca and Fasn expression may be through inhibiting the 
expression of sterol response element binding protein-1c (Srebp-1c) and PPARγ, and 
subsequently their downstream lipogenic genes comprising Fasn and Acaca (Lin et al., 
2012b; Jin et al., 2013; Andrade et al., 2014a), up-regulation and activation of Sirt1 (Qiang 
et al., 2012; Andrade et al., 2014a), which has also been shown to affect the expression 
and activity of FAS and ACC (Cheng Xu et al., 2013; Zhang et al., 2014) 
In summary, changes in the DNA methylation at the CpG sites measured by in our 
assay appears to be not an important factor in the controlling the expression of Acaca and 
Fasn genes as neither the differentiation process nor resveratrol treatment induced 
changes in DNA methylation at these sites. Thus, future experiments to explore the role 
of DNA methylation and the basis of the action of resveratrol to reduce Acaca and Fasn 
mRNA in 3T3-L1 cells could measure different CpG sites in the promoter and enhancer 
regions of these genes or of their upstream transcription factors. Additionally other 
mechanisms such as changes in transcription factor expression should be investigated 
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Chapter 7 
7. Summary discussion and Conclusions 
The consumption of dietary polyphenols, including resveratrol and genistein, has 
been encouraged recently with the aim of deriving health-beneficial effects. A wide range 
of possible health benefits related to consuming resveratrol and genistein have been 
shown in numerous epidemiological and experimental studies. The possible positive 
actions include anti-cancer activity (Wang et al., 2002; Sales and Resurreccion, 2013), 
antioxidant effects (Hoshino et al., 2010; Sales and Resurreccion, 2013), and antilipogenic 
activity (Kim et al., 2010; Jin et al., 2013). This study aimed to investigate certain actions 
of these dietary polyphenols in relation to aspects of molecular physiology relevant to 
metabolic health and aging, and to explore the possible mechanisms of such actions. The 
dietary polyphenol genistein was the main focus of this study. 
 Genistein appears to have pleiotropic cellular actions mediated through different 
molecular targets, and it is difficult to attribute physiological effects to specific actions at 
the molecular level. The main focus was its possible use as an agent to reduce 
adipogenesis. Related benefits would include alleviation of obesity-related health 
problems such as cardiovascular disease, type-2 diabetes and non-alcoholic fatty liver 
disease. 
Previous research in the laboratory using the mouse 3T3-L1 adipocyte model showed 
that resveratrol affected the expression of genes involved in lipogenesis, specifically 
Acaca and Fasn. I proposed that genistein, which has some structural and possibly 
functional similarity to resveratrol, would have a similar action.  However, addressing this 
hypothesis led to the serendipitous discovery that genistein had dose and time dependent 
effects on the appearance of brown/beige rather than white adipocytes as indicated by 
accumulation of small paucilocular lipid-droplets within the cytoplasm of genistein 
treated cells, which opposed the typical large fat droplets observed in the control 
differentiated cells. Consistent with this morphological change there was a decrease in 
the expression of the mRNA levels of genes that characterise white adipocytes, specifically 
Fasn, Fabp4, Lipe, Rarres2 and Retn. A notable exception to this pattern of gene responses 
consistent with genistein promoting a beige adipocyte gene expression profile was Acaca, 
which initially increased after the application of a high dose of genistein but was ultimately 
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(like the other markers of white adipocytes) down-regulated. The metabolic rationale for 
this observation is not clear, and a search of current literature did not reveal any evidence 
that ACC has a specific role in white into brown adipocyte interconversion. Thus, probing 
the role of ACC may be an interesting and important objective for future study to 
understand distinct metabolic activities of the different types of adipocyte tissue. As 
expected, concomitant with a reduction in the expression of genes that characterise white 
adipocytes, there was an increase in the expression of genes involved in the process of 
white into brown adipocyte interconversion (Sirt1, Cebpb, Ppargc1a) accompanied by an 
increase in the expression of genes that characterise beige adipocytes (Ucp1 and Tnfrsf9). 
Uncoupled mitochondria, due to expression of UCP1, are a key phenotypic feature of 
brown and beige adipocytes. In parallel with a marked increase in UCP1 expression 
observed in 3T3-l1 cells in response to genistein there was an increase in basal and 
uncoupled oxygen consumption rate. Furthermore, the proportion of the total oxygen 
consumption rate that was uncoupled before addition of uncoupling agent FCCP and after 
activation of UCP1 by the retinoid TTNBP was increased. Together these findings are 
consistent with increased uncoupling of mitochondrial oxygen consumption from ATP 
synthesis and thus with the induction of a beige adipocyte phenotype.  
These observations suggest that genistein, which is present in a large quantities in 
soya-based products (e.g. including tofu, fermented bean paste and soya milk), may 
protect against obesity by enhancing the development of brown, rather than white, 
adipose tissue. However, to substantiate such claims it is essential to demonstrate these 
effects in human volunteers. There are many other limitations and caveats to this work, 
which should be addressed in future studies. Firstly, these observations were made after 
direct exposure of 3T3-L1 cells to genistein, which is not achieved when genistein is 
consumed in the diet. The parent compound genistein, rather than its metabolites, may 
be the active stimulator of the process of white to beige adipocyte conversion. Thus 
further work should investigate if genistein is metabolized in this cell culture system, and 
should determine if individual metabolites of genistein, which are commercially available, 
evoke the same response.  
The fact that I derived beige adipocytes from 3T3-L1 cells provides further evidence 
to support published reports that beige adipocytes originate from the same precursor as 
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white adipocytes, which is different from that of classical brown adipocytes. Further work 
is required, however, to determine if the process of interconversion is transdifferentiation 
of mature white adipocytes or de novo differentiation of precursor cells induced by 
genistein. The in vitro system affords the opportunity to address this fundamental 
question through approaches such as genetically marking the mature white adipocytes 
(for example, with β‐galactosidase under the control of white‐adipocyte‐specific 
promoter) then observing the distribution of marked cells after induction of the 
phenotypic change by genistein. 
Genistein has structural similarities with 17β-estradiol and is, therefore, described as 
a non-steroidal phytoestrogen. Thus, I determined if the responses I observed in 3T3-L1 
cells were mediated via the ER. This was achieved by determining the effect of the ER 
antagonist fulvestrant on the observed responses to genistein. The results indicated that 
browning of white adipocytes is probably not mediated through the ER as the observed 
change in the morphology of cells induced by genistein was not suppressed and the 
changes in expression of our test gene panel was not abolished by fulvestrant.  
Changes in Sirt1 expression occurred early in the sequence of effects I observed, and 
previous studies demonstrated a likely role of Sirt1 in mediating browning of white 
adipocytes (Qiang et al., 2012; Fu et al., 2014). Thus, I proposed that Sirt1 activity may be 
a key initiating step in the process of white into beige adipocyte interconversion induced 
by genistein. In support of this hypothesis, the responses of Ucp1 and Cebpb genes to 
genistein were significantly attenuated when the activity of Sirt1 was inhibited by EX-527, 
which is a specific and potent Sirt1 inhibitor with the ability to bind in the nicotinamide 
pocket of the Sirt-1 protein (Gertz et al., 2013). Also, the genistein-induced reduction in 
the expression of genes that characterise white adipocytes (Acaca, Fasn, Fabp4, Lipe, 
Rarres2 and Retn) was not attenuated by EX-527. From these observations I conclude that 
Sirt1 activity is a component of the process that initiates white to beige adipocyte 
conversion. I also showed a moderate (2 fold) increase in Sirt1 mRNA and a sharp increase 
(approximately 12 fold) in Sirt1 protein, which further indicated that increased Sirt1 action 
was a vital mediator in the observed changes.  
The effect of genistein on Sirt1 expression was also shown to not be unique to 
adipocytes. Genistein also was found to promote an increase in the expression of Sirt1 in 
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MCF-7 breast cancer cells and the effect was ER-independent, similar to the observations 
made in 3T3-L1 cells. The role of Sirt1 in promoting white into beige adipocyte conversion 
could be further investigated by targeting Sirt1 with other potent pharmacological or 
dietary agents, which may allow a better understanding of this process, and may 
ultimately allow the development of new dietary or pharmacological strategies to 
promote beige adipocyte tissue development and thus protect against metabolic diseases. 
To develop previous work conducted in the laboratory on novel actions of resveratrol 
(Alatawi, 2012), we proposed that genistein like resveratrol would affect histone 
expression. Histone proteins control gene expression (Chen et al., 2013a) and may 
influence life expectancy (Feser et al., 2010a; Hu et al., 2014). We also proposed that 
genistein may have a synergistic effect on histone expression when combined with 
resveratrol. Lower reporter gene expression was measured in extracts from Caco-2 cells 
transfected with a histone H3 (variant H3b) promoter-reporter construct after treatment 
of cells with resveratrol and/or genistein. The effect of resveratrol and genistein in 
combination, however, was not greater than that seen with either compound separately, 
indicating that the compounds probably affect histone H3 gene transcription through the 
same mechanism but don’t act in synergy. However, in this study an interacting effect of 
genistein and resveratrol was tested only with respect to a very selective action. Thus, I 
should not exclude the likelihood that these compounds interaction over a broader 
spectrum of actions. Interaction of genistein with resveratrol and other dietary 
polyphenols would be worth investigating more broadly.  
The effect of genistein on histone protein abundance contrasted with our 
observations that genistein repressed transcription from the histone H3.1 (variant H3b) 
promoter-reporter construct. Genistein induced an increase in the expression of histone 
H3 and H4 proteins in both Caco-2 and MCF-7 cells. I suggested that genistein might have 
differential actions on specific histone variant mRNAs. In support of this hypothesis, 
histone H3d and H3.3 mRNAs were found to increase in response to genistein whereas all 
other variants measured were reduced.  Again, the ER antagonists fulvestrant and G15 did 
not affect any of these responses, indicating that, like the other actions studied in this 
body of work, these effects of genistein were though pathways independent of ERs.  
Observations of these ER-independent actions of genistein on histone expression 
190 
 
extended also into 3T3-L1 adipocytes, the main focus of the body of work in this thesis. 
The significance of this finding with respect to cell physiology is not yet clear. However, 
gene expression through specific alterations in chromatin structure may be one of the 
mechanisms through which genistein has its reported pleiotropic beneficial effects.  
Specific and distinct roles of histone H3 variants have been shown; thus the findings are 
likely to be important. For example, the presence of histone H3.3, especially at specific 
gene promoter and enhancer regions, was associated with transcriptional activity (Ahmad 
and Henikoff, 2002; Hake and Allis, 2006; Chen et al., 2013a). However, to establish an 
association between a genistein‐stimulated increase in the level of histone proteins and 
actions of genistein on gene expression further study is needed. For example, histone 
proteins could be enriched using chromatin immune precipitation (CHIP) then their 
associated genes could be detected using PCR. Furthermore, the observed stimulatory 
effect of genistein on histone protein abundance may promote longer life expectancy 
(Feser et al., 2010b; O'Sullivan et al., 2010). To address this hypothesis work could include 
investigating the effect of genistein on lifespan and histone expression in animal models.  
Because of the structural similarities between genistein and 17β-estradiol I 
investigated if genistein affects the expression of the ER, since 17β-estradiol has 
autoregulatory feedback action via repression of ERα expression. The observations made 
were potentially important because I showed that genistein has selective actions on ERα 
versus ERβ, reducing mRNA corresponding to ERα while increasing ERβ mRNA.  Once 
more, these responses were not affected by ER antagonists fulvestrant and G-15. The 
down-regulation of ERα concomitant with an increase in the expression of ERβ may be 
physiologically beneficial. ERα activity is generally detrimental while ERβ activity appears 
to be of benefit in the prevention or treatment of breast cancer (Stettner et al., 2007; 
Hartman et al., 2009; DeSantis et al., 2011; Liao et al., 2014). The potential of genistein to 
reactivate the expression of ERβ in ERβ‐negative cancer patients may have therapeutic 
potential for the prevention or treatment of hormone‐dependent cancers prior to and 
during hormonal therapy. 
Finally, I developed previous research in the laboratory on actions of resveratrol in 
3T3-L1 cells. The earlier work showed that resveratrol reduced mRNA levels of genes 
involved in the initial steps of lipogenesis, specifically Acaca and Fasn. I reconfirmed this 
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finding in the work presented in this thesis. We proposed that this action may be 
accompanied by a change in DNA methylation of the corresponding gene promoter 
regions, which is a plausible mechanism of regulation given the other reported effects of 
resveratrol to alter DNA methylation.  However, resveratrol had no effect on DNA 
methylation in the regions measured. Thus, this initial observation suggested that DNA 
methylation may be an unlikely mechanism underlying the effect of resveratrol on 
expression of these genes.   
Together the body of work presented in this thesis uncovers novel actions of the 
dietary polyphenol genistein, particularly in reaction to adipocyte tissue browning, but 
also more broadly, encompassing action on histone and ER expression in adipocytes but 
also other cell types. Our findings indicate that genistein mediates white to beige 
adipocyte interconversion. This action may, in the context of a favourable background 
diet, aid in the prevention of obesity and its related disorders including cardiovascular 
diseases and diabetes. In addition, a differential regulatory effect of genistein on ER 
expression that I uncovered may be of benefit in the prevention and/or treatment of 
hormone-dependent cancers. Alteration in chromatin structure driven through 
differential effects on the expression of specific histone variants is one of the possible 
mechanisms through which genistein may have its pleiotropic actions on gene expression.  
Despite the structural similarity between genistein and the endogenous ER ligand 17β-
estradiol, I showed that all of the actions of genistein were mediated through ER-
independent mechanisms. 
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Appendix 1: Representative amplification curves, melting curves and melting peaks for 
RT-qPCR. 
 
 
 
 
50 and 100 µM genistein 
treatment 
Control 
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Appendix 2: Histone H3b and H3d promoter alignment 
H3d      TATGAAACC------AATTTGACA----------------AGGGACACATCACAGCACAA 
H3b      TGTGGCACTTTTAGTAATTTGTCCTGCAGAAATTAGATCCATAGAAAC--CTCAGGAATT 
         *.**..**       ******:*.                * .**.**  *:*** *.:: 
 
H3d      -----CATAAGAAAAATGTGCTTATCAGCACAATGGGCTAGCCTTCTAACCAGCACTTGG 
H3b      CTAGGTATGTGGGAGAAGTGCCATGCAGCACAAAAC--ATG-----TTT-----AC-AGG 
               **.:*..*.*:**** :: ********:.   ::*     *::     ** :** 
 
H3d      GGTAAAACA----------AACATG---------CTACGGTTAAGT--ATAGCAT--TTT 
H3b      GGTGATTCGCGTTAAGTTTCACACACAGCAGTTACTACATTTTAGAGGAAGGAAATTATA 
         ***.*::*.          .*** .         ****. **:**:  *:.*.*:  :*: 
 
H3d      CC-T----------TCAACCAGTCAAAAGAACTGTGGTCTAGACCTACACAGCAGCAACC 
H3b      CCCATGAGTGCATTCCTAACTATCTT--GAAT---GGAAGTGT---TAAAACCCGCATGC 
         ** :           *:*.*:.**::  ***    **:. :*:   :.*.* *.***: * 
 
H3d      CCCTCAAATG--AGGATAAAACCAAACCTGTTGGT------------GGTAAACACGGAA 
H3b      CCCACACAAGTTTGAAT-ATGTCATACCATTTGCTGTAGCAATTAATGGCATACACAATT 
         ***:**.*:*  :*.** *:. **:***: *** *            ** *:****..:: 
 
H3d      AATATGCAGGTAATTACAACTCTATAGCTGAAAAAGTGGGT----GGCT-CTTAAAAGAG 
H3b      -----GAGAGCACACAC---ATTACCACTGAACATTTGAGTATGTATTTCCCAAAATGAG 
              *...* *.: **   : ** ..*****.*: **.**    .  * * :***:*** 
 
H3d      CCTTTG---GGATTGGGTATGAAGACGTTAGAATTACTTAGAGCTGGTGTACTTGGTGAC 
H3b      CTTTTTTCCAGTTTGGGGAT----------GTTTTGCTTTGTTTTGGGG----TGGAGTC 
         * ***    .*:***** **          *::**.***:*:  *** *    ***:*:* 
 
H3d      GGCCTTGGTGCCCTCTGACACGGCGTGCTTAGCCAGCTCCCCGGGCAGCAGCAGGCGCAC 
H3b      ---------TCCCTCTCGCCCAAGCTG-------------CAGTGCAGCGGCGTGATAAC 
                   ****** .*.*..  **             *.* *****.**. *. .** 
 
H3d      GGCCGTCTGGATCTCCCTGGA--GGTGATGGTGGAGCGCTTGT--------TGTAAT--- 
H3b      AGCTCACTGTAACCTCGAACTCGGGCTCAAGCGATCCTCTTGACAGCCTTCTGAGTAGCT 
         .**  :*** *:*  * :. :  **  .:.* *.: * ****:        **:.::    
 
H3d      ---GCGCCAGGCGG--GAAGCCTCGCCAG-CGATGCGCTCGAAGATATCGTTGACGAAGG 
H3b      GGGATTACAGGCGAGAGCCGCCACGCCCGGCTAAGAGCATT------------------- 
            .  .******.  *..***:****.* * *:*.**:                      
 
H3d      AGTTCATGATGCCCATGGCCTTGGATGAGATGCCGGTGTCGGGGTGGACCTGCTTTAGCA 
H3b      -TTTCTAATTGCCCACA-CTTCTTATGCGA----------------------------CA 
           ***::.:****** . * *   ***.**                            ** 
 
H3d      CCTTGTACACGTACACGGAATAGCTCTC--CTTGCGGCTACGCTTGCGCTTCTTACCATC 
H3b      CCCA-------------GAAAAATACAATTTTAAATAAAGCGCATATGCAAATTTCC--- 
         ** :             ***:*. :*:.   *:.. ..:.***:*. **::.**:**    
 
H3d      CTTCTTCTGCGCCTTG-GTCACCGCCT---TTTTGGAGCCCTTTTTTGGAGCAGGA-GCG 
H3b      -CTAATCGTCTCCAATATTCTCTGATTTCTTTTTTATATTTTAACTAGAAACAATTGGAG 
           *.:**  * **::   **:* *. *   **** .:.   *:: *:*.*.**. : *.* 
 
H3d      GA-----CTTAGCAGGTTCAGGCATGATAAATAAACACT--------------------- 
H3b      GTTTCCGCGTTGCTTTGTGTGGTTGTAAATTTTAAGACTTCAGGAAACTTTTCCAGTACA 
         *:     * *:**:   * :** :  *:*::*:** ***                      
 
H3d      ----TCGTCCACAACCT-----------AAAGAGAAATGCAAGTGTCCTCACTCTGCAGC 
H3b      AGACTTGTCCACAGTGGATATAGCAGCTAAGGGGTTAACAAAATGACGTCAG--AGTAGC 
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             * *******.              **.*.*::*: .**.**:* ***   :* *** 
 
H3d      TGGTAATATTTGTAGAGCTCCTATCGTAAACTGGCATTTAAAAGCTTACACATTGATTGG 
H3b      TACGG-TAATGGGCAGGAGCCTCTCTTAATCTGC-------AACCAGGCACAGAGATGGA 
         *.  . **:* * ...*. ***.** ***:***        ** *: .**** :*** *. 
 
H3d      ATGAATTGTCTCT-GTGTGCCCTGTGGTATGCAAATTAGGTGATTCTAGCGTTTCTTTGC 
H3b      ----CCAATCCAAGAAGGGCGCGGGGAT------TTTTGAATTTTCTTGGGT-------C 
             . :.** .: .:* ** * * *.*      :**:*.: :****:* **       * 
 
H3d      AATTGGTTGGTTGTTCTAGCC-AATCA-AATAGCGTT--ATTTACAATTCGACCTCCAAG 
H3b      CAATAGTTGGTGGT-CTGACTCTATAAAAGAAGAGTAGCTCTTTCCTTTC---CTCCA-- 
         .*:*.****** ** **..*  :**.* *.:**.**:  : **:*.:***   *****   
 
H3d      TATAATAGTTTCTCACTTGCTAACAAAACTCACTTTTACATTTTTGTCTTCATTGCTTAA 
H3b      -------------------------------------------CAGACGTCTCTGCAGGC 
                                                     :*:* **: ***: .. 
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Appendix 3: (A) Agarose gel electrophoresis of human ERβ PCR products and restriction 
digestion. Human genomic DNA was used to amplify about 1600 bp of ERβ promoter 
region and restriction enzymes digestion by Hind III and EcoR1. (B) Agarose 
electrophoresis gel of the plasmid (pSF-pA-PromMCS-BetaGal vector) before and after 
restriction enzymes digestion by Hind III and EcoR1. (C) Agarose gel electrophoresis of 
recombinant plasmids to screen for those containing the ERβ promoter region. The DNA 
molecular weight marker (hyperladder I) was run in parallel to monitor the size of 
products. 
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Appendix 4: Acaca and Fasn promoter sequence before and after bisulfite modification 
are shown. 
Acaca gene promoter DNA sequence: 
 
TAATATTATCAATTTTACTATTTTTGTACTAGACTGAGTAGAACTGGAATTGAGAAAAAAAATTGGTTTTTA
AAAGAAGAAAAAGAAAACCAAATGAACAGAAAAAGCAACCTTCAAATCTCTGTTTTTCTCTTTATTTAGTTC
TTTTTGGAGGCGGATATCTGCTGAGACAATAAGAATTATAAGAGGTCAGTTTCAAATAATAGTCTTTTATGT
TTACACTGTAGTAAAAGTTTTAATGTGCTAAGATGTTAAACTGTGGGTTTCTGTTGTCTTCCACAAAGAATA
TTGGCAGACGTAGGGTGAGTGACCCAAGCGAACAGGGAGGCTGACAATGACAACGGTGGTGACCCACTGCCT
TCTCTCTAATTTAGGACTGGAATCAATGGAAATGGGACAGGCTGTGGCAGCTTCTAGAGTGTCTGGATGGCT
ACTCAGTGATTTTCCAGGCATGACCTCCCTTTCTGGTGGCATACATGCCTGCGCTAGGGAGCAGTGTTCCGT
ACAGGTGCTTGCCGCTGGGCAGGCGTCAGTTGTTAAACACGGCTGCTTCCAGTCTGTGCAGCCCTTAGAAAA
GGCTGCCTGGGTTCTGGCCGCTAGGAGGGGCCAGGATGAAGGGCTGTGCTGAGCCTTTCATTCATCAGCCCA
GGGACTGTATTTTACTAACGCTGACCTTCTTTACTTTCATGATCTCCAAGCGTCACTACTTTCTCATGAACT
TTATTTTATTTTTGTGACCATCAGATTTCAGTCAGATTATAAATTAGAATGTACACCTGTGTGCCTTGGTTC
CCTTGTGAAGGCAGCAGCTGTGAGCCAGGTGTGGAGGTGTACTAATGTCATCCCAGCTATAGGTATCCCCTG
CTGTAGAAGTTTGGGGTTAGCCTGACTGTGAGATGCTGTCTCTTCCCTGCCTCTCCAAATACTTGGCCAGCT
TTCATTTTTTTATTCTCTCGGTTGCTGTATCTTTTATTATTTTTAACATGGTCAGTGTATTGGAATGTCACT
TTTTCCTTTCCTCTTATTCCCTAACTCAATTTTTCTTTTTTTTTTTAAGATTTATTTATTTATTTTATGTAT
ATGAGTACACTGTAGCTGTACAGATGGTTGTGAGCCTTCATGTGGTTGTTGGAAATTGAATTTAGGACCTCT
GCTCGCTCTGGTCCATAGATTCATTTATTATTATACATAAGTACACTGTAGCTGTCTTCAGACACACCAGAA
GAGAGTGTCAGATCTCATTACTGATGGTTGTGAACCACCATGTGGTTGCTGGAATTTGAACTCAGGACCTTC
AGAAGAGCAGTCAGTCTTACCTGCTGAGCCACTTCACCAGCCCTCCCCTTTTCTTCTAATGATTTGGTTGTC
TTTTAGACTGAACTCCATACACTTTGGAGACTAAAAAAAAAAAAAGAAATACAATACAGAGATCTGTCTTCT
AATAGTTTCATGCCCTGGAACTCACAGAGATCTACCTGCTTCTGCTTCTTGAGTGCTGGGATTAAAGGCATG
TGCCACCATACCATGATTTAAAGTTTTTAAAATAAGTATGTTGAAGGGAAAGAATACTTTTAACTTTGTTTG
TTTTTGTTTTCTTATGGGGCTTTGAACTGGTAACTATTTTTGGTCAGGTTTGTTCATTATCTACTGATGATA
GCTAGTAAGGTCCACTATCTAGAAAAATGGAGTTTGTGATGGCACATCAACCACTTTGAATACAGATTTAAA
ATTTGGTAGTAGATTCACTCCCTCTACCAATTCTGTGTACAGAACTAAACAACAAAAATAGACATTTGGGGG
TAGATTTTTAAAATAATCAGTTGAAAAAAAAACCTCATGTACACACACGAGGTTTTGTTGTTTTACTTTAAA
TACATATGTTTAGTAAAATTCATAACTTTCATTGTATTGTGTTTGGCACCAGGTGATCATTATGTAGTTTAA
CCACCCAGTTTCAAGCAACTTCCACTCTTGCTAAACTCTTTAGCACTCTTTACCCACGCTGCTACAGATGAG
TCACAGTCTCACAACAGCTTTGCTTACAGGAAAGTGTTCCCATTGGTATAGTTATTCCTTCAGTCTCACTGA
AATTGTGAAGAGATTGGTAATGCGCATACTGTGAGAACTACTTCTAAAACTTTTAATTTATAAGCATAGTTA
CCACAACCTCTCTTTTCCTCCCTTGGAGGAAACAAACATACTGGAATAGAATAGCCATGGAAGCCAGGCTTT
AATCTCAGCACTTGGGAGGCAAAGGTAAGTGGATCTCTGTGAGTTCAAGGCCAGGCTGATCTGTAGAGTAAG
TTCCTGGACAGCCAAGGCTAAACAGACAAACCCTGTTTTAAAAAAACCAAAAAAACCCAAAAAGAGTAGCCA
AGCAAGCCAGTTCTTAGACTCAGACTTATTTCCAAGCCACTTGTGGTTTATGCTTTACTTTCTTGTGTGTTC
TCATCTATAGGTTATTGCTTATAACCTACTTTTCTCTTAATTTTTCCCATAGCTCTGAGAGCTTATTTTGAA
AGAATAATGGATGAACCATCTCCGTTGGCCAAAACTCTGGAGCTAAACCAGCACTCCCGATTCATAATTGGG
TCTGTGTCTGAAGACAACTCAGAAGATGAGATCAGTAACCTGGTGAAGCTGGACCTAGAAGAGAAGGAGGGC
TCCCTGTCACCAGCCTCCGTCAGCTCAGATACACTTTCTGATTTGGGGATCTCTGGCTTACAGGATGGTTTG
GCCTTTCACATGAGGTGAGAAGAA 
Bisulfite modified Acaca gene promoter DNA sequence: 
TAATATTATTAATTTTATTATTTTTGTATTAGATTGAGTAGAATTGGAATTGAGAAAAAAAATTGGTTTTTA
AAAGAAGAAAAAGAAAATTAAATGAATAGAAAAAGTAATTTTTAAATTTTTGTTTTTTTTTTTATTTAGTTT
TTTTTGGAGGC/TGGATATTTGTTGAGATAATAAGAATTATAAGAGGTTAGTTTTAAATAATAGTTTTTTAT
GTTTATATTGTAGTAAAAGTTTTAATGTGTTAAGATGTTAAATTGTGGGTTTTTGTTGTTTTTTATAAAGAA
TATTGGTAGAC/TGTAGGGTGAGTGATTTAAGC/TGAATAGGGAGGTTGATAATGATAAC/TGGTGGTGATT
246 
 
TATTGTTTTTTTTTTAATTTAGGATTGGAATTAATGGAAATGGGATAGGTTGTGGTAGTTTTTAGAGTGTTT
GGATGGTTATTTAGTGATTTTTTAGGTATGATTTTTTTTTTTGGTGGTATATATGTTTGC/TGTTAGGGAGT
AGTGTTTC/TGTATAGGTGTTTGTC/TGTTGGGTAGGC/TGTTAGTTGTTAAATAC/TGGTTGTTTTTAGTT
TGTGTAGTTTTTAGAAAAGGTTGTTTGGGTTTTGGTC/TGTTAGGAGGGGTTAGGATGAAGGGTTGTGTTGA
GTTTTTTATTTATTAGTTTAGGGATTGTATTTTATTAAC/TGTTGATTTTTTTTATTTTTATGATTTTTAAG
C/TGTTATTATTTTTTTATGAATTTTATTTTATTTTTGTGATTATTAGATTTTAGTTAGATTATAAATTAGA
ATGTATATTTGTGTGTTTTGGTTTTTTTGTGAAGGTAGTAGTTGTGAGTTAGGTGTGGAGGTGTATTAATGT
TATTTTAGTTATAGGTATTTTTTGTTGTAGAAGTTTGGGGTTAGTTTGATTGTGAGATGTTGTTTTTTTTTT
GTTTTTTTAAATATTTGGTTAGTTTTTATTTTTTTATTTTTTC/TGGTTGTTGTATTTTTTATTATTTTTAA
TATGGTTAGTGTATTGGAATGTTATTTTTTTTTTTTTTTTTATTTTTTAATTTAATTTTTTTTTTTTTTTTT
AAGATTTATTTATTTATTTTATGTATATGAGTATATTGTAGTTGTATAGATGGTTGTGAGTTTTTATGTGGT
TGTTGGAAATTGAATTTAGGATTTTTGTTC/TGTTTTGGTTTATAGATTTATTTATTATTATATATAAGTAT
ATTGTAGTTGTTTTTAGATATATTAGAAGAGAGTGTTAGATTTTATTATTGATGGTTGTGAATTATTATGTG
GTTGTTGGAATTTGAATTTAGGATTTTTAGAAGAGTAGTTAGTTTTATTTGTTGAGTTATTTTATTAGTTTT
TTTTTTTTTTTTTAATGATTTGGTTGTTTTTTAGATTGAATTTTATATATTTTGGAGATTAAAAAAAAAAAA
AGAAATATAATATAGAGATTTGTTTTTTAATAGTTTTATGTTTTGGAATTTATAGAGATTTATTTGTTTTTG
TTTTTTGAGTGTTGGGATTAAAGGTATGTGTTATTATATTATGATTTAAAGTTTTTAAAATAAGTATGTTGA
AGGGAAAGAATATTTTTAATTTTGTTTGTTTTTGTTTTTTTATGGGGTTTTGAATTGGTAATTATTTTTGGT
TAGGTTTGTTTATTATTTATTGATGATAGTTAGTAAGGTTTATTATTTAGAAAAATGGAGTTTGTGATGGTA
TATTAATTATTTTGAATATAGATTTAAAATTTGGTAGTAGATTTATTTTTTTTATTAATTTTGTGTATAGAA
TTAAATAATAAAAATAGATATTTGGGGGTAGATTTTTAAAATAATTAGTTGAAAAAAAAATTTTATGTATAT
ATAC/TGAGGTTTTGTTGTTTTATTTTAAATATATATGTTTAGTAAAATTTATAATTTTTATTGTATTGTGT
TTGGTATTAGGTGATTATTATGTAGTTTAATTATTTAGTTTTAAGTAATTTTTATTTTTGTTAAATTTTTTA
GTATTTTTTATTTAC/TGTTGTTATAGATGAGTTATAGTTTTATAATAGTTTTGTTTATAGGAAAGTGTTTT
TATTGGTATAGTTATTTTTTTAGTTTTATTGAAATTGTGAAGAGATTGGTAATGC/TGTATATTGTGAGAAT
TATTTTTAAAATTTTTAATTTATAAGTATAGTTATTATAATTTTTTTTTTTTTTTTTTGGAGGAAATAAATA
TATTGGAATAGAATAGTTATGGAAGTTAGGTTTTAATTTTAGTATTTGGGAGGTAAAGGTAAGTGGATTTTT
GTGAGTTTAAGGTTAGGTTGATTTGTAGAGTAAGTTTTTGGATAGTTAAGGTTAAATAGATAAATTTTGTTT
TAAAAAAATTAAAAAAATTTAAAAAGAGTAGTTAAGTAAGTTAGTTTTTAGATTTAGATTTATTTTTAAGTT
ATTTGTGGTTTATGTTTTATTTTTTTGTGTGTTTTTATTTATAGGTTATTGTTTATAATTTATTTTTTTTTT
AATTTTTTTTATAGTTTTGAGAGTTTATTTTGAAAGAATAATGGATGAATTATTTTC/TGTTGGTTAAAATT
TTGGAGTTAAATTAGTATTTTC/TGATTTATAATTGGGTTTGTGTTTGAAGATAATTTAGAAGATGAGATTA
GTAATTTGGTGAAGTTGGATTTAGAAGAGAAGGAGGGTTTTTTGTTATTAGTTTTC/TGTTAGTTTAGATAT
ATTTTTTGATTTGGGGATTTTTGGTTTATAGGATGGTTTGGTTTTTTATATGAGGTGAGAAGAA 
 
Fasn gene promoter DNA sequence: 
TGGCTGGCTCACATGGTGGGCCATCACAACATTACAGGGAAGCCCACACTCAGTAATGTGGTCTTGGATGCC
AGTTGAATAACTCAGGCCTAGGTAGCAGACATCTGCAGATCACTCCTGCTGTGGGTCTGTAGTAGGTAGCTC
TCAAGGTGCATATGCAAAGAGAGAGCCATAGGATGCTTTTACAAGAGCCCACCTAGGTACACTGTGCTGTTT
TCACGACTGGCAGGGGCCATGGCAGGCCATCCTGACGTGGCTCTCTCATATCCACATCTGGCAATCCACTTT
GTTTGTCACGTGTTTCTGAGATGTAGCCATGCAACTTCCTTTGGTGAAAAGATGATCAGAGAAGTTTGCTCT
GCCCTCAGCATCCTGCTCTGTGCACGGCCCAGACTCTGCATCCCTGGGTTACATCTCCTCCAGCTGAGACCC
TGACAGCTGCAGAGGGCAGAGCTCTGCTGACCACTTAGGGTTGGCCAGCAGCCTGGCCAGTGAGAAGGCAAA
CATGACCTATCTCAAGGCACCAGGAGCTGGGGTGGGACTGCTCTGGCTAGTATGTGTACAGGCCTTTTGTAA
AACTTTCCTAGGCTGGCCCTGAAACCCAAAGACACCCACAAAGGCATAGGGGCAAAATGGGAGAGCTTGGGG
GCAAGCCAGCTTATGGGCAGAATACACCTGCCAGTCCTATAGGCTGCCCTTCAGGGTCCCTGCTTAGCCTCC
TTCCACAGAAAGCCTGGGTGGATAGCCAAGTTGGAGAAGCTAGAAGCCAGGGTTGACAAGCAAGGCTCTGAG
GCTCTGGCTTTTGCTATAGACTTGCAGTCAAGGACCACTGACACTAGCCCCCTTCCCCCTCCCCCCCACTCC
CGGGCCATTACCCCATAAGGAGGTCAGTCTTAGTGGCCTGGGCCTGTAGTGGAAGGACAGGAGGGAAGGGAA
CAACCTCTCTAGGCACTCAAGGGACCCAACCCTGAGAAGTCTGTGTCTTTTTGGACGGTGAGTTTTGTCATC
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CCCCGCCCCCAAATTCGATAACCCTTTGAAAAGAGGAATTTAAAGGGAGGGAGGGAGAGGGTCCCGGAAACT
CAGGGAGGCGCGCAGCAGCTCCTTTGTTCCCACCAGGCGGGGGAGGGGTGGTATCCCGCTCGCCAGATGGCC
GCGCCTGGACACTGAGCGGACTCCGGAGGCCGCCACACGCGCCCGTCAGTGTTCCCTATCCTGCCTACTGCT
CCCGTCCCTGCCCGCATCCTGGTCTCCAAGGTGGCCACAGAGGGTGGGAGTCCGAGAAAGCTGGGCCACGAT
GACCGGTAGTAACCCCGCCTGAGGCGCCCTCCGCCAGGGTCAACGACCGCGCTTGCGCGGGGGCCCGCGAAG
TGCTTTGCCGCTGTTGCCGGCCCATCACCCTATTGCCTAGCAACGCCCACCCGCGCGCCGCCATTGGGCCAC
CGAGAACGGCCTCGGTGTCCAATTGGTTTCGATGTGGAGCAGGCCACGCCCCTCGGTTCCGCGCGCGCTACG
ATCGCGGCGTGGAATCGCAGCGACACGGACCTGTCCCCCCGCGTGGCCCTGGTGTCCTCCTCAGTGCAGAGT
TTCCAGTGTGACCAAGCACGCCCGACCCACACTGCGCGCGCACAGTGCACACCTGGCACCGGCCGCGAGGGG
GTGGGGGTGGGAGGACAGAGATGAGGGCGTCGGGATGAGCCCCGCGTGGCCCGCGCGAGGCCGGGGGCGGGG
ACGGAAGCAGGCGGGGGCTGCGCGTTCCTTGTGCTCCAGCGCGCGCCCGTGCAGGGTCCCGGCTGGGGGCGG
CGCGCGCGGGCATCACCCCACCGGCGGCGGCGCGCCGGGTCCCGGGGCGCAGCCCCGACGCTCATTGGCCTG
GGCGGCGCAGCCAAGCTGTCAGCCCATGTGGCGTGGCCGCGCGGGGATGGCCGCGGTTTAAATAGCGCCGGC
GCGGCCTAGAGGGAGCCAGAGAGACGGCAGCGGCGTCCCGTCCAGTTCGCCTGCCGCGCTCCTCGCTTGTCG
TCTGCCTCCAGAGCCCAGACA 
 
Bisulfite modified Fasn gene promoter DNA sequence: 
TGGTTGGTTTATATGGTGGGTTATTATAATATTATAGGGAAGTTTATATTTAGTAATGTGGTTTTGGATGTT
AGTTGAATAATTTAGGTTTAGGTAGTAGATATTTGTAGATTATTTTTGTTGTGGGTTTGTAGTAGGTAGTTT
TTAAGGTGTATATGTAAAGAGAGAGTTATAGGATGTTTTTATAAGAGTTTATTTAGGTATATTGTGTTGTTT
TTAC/TGATTGGTAGGGGTTATGGTAGGTTATTTTGAC/TGTGGTTTTTTTATATTTATATTTGGTAATTTA
TTTTGTTTGTTAC/TGTGTTTTTGAGATGTAGTTATGTAATTTTTTTTGGTGAAAAGATGATTAGAGAAGTT
TGTTTTGTTTTTAGTATTTTGTTTTGTGTAC/TGGTTTAGATTTTGTATTTTTGGGTTATATTTTTTTTAGT
TGAGATTTTGATAGTTGTAGAGGGTAGAGTTTTGTTGATTATTTAGGGTTGGTTAGTAGTTTGGTTAGTGAG
AAGGTAAATATGATTTATTTTAAGGTATTAGGAGTTGGGGTGGGATTGTTTTGGTTAGTATGTGTATAGGTT
TTTTGTAAAATTTTTTTAGGTTGGTTTTGAAATTTAAAGATATTTATAAAGGTATAGGGGTAAAATGGGAGA
GTTTGGGGGTAAGTTAGTTTATGGGTAGAATATATTTGTTAGTTTTATAGGTTGTTTTTTAGGGTTTTTGTT
TAGTTTTTTTTTATAGAAAGTTTGGGTGGATAGTTAAGTTGGAGAAGTTAGAAGTTAGGGTTGATAAGTAAG
GTTTTGAGGTTTTGGTTTTTGTTATAGATTTGTAGTTAAGGATTATTGATATTAGTTTTTTTTTTTTTTTTT
TTTATTTTC/TGGGTTATTATTTTATAAGGAGGTTAGTTTTAGTGGTTTGGGTTTGTAGTGGAAGGATAGGA
GGGAAGGGAATAATTTTTTTAGGTATTTAAGGGATTTAATTTTGAGAAGTTTGTGTTTTTTTGGAC/TGGTG
AGTTTTGTTATTTTTC/TGTTTTTAAATTC/TGATAATTTTTTGAAAAGAGGAATTTAAAGGGAGGGAGGGA
GAGGGTTTC/TGGAAATTTAGGGAGGC/TGC/TGTAGTAGTTTTTTTGTTTTTATTAGGC/TGGGGGAGGGG
TGGTATTTC/TGTTC/TGTTAGATGGTC/TGC/TGTTTGGATATTGAGC/TGGATTTC/TGGAGGTC/TGTT
ATAC/TGC/TGTTC/TGTTAGTGTTTTTTATTTTGTTTATTGTTTTC/TGTTTTTGTTC/TGTATTTTGGTT
TTTAAGGTGGTTATAGAGGGTGGGAGTTC/TGAGAAAGTTGGGTTAC/TGATGATC/TGGTAGTAATTTC/T
GTTTGAGGC/TGTTTTTC/TGTTAGGGTTAAC/TGATC/TGC/TGTTTGC/TGC/TGGGGGTTC/TGC/TGA
AGTGTTTTGTC/TGTTGTTGTC/TGGTTTATTATTTTATTGTTTAGTAAC/TGTTTATTC/TGC/TGC/TGT
C/TGTTATTGGGTTATC/TGAGAAC/TGGTTTC/TGGTGTTTAATTGGTTTC/TGATGTGGAGTAGGTTAC/
TGTTTTTC/TGGTTTC/TGC/TGC/TGC/TGTTAC/TGATC/TGC/TGGC/TGTGGAATC/TGTAGC/TGAT
AC/TGGATTTGTTTTTTC/TGC/TGTGGTTTTGGTGTTTTTTTTAGTGTAGAGTTTTTAGTGTGATTAAGTA
C/TGTTC/TGATTTATATTGC/TGC/TGC/TGTATAGTGTATATTTGGTATC/TGGTC/TGC/TGAGGGGGT
GGGGGTGGGAGGATAGAGATGAGGGC/TGTC/TGGGATGAGTTTC/TGC/TGTGGTTC/TGC/TGC/TGAGG
TC/TGGGGGC/TGGGGAC/TGGAAGTAGGC/TGGGGGTTGC/TGC/TGTTTTTTGTGTTTTAGC/TGC/TGC
/TGTTC/TGTGTAGGGTTTC/TGGTTGGGGGC/TGGC/TGC/TGC/TGC/TGGGTATTATTTTATC/TGGC/
TGGC/TGGC/TGC/TGTC/TGGGTTTC/TGGGGC/TGTAGTTTC/TGAC/TGTTTATTGGTTTGGGC/TGGC
/TGTAGTTAAGTTGTTAGTTTATGTGGC/TGTGGTC/TGC/TGC/TGGGGATGGTC/TGC/TGGTTTAAATA
GC/TGTC/TGGC/TGC/TGGTTTAGAGGGAGTTAGAGAGAC/TGGTAGC/TGGC/TGTTTC/TGTTTAGTTC
/TGTTTGTC/TGC/TGTTTTTC/TGTTTGTC/TGTTTGTTTTTAGAGTTTAGATA 
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Appendix 5: Representative pyrogram of Acaca and Fasn 
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